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ABSTRACT 
Breast cancer is the most commonly occurring cancer in women, with incidence 
rates approaching 1.38 million cases per year worldwide. Over the last few 
decades, there have been numerous attempts to develop, synthesise and advance 
into the clinic novel and selective breast cancer therapies. Research work has 
shown that bisnaphthalimidopropyl diaminodicyclohexylmethane (BNIPDaCHM) 
exerts potent in vitro anti-cancer activities and strong DNA binding properties. The 
aim of this thesis was to synthetise novel bisnaphthalimidopropyl derivatives 
(BNIPs) and investigate their subsequent modes of action within two human 
metastatic breast cancer cell lines, MDA-MB-231 and SKBR-3. A series of novel 
BNIPs, bisnaphthalimidopropyl-piperidylpropane (BNIPPiProp), 
bisnaphthalimidopropyl- ethylenedipiperidine (BNIPPiEth) and (trans(trans))-4,4’-
methylenebis-cyclohexylamine (trans,trans-BNIPDaCHM) were synthesised, 
characterised and studied in comparison to BNIPDaCHM for their DNA binding and 
anti-cancer activities against MDA-MB-231 and SKBR-3 cells. Thermal 
denaturation studies have shown that BNIPs can intercalate and stabilize the 
double helix of Calf Thymus, each BNIP can competitively displace EtBr from DNA 
in a dose dependent manner and by UV binding studies, high affinity was found 
for the three novel BNIPs. After 24 hours treatment, all novel BNIPs, exhibited 
strong cytotoxicity with IC50 values ranging from 1.4 μM to 3.3 μM in MDA-MB-231 
cells and 0.2 - 0.7 μM in SKBR-3 cells, confirming the importance of 
bisnaphthalimidopropyl functionality. BNIPs were also found to increase 
intracellular ROS levels after 8 hours treatment and induce a significant increase 
in DNA strand breaks compared to endogenous levels, after 24 hour treatment in 
both cell lines. After cell synchronisation, cell cycle distribution was studied, 
revealing that trans,trans-BNIPDaCHM induces sub-G1 cell population arrest in 
 v 
MDA-MB-231 and SKBR-3 cells, after 24 hours treatment. In addition, BNIPs 
induced apoptotic phosphatidylserine exposure, after 0.5 hours treatment, 
inhibited Caspase-3 activity and increased autophagy, after 24 hour treatment in 
MDA-MB-231 and SKBR-3 cells. Moreover, BNIPs inhibited histone deacetylases 
(HDAC) activity after 24 hours treatment in MDA-MB-231 and SKBR-3 cells and 
BNIPDaCHM was identified as a potential SIRT2 inhibitor, in SKBR-3 cells. 
According to Proteome Profiler Arrays, BNIPDaCHM and BNIPPiEth altered the 
expression of cell stress-related proteins in a cell dependent manner and 
bioinformatic analysis revealed two novel, putative pathways for BNIP-induced 
oxidative stress-mediated cell death in MDA-MB-231 and SKBR-3 cells. The above 
findings indicate that BNIPs represent promising candidates for future breast 
cancer studies and cancer treatment. 
Keywords: Bisnaphthalimidopropyl, DNA binding, DNA damage, Apoptosis, 
Autophagy, HDAC inhibition, Bioinformatics.  
  
 vi 
CONTENTS 
Declaration................................................................................................. i 
Acknowledgements .................................................................................... ii 
Abstract ................................................................................................... iv 
Contents .................................................................................................. vi 
List of figures .......................................................................................... xiv 
List of tables and schemes ....................................................................... xxii 
Abbreviations ........................................................................................ xxiv 
 
CHAPTER 1 - Introduction ....................................................................... 1 
1.1 Cancer: an overview  ............................................................................ 2 
1.1.1 Breast Cancer  .................................................................................. 6 
1.1.2 Different types of breast cancer  .......................................................... 8 
1.2 Risk factors  ......................................................................................... 8 
1.2.1 Reactive Oxygen Species  ................................................................. 11 
1.2.2 ROS-mediated signalling pathways  ................................................... 13 
1.3 Epigenetics and cancer ........................................................................ 14 
1.3.1 HDAC inhibitors in cancer treatment ................................................... 17 
1.4 Cancer therapeutics: use and limitations of chemotherapy ....................... 19 
1.4.1 DNA binding properties of derivatives with therapeutic potential ............ 21 
1.4.2 Synthesis of mononaphthalimide and bisnaphthalimide derivatives ........ 22 
1.4.3 Synthesis of novel bisnaphthalimidopropyl polyamine derivatives .......... 23 
1.5 Aims and thesis Layout ....................................................................... 26 
 
 vii 
CHAPTER 2 - Synthesis and characterisation of novel 
bisnaphthalimidopropyl derivatives ...................................................... 29 
2.1 Introduction .................................................................................... 30 
2.1.1 Aims .............................................................................................. 30 
2.1.2 Synthetic method of bisnaphthalimidopropyl derivatives ....................... 33 
2.1.3 Separation, identification and characterisation of bisnaphthalimidopropyl 
derivatives .............................................................................................. 38 
 
2.2 Materials ......................................................................................... 41 
 
2.3 Instrumentation .............................................................................. 42 
 
2.4 Results and Discussion: Synthesis of bisnaphthalimidopropyldi-
aminodicyclohexylmethane (BNIPDaCHM) ............................................ 43 
2.4.1 Synthesis of N-(3-hydropropyl)naphthalimide ...................................... 43 
2.4.2 Synthesis of toluenesulfonyloxypropylnaphthalimide ............................ 45 
2.4.3 Synthesis of N4,N4-dimesityl-dicyclohexylmethane N-alkylation reaction . 47 
2.4.4 N-alkylation reaction ........................................................................ 49 
2.4.5 Deprotection reaction ....................................................................... 52 
 
2.5 Results and Discussion: Synthesis of bisnaphthalimidopropyl-
piperidylpropane (BNIPPiProp)............................................................. 56 
2.5.1 Synthesis of bisnaphthalimidopropyl-dipiperidyl-propane base ............... 56 
2.5.2 Synthesis of BNIPPiProp salt ............................................................. 58 
 
 viii 
2.6 Results and Discussion: Synthesis of bisnaphthalimidopropyl- 
ethylenedipiperidine (BNIPPiEth) ......................................................... 61 
2.6.1 Synthesis of 4,4-Ethylenedipiperidine ................................................. 61 
2.6.2 Synthesis of BNIPPiEth base .............................................................. 62 
2.6.3 Synthesis of BNIPPiEth salt ............................................................... 64 
 
2.7 Results and Discussion: Synthesis of trans,trans-bisnaphthalimido-
propyldiaminodicyclohexylmethane (trans,trans-BNIPDaCHM) ............ 68 
2.7.1 Synthesis of trans,trans-N4,N4-dimesityl-dicyclohexylmethane ............... 68 
2.7.2 N-alkylation reaction ........................................................................ 71 
2.7.3 Deprotection reaction ....................................................................... 73 
 
2.8 Melting Points determination .......................................................... 77 
 
2.9 Conclusion ...................................................................................... 80 
 
CHAPTER 3 - DNA binding studies on bisnaphthalimidopropyl derivatives.
 ............................................................................................................. 81 
3.1 Introduction .................................................................................... 82 
3.1.1 Naphthalimides, bisnaphthalimides and DNA intercalation ..................... 82 
3.1.2 Assessment of DNA binding interactions ............................................. 83 
3.1.3 Aims .............................................................................................. 87 
 
3.2 Materials ......................................................................................... 88 
3.2.1 Materials ........................................................................................ 88 
3.2.2 Instrumentation .............................................................................. 88 
 ix 
3.3 Methods .......................................................................................... 89 
3.3.1 Thermal denaturation studies of BNIPs ............................................... 89 
3.3.2 Ethidium Bromide fluorescence studies ............................................... 89 
3.3.3 UV binding studies ........................................................................... 91 
3.3.4 Statistical analysis ........................................................................... 92 
 
3.4 Results and Discussion .................................................................... 93 
3.4.1 Thermal denaturation studies: The effect of BNIPs on DNA binding ........ 93 
3.4.2 Competitive displacement of EtBr by BNIPs ......................................... 95 
3.4.3 UV binding studies and the effect of BNIPs on DNA binding ................... 98 
 
3.5 Conclusion .................................................................................... 101 
 
CHAPTER 4 - Cytotoxicity, reactive oxygen species and DNA damage 
studies ................................................................................................ 103 
4.1 Introduction .................................................................................. 104 
4.1.1 Anti-cancer drugs and in vitro cytotoxicity ........................................ 104 
4.1.2 ROS levels in cancer cells ............................................................... 108 
4.1.3 DNA damage in cancer cells ............................................................ 110 
4.1.4 Aims ............................................................................................ 114 
 
4.2 Materials ....................................................................................... 115 
4.2.1 Cell culture maintenance of MDA-MB-231 and SKBR-3 cells ................ 115 
4.2.2 Colourimetric 3-(4, 5-Dimethylthiazol-2-yl)-2, 5 diphenyltetrazodium 
bromide assay ....................................................................................... 115 
4.2.3 Reactive Oxygen Species Level Detection ......................................... 115 
 x 
4.2.4 COMET assay ................................................................................ 116 
4.2.5 Instrumentation ............................................................................ 117 
 
4.3 Methods ........................................................................................ 118 
4.3.1 Cell culture maintenance of MDA-MB-231 and SKBR-3 cells ................ 118 
4.3.2 Colourimetric 3-(4, 5-Dimethylthiazol-2-yl)-2, 5 diphenyltetrazodium 
bromide assay ....................................................................................... 119 
4.3.3 ROS Level Detection....................................................................... 120 
4.3.4 COMET assay ................................................................................ 121 
4.3.5 Statistical analysis ......................................................................... 123 
 
4.4 Results and Discussion .................................................................. 124 
4.4.1 Cytotoxicity ................................................................................... 124 
4.4.2 ROS levels .................................................................................... 128 
4.4.3 DNA damage studies ...................................................................... 135 
 
4.5 Conclusion .................................................................................... 139 
 
CHAPTER 5 - Effect of novel bisnaphthalimidopropyl derivatives on cell 
cycle distribution and cell death ......................................................... 141 
5.1 Introduction .................................................................................. 142 
5.1.1 Cell cycle and cancer ...................................................................... 142 
5.1.2 Cell death shapes cancer ................................................................ 144 
5.1.3 Crosstalk between cell death machineries ......................................... 147 
5.1.4 Aims ............................................................................................ 150 
 
 xi 
5.2 Materials ....................................................................................... 151 
5.2.1 Cell cycle analysis/ propidium iodide (PI) staining .............................. 151 
5.2.2 Annexin V-FITC/7-AAD staining ....................................................... 151 
5.2.3 Caspase-3 colourimetric assay......................................................... 151 
5.2.4 Autophagy microplate assay ............................................................ 151 
5.2.5 Instrumentation ............................................................................ 152 
 
5.3 Methods ........................................................................................ 153 
5.3.1 Cell cycle analysis/ propidium iodide staining .................................... 153 
5.3.2 Annexin V-FITC/7-AAD staining ....................................................... 155 
5.3.3 Caspase-3 colourimetric assay......................................................... 157 
5.3.4 Autophagy microplate assay ............................................................ 158 
5.3.5 Statistical analysis ......................................................................... 159 
 
5.4 Results and Discussion .................................................................. 160 
5.4.1 Cell cycle analysis in MDA-MB-231 and SKBR-3 cells .......................... 160 
5.4.2 Annexin V-FITC/7-AAD studies in MDA-MB-231 and SKBR-3 cells ........ 164 
5.4.3 Caspase-3 studies in MDA-MB-231 and SKBR-3 cells .......................... 170 
5.4.4 Autophagy studies in MDA-MB-231 and SKBR-3 cells ......................... 173 
 
5.5 Conclusion .................................................................................... 177 
 
CHAPTER 6 - Effect of bisnaphthalimidopropyl derivatives on histone 
deacetylases and cell stress-related proteins. .................................... 179 
6.1 Introduction .................................................................................. 180 
6.1.2 Sirtuins and their role in tumourigenesis ........................................... 183 
 xii 
6.1.3 Aims ............................................................................................ 183 
 
6.2 Materials ....................................................................................... 184 
6.2.1 HDAC cell-based activity assay ........................................................ 184 
6.2.2 Total protein extraction .................................................................. 184 
6.2.3 Bradford protein concentration assay ............................................... 184 
6.2.4 Sodium dodecyl sulphate polyacrylamide gel electrophoresis ............... 184 
6.2.5 Western blotting and Detection........................................................ 186 
6.2.6 Proteome Profiler Array .................................................................. 186 
6.2.7 Instrumentation ............................................................................ 187 
 
6.3 Methods ........................................................................................ 188 
6.3.1 HDAC cell-based activity assay ........................................................ 188 
6.3.2 Total protein extraction .................................................................. 188 
6.3.3 Bradford protein concentration assay cells ........................................ 189 
6.3.4 Sodium dodecyl sulphate Polyacrylamide gel electrophoresis ............... 189 
6.3.5 Proteome Profiler Array .................................................................. 191 
6.3.6 Bioinformatic studies ...................................................................... 194 
6.3.7 Statistical analysis ......................................................................... 194 
 
6.4 Results and Discussion .................................................................. 195 
6.4.1 Histone deacetylase activity of BNIPs ............................................... 195 
6.4.2 SIRT2 expression in MDA-MB-231 and SKBR-3 cells ........................... 199 
6.4.3 Human cell stress-related proteins expression after treatment with BNIPs in 
MDA-MB-231 and SKBR-3 cells ................................................................ 203 
6.4.4 Construction and analysis of Protein–Protein Interaction Networks ....... 208 
 xiii 
6.5 Conclusion .................................................................................... 223 
 
CHAPTER 7 – General conclusion and future work .............................. 226 
 
REFERENCES ....................................................................................... 236 
APPENDICES ....................................................................................... 264 
PUBLIC OUTPUT .................................................................................. 271 
 
  
 xiv 
List of Figures 
CHAPTER 1 
Figure 1.1.: Age-standardised incidence rates by sex, area and country in Europe 
2012: all cancers excluding non-melanoma skin cancers ................................. 3 
Figure 1.1.1.: Anatomy of the breast and its compartments ........................... 7 
Figure 1.2.: Hereditary mutations in breast cancer susceptibility genes ......... 10 
Figure 1.2.1.: Dual role of ROS levels ....................................................... 12 
Figure 1.4.1.: Chemical structures of agents that interact with DNA .............. 21 
Figure 1.4.3.: Chemical structures of bisnaphthalimidopropyl polyamine 
derivatives: BNIPPut, BNIPOPut, BNIPSpd, BNIPSpm and BNIPOSpm ............. 24 
Figure 1.5.: Layout of thesis. ................................................................... 28 
CHAPTER 2 
Figure 2.1.1.: Chemical structures of BNIPs: BNIPDaCHM with its three stereo 
isomers, bisnaphthalimidopropyl-piperidylpropane (BNIPPiProp), 
bisnaphthalimidopropyl- ethylenedipiperidine (BNIPPiEth) and trans,trans-
4,4’Methylenebis(cyclohexylamine) (trans,trans-BNIPDaCHM). ...................... 31 
Figure 2.1.2a.: General synthetic method for the synthesis of 
bisnaphthalimidopropyl derivatives: [1] 3-amino-1-propanol, DMF/DBU, 85°C, 5 
hours [2] p-toluenesulfonyl chloride (Ts-Cl), anhydrous pyridine, 4°C, 12 
hours ..................................................................................................... 34 
Figure 2.1.2b.: Synthetic pathway of bisnaphthalimidopropyl-piperidylpropane 
(BNIPPiProp) and bisnaphthalimidopropyl- ethylenedipiperidine dihydrobromide 
(BNIPPiEth) ............................................................................................. 35 
 xv 
Figure 2.1.2c.: Synthetic pathway of trans,trans-4,4’-
Methylenebis(cyclohexylamine) (trans,trans-BNIPDaCHM) ............................ 37 
Figure 2.1.3.: Silica gel plate and calculation of Rf value, where Rf=y/x (always 
≤1) ........................................................................................................ 39 
Figure 2.4.1a.: Synthesis of N-(3-hydropropyl)naphthalimide ...................... 43 
Figure 2.4.1b.: Equivalent protons of N-(3-hydroxypropyl)naphthalimide ...... 44 
Figure 2.4.2a.: Synthesis of toluenesulfonyloxypropylnaphthalimide. ............ 45 
Figure 2.4.2b.: Equivalent hydrogens of toluenesulfonyloxypropyl-
naphthalimide.......................................................................................... 46 
Figure 2.4.3a.: Synthesis of N4,N4-dimesityl-dicyclohexylmethane. ............... 47 
Figure 2.4.3b.: Equivalent hydrogens of N4,N4-dimesityl-dicyclohexylmethane 
 ............................................................................................................. 48 
Figure 2.4.4a.: Synthesis of protected bisnaphthalimidopropyl-dimesityl-
dicyclohexylmethane ................................................................................ 49 
Figure 2.4.4b.: Equivalent proton and carbons of bisnaphthalimido-dimesityl-
dicyclohexylmethane ................................................................................ 50 
Figure 2.4.5a.: Synthesis of bisnaphthalimidopropyl-diamino-
dicyclohexylmethane dihydro-bromide salt (BNIPDaCHM) ............................. 52 
Figure 2.4.5b.: 1H-NMR spectrum for BNIPDaCHM ...................................... 53 
Figure 2.4.5c.: 13C-NMR spectrum for BNIPDaCHM ..................................... 54 
Figure 2.4.5d.: Equivalent protons and carbons of bisnaphthalimidopropyl-
diamino-dicyclohexylmethane dihydro-bromide salt (BNIPDaCHM) ................. 54 
Figure 2.4.5e.: High resolution mass spectrum of BNIPDaCHM: M+=630.3344 
 ............................................................................................................. 55 
Figure 2.5.1a.: Synthesis of BNIPPiProp free base. ..................................... 56 
Figure 2.5.1b.: Equivalent hydrogen of BNIPPiProp base ............................. 57 
 xvi 
Figure 2.5.2a.: Synthesis of BNIPPiProp salt. ............................................. 58 
Figure 2.5.2b.: 1H-NMR spectrum for BNIPPiProp ....................................... 59 
Figure 2.5.2c.: 13C-NMR spectrum for BNIPPiProp ....................................... 59 
Figure 2.5.2d.: Equivalent protons and carbons of BNIPPiProp salt ............... 60 
Figure 2.5.2e.: High resolution mass spectrum of BNIPPiProp: M+=685.3733  60 
Figure 2.6.1.: Synthesis of 4,4-Ethylenedipiperidine ................................... 61 
Figure 2.6.2a.: Synthesis of BNIPPiEth base. ............................................. 62 
Figure 2.6.2b.: Equivalent protons for BNIPPiEth ........................................ 63 
Figure 2.6.3.a: Synthesis of BNIPPiEth salt ................................................ 64 
Figure 2.6.3b: 1H-NMR spectrum for BNIPPiEth. ......................................... 65 
Figure 2.6.3c.: 13C-NMR spectrum for BNIPPiEth ........................................ 66 
Figure 2.6.3d.: Equivalent protons and carbons for BNIPPiEth salt. ............... 66 
Figure 2.6.3e.: High resolution mass spectrum of BNIPPiEth: M+=671.3572. . 67 
Figure 2.7.1a.: Synthesis of trans,trans-N4,N4-dimesityl-
dicyclohexylmethane. ............................................................................... 68 
Figure 2.7.1b.: Equivalent hydrogen atoms of trans, trans-N4,N4-dimesityl-
dicyclohexylmethane. ............................................................................... 69 
Figure 2.7.2a.: Synthesis of protected trans,trans-bisnaphthalimidopropyl-
dimesityl-dicyclohexylmethane. ................................................................. 70 
Figure 2.7.2b.: Equivalent proton and carbons of trans,trans-bisnaphthalimido-
dimesityl-dicyclohexylmethane. ................................................................. 71 
Figure 2.7.3a.: Synthesis of trans,trans-bisnaphthalimidopropyl-diamino-
dicyclohexylmethane dihydro-bromide salt (trans,trans-BNIPDaCHM). ............ 73 
Figure 2.7.3b.: 1H-NMR spectrum for trans,trans-BNIPDaCHM ..................... 74 
Figure 2.7.3c.: 13C-NMR spectrum for trans,trans-BNIPDaCHM ..................... 75 
 xvii 
Figure 2.7.3d.: Equivalent protons and carbons of trans,trans-
bisnaphthalimidopropyl-diamino-dicyclohexylmethane dihydro-bromide salt 
(trans,trans-BNIPDaCHM). ........................................................................ 75 
Figure 2.7.3e.: High resolution mass spectrum of trans,trans-BNIPDaCHM: 
M+=685.3732. ......................................................................................... 76 
CHAPTER 3 
Figure 3.1.2.1.: Method of DNA thermal denaturation studies ...................... 84 
Figure 3.1.2.2.: Method of competitive displacement of DNA bound EtBr on 
Shimadzu RF-5301 spectrophotometer ....................................................... 85 
Figure 3.1.2.3.: Method of UV binding studies on Agilent 8453 UV-visible 
Spectroscopy System ............................................................................... 86 
Figure 3.3.2.: Fluorescence emission of different Ethidium Bromide 
concentrations in presence of Calf Thymus DNA ........................................... 91 
Figure 3.4.3.: a) Interaction between BNIPs and Calf Thymus DNA by UV 
spectroscopy. Plot of A0/ (A-A0) versus 1/CBNIP of the interaction between BNIPs 
and Calf Thymus DNA. b) K constant values of BNIPs after UV binding 
studies ................................................................................................. 100 
Figure 3.5.: Summary of DNA binding studies. ......................................... 102 
CHAPTER 4 
Figure 4.1.1.1.: Structure of tetrazolium and formazan salt. ...................... 105 
Figure 4.1.1.2.: A microtiter 96 well plate after an MTT assay .................... 106 
Figure 4.1.2.1.: Electron structures of common reactive oxygen species ..... 108 
Figure 4.1.2.2.: Chemical structure of CM-H2DCFDA probe ........................ 110 
 xviii 
Figure 4.1.3.: DNA damage in MDA-MB-231 cells as determined by comet assay.
 ........................................................................................................... 113 
Figure 4.3.1.: Counting areas on Neubauer Haemocytometer ..................... 119 
Figure 4.3.3.: ROS levels in MDA-MB-231 cells before (left) and after 8 hour 
treatment with BNIPDaCHM IC25 (right). ................................................... 121 
Figure 4.4.1.: The growth inhibition curve of BNIPDaCHM in MDA-MB-231 cells 
after 24, 48, 72 and 96 hours .................................................................. 124 
Figure 4.4.2.1.: Quantification of ROS levels by flow cytometry following ROS 
dye staining after 4, 8 and 12 hours treatment with BNIPPiProp (IC50) in MDA-MB-
231 (a) and SKBR-3 cells (b) ................................................................... 130 
Figure 4.4.2.2.: Quantification of ROS levels by flow cytometry following ROS 
dye staining after 8 hours treatment with BNIPDaCHM, BNIPPiProp, BNIPPiEth and 
trans,trans-BNIPDaCHM in MDA-MB-231 (a) and SKBR-3 cells (b), 
respectively ........................................................................................... 132 
Figure 4.4.3.: DNA strand breaks in MDA-MB-231 and b. SKBR-3 cells after 24 
hours treatment determined by comet assay. Data obtained after treating (a) 
MDA-MB-231 and (b) SKBR-3 cells with BNIPs (IC25) for 24 hours. ............... 138 
Figure 4.5.: Summary of cytotoxicity, ROS levels and DNA damage studies. 140 
CHAPTER 5 
Figure 5.1.1.: Schematic representation of the cell cycle ........................... 142 
Figure 5.1.2.1.: Cytology of apoptosis .................................................... 145 
Figure 5.1.2.2.: Translocation of membrane PS from the inner side to the surface 
of the plasma membrane in apoptotic cell. ................................................ 146 
Figure 5.1.3.: The relationship between apoptosis and autophagy .............. 148 
 xix 
Figure 5.3.1.: Cell cycle distribution of MDA-MB-231 cells before (left) and after 
24 hour treatment with BNIPDaCHM IC25 (right) ........................................ 154 
Figure 5.3.2.: Apoptotic (A4) and necrotic distribution (A2) of MDA-MB-231 cells 
before (left) and after 0.5 hour treatment with BNIPDaCHM IC25 (right) ........ 156 
Figure 5.4.1.: a) Synchronisation of MDA-MB-231 and b) SKBR-3 cell cultures 
after 24 hour serum deprivation............................................................... 162 
Figure 5.4.1.1.: a) Cell cycle distribution of MDA-MB-231 and b) SKBR-3 cells 
after BNIP treatment .............................................................................. 163 
Figure 5.4.2.: PS exposure and membrane integrity profiles of MDA-MB-231 after 
0.5, 2, and 4 hour treatment with IC25 BNIPDaCHM. ................................... 164 
Figure 5.4.2.1.: a) PS exposure and membrane integrity profiles of MDA-MB-231 
and b) SKBR-3 cells, after 0.5 hour treatment with IC25 BNIPs. .................... 169 
Figure 5.4.3.: a) Effect of BNIPs on Caspase-3 activity in MDA-MB-231 and b) 
SKBR-3 cells, after 24 hours treatment at 37oC with BNIPDaCHM, BNIPPiProp, 
BNIPPiEth and trans,trans-BNIPDaCHM. .................................................... 171 
Figure 5.4.4.: a) Detection of autophagy by microplate reader in MDA-MB-231 
and b) SKBR-3 cells. .............................................................................. 174 
Figure 5.5.: Summary of cell cycle distribution and cell death studies ......... 178 
CHAPTER 6 
Figure 6.4.1.: Histone deacetylase (HDAC) activity of BNIPDaCHM, BNIPPiProp, 
BNIPPiEth and trans,trans-BNIPDaCHM in a) MDA-MB-231 and b) SKBR-3 
cells ..................................................................................................... 196 
Figure 6.4.2.: Representative western blots showing the efficiency of SIRT2 and 
β-actin in MDA-MB-231 and SKBR-3 cells, after 24 hours treatment with 
BNIPDaCHM .......................................................................................... 199 
 xx 
Figure 6.4.3.1.: Comparison of BNIPDaCHM and BNIPPiEth effects upon cell 
stress related proteins in MDA-MB-231 cells. ............................................. 204 
Figure 6.4.3.2.: Comparison of BNIPDaCHM and BNIPPiEth effects upon cell 
stress related proteins in SKBR-3 cells ...................................................... 206 
Figure 6.4.4.1.: Representation of the statistically significant (p-value threshold: 
0.05) biological processes of proteins examined via the Proteome Profiler Human 
Cell Stress R&D Array, employing Cytoscape 3.4 (ClueGO V2.3.2. and CluePedia 
V1.3.2). ................................................................................................ 210 
Figure 6.4.4.2.: Cellular compartment localisation prediction of the statistically 
significant (p-value threshold: 0.05) biological processes of proteins examined via 
the Proteome Profiler Human Cell Stress R&D Array, employing Cytoscape 3.4 
(ClueGO V2.3.2. and CluePedia V1.3.2). ................................................... 211 
Figure 6.4.4.3.: Network (a) and pie chart (b) representation of the statistically 
significant (p-value threshold: 0.05) biological processes (A), of proteins that met 
the ± 0.5 criteria (Figure 6.4.3.1) in MDA-MB-231 cells after treatment with BNIPs, 
employing Cytoscape 3.4 (ClueGO V2.3.2. and CluePedia V1.3.2) ................ 214 
Figure 6.4.4.4.: Cellular compartment localisation prediction of selected proteins 
that met the ± 0.5 criteria (Figure 6.4.3.1) in MDA-MB-231 cells after treatment 
with BNIPs, employing Cytoscape 3.4 (ClueGO V2.3.2. and CluePedia 
V1.3.2). ................................................................................................ 215 
Figure 6.4.4.5.: Network with the statistically significant (p-value threshold: 
0.05) proteins that met the ± 0.5 criteria (Figure 6.4.3.1) in MDA-MB-231 cells 
after treatment with BNIPs (in red ring), and other non-examined proteins, after 
employing String V10.0. ......................................................................... 217 
 
 xxi 
Figure 6.4.4.6.: Network (a) and pie chart (b) representation of the statistically 
significant (p-value threshold: 0.05) biological processes, of proteins that met the 
± 0.5 criteria (Figure 6.4.3.2) in SKBR-3 cells after treatment with BNIPs, 
employing Cytoscape 3.4 (ClueGO V2.3.2. and CluePedia V1.3.2) ................ 219 
Figure 6.4.4.7.: Cellular compartment localisation prediction of selected proteins 
that met the ± 0.5 criteria (Figure 6.4.3.2) in SKBR-3 cells after treatment with 
BNIPs, employing Cytoscape 3.4 (ClueGO V2.3.2. and CluePedia V1.3.2). ..... 220 
Figure 6.4.4.8.: Network with the statistically significant (p-value threshold: 
0.05) proteins that met the ± 0.5 criteria in SKBR-3 cells after treatment with 
BNIPs (in red string), and other non-examined proteins, after employing String 
V10.0 ................................................................................................... 222 
Figure 6.5.: Schematic representation of proposed mechanism for BNIP-induced 
oxidative stress-mediated cell death in MDA-MB-231 and SKBR-3 cells. Black 
arrows indicate pathways for cell death, green circles the upstream components, 
red circles the downstream components and yellow circles the linker proteins of 
the pathway .......................................................................................... 225 
CHAPTER 7 
Figure 7.1.: Schematic representation of the proposed mode of action of BNIPs 
in MDA-MB-231 and SKBR-3 cells ............................................................. 235 
 
  
 xxii 
List of Tables and Schemes 
CHAPTER 1 
Table 1.3.1.: Different classes of modification identified on histones and function 
that they regulate .................................................................................... 16 
Table 1.3.1.1.: HDAC inhibitors classified according to status of clinical 
advancement, HDAC(s) targeted and chemical class ..................................... 18 
CHAPTER 2 
Table 2.8.: Melting points of BNIPDaCHM, BNIPPiProp, BNIPPiEth and trans,trans-
BNIPDaCHM (use of variable heat: 7). ........................................................ 78 
CHAPTER 3 
Table 3.3.2.: Preparation of test solutions with different BNIP derivative 
concentrations for EtBr Fluorescence studies. .............................................. 90 
Table 3.4.1.: Tm values of Calf Thymus DNA alone and in the presence of 
BNIPs ..................................................................................................... 94 
Table 3.4.2.: Competitive displacement of EtBr from Calf Thymus DNA ......... 95 
CHAPTER 4 
Table 4.4.1.: MDA-MB-231 and SKBR-3 cells were treated with different BNIPs 
concentrations (0-10 μM) for 24 hours at 37°C .......................................... 127 
Table 4.4.2.: MDA-MB-231 and SKBR-3 cells were treated with BNIPs (IC25 
concentrations) for 24 hours at 37°C ........................................................ 129 
 
 xxiii 
CHAPTER 6 
Table 6.3.4.: Details of primary and secondary antibodies used for β-actin and 
SIRT2 protein detection. ......................................................................... 190 
Table 6.3.5.: Cell stress-related proteins that were studied before and after 
treatment with BNIPDaCHM and BNIPPiEth in MDA-MB-231 and SKBR-3 cells. 193 
Table 6.4.2.: Levels of SIRT2 antibody staining/expression (high (dark blue), 
partially detected (light blue), not detected (white)) in breast cancer tissues . 202 
Table 6.4.4.: List of examined proteins/input names for bioinformatic 
studies ................................................................................................. 209 
  
 xxiv 
Abbreviations 
AAD Aminoactinomycin D  
ADAMTS1 ADAM Metallopeptidase with Thrombospondin Type 1 Motif 1 
ADP   Adenosine Diphosphate 
ATP   Adenosine Triphosphate 
Bad   Bcl-2 Associated Agonist of Cell Death 
Bak   Bcl-2 Antagonist/Killer 
Bax   Bcl-2 Associated X 
BC Betweenness Centrality 
BCA Bicinchoninic acid 
Bcl-Xs   Bcl-2 Like 1 
Bid   BH3 Interacting Domain Death Agonist 
BNIPDaCHM  Bisnaphthalimidopropyl diaminodicyclohexylmethane  
BNIPPiEth Bisnaphthalimidopropyl- ethylenedipiperidine dihydrobromide 
BNIPPiProp Bisnaphthalimidopropyl-piperidylpropane  
BNIPPs  Bisnaphthalimidopropyl polyamine derivatives 
BNIPs   Bisnaphthalimidopropyl derivatives 
BRAF B-Raf Proto-Oncogene 
BSA Bovine Serum Albumin 
C6   Glioma cells 
CAIX Carbonic Anhydrase 
CC Closeness Centrality 
CD95   Caspase 8 
CDCl3   Chloroform-D 
CDK   Cyclin/cyclin dependent kinase 
CDKI   Cyclin/cyclin dependent kinase inhibitor 
 xxv 
CDKN2A Cyclin Dependent Kinase Inhibitor 2 Alpha 
CH3CO2H Acetic acid 
Cited-2 Cbp/P300 Interacting Transactivator with Glu/Asp Rich 
Carboxy-Terminal Domain 2  
CM-H2DCFDA Chloromethyl derivative of 2′,7′-Dichlorodihydrofluorescein 
diacetate 
COX-2 Cytochrome c Oxidase Subunit 2 
Cs2CO3 Caesium carbonate 
DAPI 4',6-Diamidino-2-Phenylindole, Dihydrochloride 
DCM   Dichloromethane 
DISC   Death-inducing signalling complex 
Dkk-4 Dickkopf WNT Signaling Pathway Inhibitor 4 
DMF   Dimethylformamide 
DMSO   Dimethyl sulfoxide 
DNA   Deoxyribonucleic Acid 
DNBC Double Negative Breast Cancer 
ds   Doubled Stranded 
ER-   Oestrogen Independent 
ER+   Oestrogen Dependent 
EtBr   Ethidium Bromide 
FABP-1 Fatty Acid-Binding Protein 1 
FBS Fetal Bovine Serum 
FITC Fluorescein Isothiocyanate 
G0   State of quiescence 
G1   Gap Phase 1 
G2   Gap Phase 2 
 xxvi 
H   Hydrogen 
H2O2  Hydrogen peroxide 
HBr   Hydrogen bromide 
HDAC   Histone Deacetylase 
HeLa   Human cervical cancer cells 
HER2- Human Epidermal growth factor Receptor 2 negative 
HER2+ Human Epidermal growth factor Receptor 2 positive 
HIF-1a Hypoxia Inducible Factor 1 Alpha Subunit 
HIF-2a Hypoxia Inducible Factor 2 Alpha Subunit 
HOCl  Hypochloride 
HRP Horseradish Peroxidase 
HSP60 Heat Shock Protein Family D (Hsp60) 
HSP70 Heat Shock Protein Family A (Hsp70) Member 1 Alpha 
IBC   Inflammatory breast cancer 
IDC   Invasive ductal carcinoma 
IDO Indoleamine 2,3-Dioxygenase 1 
INT 2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2H-tetrazolium 
chloride 
JNK Pan c-Jun N-terminal kinases Pan 
KRAS KRAS Proto-Oncogene 
LDH   Lactate dehydrogenase 
M   Mitosis 
MCLA  2-methyl-6-[p-methoxyphenyll-3,7dihydroimidazo- 
1,2-alpyrazin-3-one 
MDA-MB-231 Human metastatic breast cancer cells 
MP   Melting Points 
 xxvii 
MS   Mass Spectroscopy 
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium 
Mts-Cl  2-mesitylenesulfonyl chloride 
MTT 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium 
bromide 
N2O2  Dinitrogen dioxide 
Na2HPO4 Disodium phosphate 
NAD   Nicotinamide adenine dinucleotide 
NAD+   Nicotinamide adenine dinucleotide 
NADH   Nicotinamide adenine dinucleotide proton 
NADPH  Nicotinamide adenine dinucleotide phosphate 
NBT 2,2′-bis(4-Nitrophenyl)-5,5′-diphenyl-3,3′-(3,3′-dimethoxy-
4,4′-diphenylene)ditetrazolium chloride 3,3′-(3,3′-
Dimethoxy-4,4′-biphenylene)bis[2-(4-nitrophenyl)-5-phenyl-
2H-tetrazolium chloride] 
NFkB1 Nuclear factor NF-kappa-Beta 1 
NH2   Amide 
NMR   Nuclear Magnetic Resonance 
NO•  Nitric oxide 
NO2   Nitrogen Dioxide 
NO2+  Nitronium 
NOS   Nitric Oxide Synthase 
•OH  Hydroxyl radical 
1O2  Singlet oxygen 
O=NOOCO2−  Nitrosoperoxycarbonate anion 
 xxviii 
O2•−  Superoxide 
O2NOCO2−  Nitrocarbonate anion 
O3  Ozone/Trioxygen 
ONO−  Peroxynitrite 
p21 Cyclin-dependent kinase inhibitor 1 
p27 Cyclin-dependent kinase inhibitor 1 Beta 
p38a P38 mitogen-activated protein kinase Alpha 
p53   Phosphoprotein 53 
PAT   Polyamine Transporter 
PBS Phosphate Buffered Saline 
Phospho-HSP27 Phosphorylated Heat Shock Protein Family A (Hsp70) Member 
1 Alpha 
Phospho-JNK Pan 
(T183/Y185)  Mitogen-Activated Protein Kinase 8 
PI Propidium Iodide 
pNA p-Nitroaniline 
PON1 Paraoxonase 1 
PON2 Paraoxonase 2 
PON3 Paraoxonase 3 
PPI Protein-protein Interaction 
PR- Progesterone receptor negative 
PR+ Progesterone receptor positive 
PS Phosphatidylserine 
PVDF Polyvinylidene fluoride 
R•  Organic radicals 
RO•  Alkoxyl radicals 
 xxix 
ROO•  Peroxyl radicals 
ROOH  Organic hydroperoxides 
ROS  Reactive Oxygen Species 
ROS•  Sulfonyl radicals 
RS•  Thiyl radicals 
RSOO•  Thiyl peroxyl radicals 
RSSR  Disulfides 
S   DNA Synthesis 
SDS Sodium dodecyl sulphate 
Sir2   Silent information regulator 2 
SIRT   Sirtuin 
SIRT2   Sirtuin 2 
SKBR-3  Human metastatic breast cancer cells 
SOD2 Superoxide dismutase 2 
SSB Singe-strand Break 
SSC   Saline Sodium Citrate 
TBS/T   Tris-buffered saline, 0.1% Tween 20 
TEMED Tetramethylethylenediamine 
THF   Tetrahydrofuran 
TLC   Thin Layer Chromatography 
Tm   The melting temperature 
TNBC Triple Negative Breast Cancer 
TNFα  Tumour Necrosis Factor Alpha 
trans,trans- 
BNIPDaCHM trans,trans-4,4’-methylenebis-cyclohexylamine 
bisnaphthalimidopropyl diaminodicyclohexylmethane  
 xxx 
Ts-Cl   p-toluenesulfonyl chloride 
TXN Thioredoxin-1 
UV   Ultraviolet 
WRN   Werner syndrome helicase 
XTT 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-
carboxanilide 
Zn2+   Zinc ion 
 
1 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1 
 
Introduction 
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1.1 Cancer: an overview 
Cancer remains a leading cause of death worldwide. Nowadays, more than 200 
different types of cancer that affect humans have been identified, with incidence 
and mortality rates increasing: 25 million of people are diagnosed with cancer 
worldwide and 7 million cancer patients die on an annual basis (Popat et al, 2013). 
More specifically, an estimated 3.45 million new cases of cancer (excluding non-
melanoma skin cancer) and 1.75 million deaths from cancer were reported in 
Europe in 2012 (Ferlay et al, 2013). Incidence rates by age and sex are reported 
in Figure 1.1, according to different areas and countrys in Europe (Ferlay et al, 
2013).  
According to the GLOBOCAN project 2012 statistics, female breast (464,000 
cases), followed by colorectal (447,000), prostate (417,000) and lung cancer 
(410,000) were the four most common cancer cases, representing half of the 
overall burden of all cancer in Europe (Ferlay et al, 2013). Mortality rates revealed 
that the most common causes of death from the disease, were from cancers of 
the lung (353,000 deaths), followed by colorectal (215,000), breast (131,000) 
and stomach cancers (107,000) (Ferlay et al, 2013). The estimated numbers of 
cancer cases in Europe were approximately 1.4 million in males and 1.2 million in 
females in 2012, while 707,000 men and 555,000 women died from cancer in the 
same year (Ferlay et al, 2013). The increased incidence rates over the last few 
decades are related to the current life-span extension and living standards in 
developed countries (João, 2013). 
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Figure 1.1.: Age-standardised incidence rates by sex, area and country in Europe 
2012: all cancers excluding non-melanoma skin cancers (From: Fenley et al, 2013). 
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Cancer is a class of diseases, associated with uncontrolled cell growth that leads 
to a build-up of abnormal cells due, to irregular cell proliferation. Therefore, cancer 
impairs a cell’s functionality and affects an organism’s ability to maintain 
homeostasis (Bertoli et al, 2013). The fundamental abnormality resulting in 
irregular cell proliferation is due to changes in cell cycle regulation (Burcham, 
2014). Cell cycle checkpoints are biological stoplights, able to interrupt the cell 
cycle in order to avoid the progression or production of dysfunctional cells. 
However, there are cells that do not obey the rules of the cell cycle: they overcome 
the multiple checkpoint machinery and begin to divide in an uncontrolled manner, 
forming masses of tissue or “lumps”, known as tumours (Burcham, 2014). 
Tumours or neoplasms are divided into two basic categories: the benign (non-
cancerous) and the malignant (cancerous) (Lawrence et al, 2014). Most of the 
time, a benign tumour grows in a non-aggressive way and remains in a particular 
part of the body without spreading to nearby tissues or forming new abnormal 
growths (neoplasia). On the other hand, a malignant tumour grows in an 
uncontrolled, aggressive way that results in cells invading surrounding tissues and 
spreading to other sites of the body, affecting healthy organs (Lawrence et al, 
2014). This cancer spreading process from a primary to a secondary cancer site 
is called metastasis and it can occur through the blood circulation or the lymphatic 
system (Lee et al, 2014).  
The main differences between benign and malignant tumours are that benign 
tumours are not invasive, do not metastasise and after being removed by surgery, 
rarely redevelop (Mangham and Kindblom, 2014). There is however a higher risk 
for a malignant tumour to reoccur after surgery. Cancer mortality is indeed mainly 
associated with the development and metastasis of malignant tumours (Ward et 
al, 2014).  
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Although benign tumours are non-cancerous, they can produce excess hormones 
(e.g. steroid hormones, such as aldosterone) and cause 10% of cancer deaths 
(Feldman et al, 2016). 
Both benign and malignant tumours share similar traits, known as the hallmarks 
of cancer, which were reported by Douglas Hanahan and Robert Weinberg in 2000 
(Hanahan and Weinberg, 2000). Hanahan and Weindberg described for the first 
time the six biological capabilities acquired during the development of all human 
tumours and in 2011, they proposed four additional hallmarks (Hanahan and 
Weinberg, 2011), which are the following: 
1. Cancer cells stimulate their own growth. 
2. They resist inhibitory signals that might otherwise stop their growth. 
3. They resist their programmed cell death. 
4. They can multiply indefinitely. 
5. They stimulate the growth of blood vessels to supply nutrients to tumours.  
6. They invade local tissue and spread to distant sites. 
7. They use abnormal metabolic pathways to generate energy. 
8. They are characterised by genomic instability. 
9. They evade the immune system. 
10. They promote inflammation. 
 
The hallmarks of cancer have proved influential in the understanding of cancer’s 
common traits, the mechanisms that underlie the ability of cancers to kill the 
patients and have helped the research community to gain insights into therapeutic 
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targets. In the recent years, researchers have revisited the hallmarks of cancer, 
suggesting the inclusion\exclusion of specific hallmarks (eg. invasion and 
metastasis are not shared by both benign and malignant growths, as mentioned 
above) (Lazebnik, 2000), which will emphasise the fact that cancer is not a single 
disease and that many hallmarks are variable among different tumour types 
(Fouad and Aanei, 2017). 
 
1.1.1 Breast cancer 
Breast cancer is the most common malignancy in women and according to 2008 
GLOBOCAN estimates, incidence approached 1.38 million cases per year 
worldwide (Ma and Ahmedin, 2013). In the United Kingdom, almost 54,833 
women and 389 men were diagnosed with breast cancer in 2014 (Cancer Research 
UK, 2014). Despite improvements in overall survival rates over the past 10 years, 
breast cancer still causes the most deaths after lung and colorectal cancers. 
Moreover, Western Europe has the highest incidence rates of breast cancer, which 
has been associated with lifestyle and environmental changes that occurred in the 
last decades, such as diet, smoking or radiation exposures (Munsell et al, 2014). 
An adult (female) breast consists of three main types of tissue: adipose tissue 
(fat), gland tissue (lobules) and connective tissue (Figure 1.1.1). During lactation, 
the lobules produce milk that is transferred to the nipples via a number of tubes, 
called lactiferous ducts and released from the aerola (Chinyama, 2014).  
A wide range of sex hormones (oestrogen, progesterone, prolactin and oxytocin) 
have an important impact on breast development and other major biological 
functions, like breast cell proliferation, division or milk production stimulation 
(Munsell et al, 2014). Breast growth and development are mainly promoted by 
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oestrogen, the levels of which are increased, during puberty and pregnancy. In 
men, the levels of oestrogen remain low, which explains why the male breast 
enlargement is limited (Munsell et al, 2014). Having said that, there are cases of 
breast enlargement in males, however it is rare (Cancer Research UK, 2016). This 
abnormal condition is called gynecomastia and can occur due to hormone 
imbalances (lower levels of testosterone), aging or malnutrition (Sandoval et al, 
2014). 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.1.: Anatomy of the breast and its compartments (From: Wexner Medical 
Center). 
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1.1.2 Different types of breast cancer  
According to Cancer Research UK statistics, there are about 100 different types 
and subtypes of breast cancer (Cancer Research UK, 2016). Ducts and lobules are 
the two parts of the breast that are mainly affected by cancer and as a result, 
these types of cancer are called ductal carcinoma or lobular carcinoma, 
respectively (Cancer Research UK, 2016). Almost 80% of breast cancer cases are 
ductal, 8% lobular and the rest a combination of the two (Hida et al, 2012). Cancer 
of the nipple (known as Paget’s disease of the breast) is the least common type 
and was first characterised in 1874, by Sir James Paget (Hida et al, 2012).  
In parallel, breast cancer, depending on its potential of spreading to nearby 
tissues, can also be characterised as non-invasive, invasive or inflammatory. In 
non-invasive breast cancer, the cancer cells remain restricted to the lobules or 
ducts and do not spread (Fernandez et al, 2013). Invasive ductal carcinoma (IDC) 
is the predominant breast cancer type, which begins in the ducts and then spreads 
to other parts of the breast or body. If the spread occurs in an aggressive way 
and blocks the lymph system of the breast, it is characterised as an inflammatory 
breast cancer (IBC). IBC can metastasise to the lymph nodes, lungs, liver, brain 
and bones (Fernandez et al, 2013).  
 
1.2 Risk factors 
Several studies have shown that breast cancer is a multifactorial disease, however 
its full aetiology remains unknown (Brinton et al, 2013). The most common risk 
factors that have been associated with the development of breast cancer are 
divided in two groups: the first group includes inherent factors such as age, sex, 
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genetics/heredity and race, while the second group includes extrinsic factors, such 
as lifestyle, diet and environment (Yang et al, 2011). 
Age is the first basic factor to be considered in the aetiology of the disease, as 
women around menopause develop breast cancer more frequently compared to 
women below 45 years of age (Kaminska et al, 2015). In addition, reproductive 
factors, such as younger age at menarche, older age at first birth, older age at 
menopause and hormonal factors, such as oestrogen receptor overexpression or 
hormone replacement therapy (HRT) (eg. oral contraceptives), have been also 
associated with the development of breast cancer (Kaminska et al, 2015). 
In relation to sex, it can be firmly stated that women are predominantly diagnosed 
with breast cancer (Gnerlich et al, 2011). Incidental occurrence in men is rare and 
mainly linked to excessive obesity and longer life expectancy (Gnerlich et al, 
2011). 
An additional intrinsic factor elevating the risk of breast cancer development are 
genetic/heredity factors. Almost 10% of breast cancers arise from hereditary 
mutations in breast cancer susceptibility genes (Yang et al, 2010). The majority 
of them are tumour suppressor genes and as a result, loss or reduction in their 
function leads to cancer progression. The most common mutations have been 
reported on Breast Cancer 1 (BRCA1), Breast Cancer 2 (BRCA2), followed by 
Phosphatase and tensin homolog (PTEN) and Tumour suppressor p53 (p53) genes 
(Figure 1.2) (Yang et al, 2010). Additional genes that have been added to the 
category of breast cancer susceptibility genes are ATM serine/threonine kinase 
(ATM), Checkpoint kinsase 2 (CHEK2), BRCA1 interacting protein C-terminal 
helicase 1 (BRIP1) and partner and localizer of BRCA2 gene (PALB2) (Figure 1.2).  
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Figure 1.2.: Hereditary mutations in breast cancer susceptibility genes (From: 
Yang et al, 2011). 
 
The above genes are involved in transcriptional regulation, control of cell cycle 
and induction of cell death and as a result, mutations in these genes are associated 
with high risk of hereditary breast cancer development (Yang et al, 2011). Patients 
who are positive for these mutations have an 80% risk in developing breast 
cancer, compared to individuals with the corresponding wild-type genes (Yang et 
al, 2011). However, gene mutations are only responsible for a small percentage 
(10%) of breast cancer development compared to the total number of breast 
cancers, which supports the existing evidence that breast cancer is a multifactorial 
disease (Abdulkareem, 2013).  
Race is another risk factor associated to breast cancer. More specifically, African 
American, Hispanic, and Asian women are less likely to develop breast cancer 
compared to white women, suggesting the impact of extrinsic factors, such as 
lifestyle, environment and diet, to the development of the disease (Kaminska et 
al, 2015). In addition, cases of breast cancer are higher in developed countries, 
due to dietary habits that often lead to excess weight or obesity (Kaminska et al, 
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2015). Further studies have revealed that several polymorphisms in breast cancer 
susceptibility genes in combination with exogenous factors that generate free 
radicals, such as pollution, alcohol consumption, or endogenous factors (oestrogen 
levels), increase the risk for breast cancer pathogenesis (Abdulkareem, 2013). 
 
1.2.1 Reactive Oxygen Species 
Increased generation of oxygen radicals, ions and molecules, known as Reactive 
Oxygen Species (ROS), within cells results in deoxyribonucleic acid (DNA) 
damage, tumour development and progression. ROS are mainly produced as 
inevitable by-products during mitochondrial electron transport of oxidative 
phosphorylation (Ray et al, 2012). Recent studies have revealed a dual role of 
ROS, depending on their intracellular levels (Figure 1.2.1) (Ramis et al, 2015). 
Physiological levels of ROS are responsible for cellular stress responses that 
promote cell survival, while high levels of ROS can cause oxidative damage to 
important macromolecules, such as DNA, proteins and lipids, changing their 
structure and functions (Ramis et al, 2015). These changes contribute to the 
progression of cancer, as well as to a wide range of inflammatory diseases, 
ischemic diseases and neurological disorders (Ramis et al, 2015). In addition, ROS 
can act as both intra- and inter-cellular messenger and play an important role in 
cell signalling, activating cell death processes such as apoptosis (Sena and 
Chandel, 2012). 
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Figure 1.2.1.: Dual role of ROS levels (Adapted from: Ramis et al, 2015). 
 
In almost all cancers, elevated ROS levels have been detected and appear to 
promote tumour development and progression, by altering redox balance and 
deregulating redox signalling due to genetic, metabolic and microenvironment-
associated alterations (Liou et al, 2010, Panieri and Santoro, 2016). However, 
tumour cells tend to express increased levels of antioxidant enzymes or molecules, 
such as catalase, glutathione peroxidase (GPX) and peroxiredoxins (Prx), to 
detoxify ROS by reducing them to water (Liou et al, 2010, Liou and Storz, 2014), 
suggesting a dual role of ROS. Thus, it has been suggested that cancer cell 
function can be maintained only via a delicate balance of intracellular ROS levels, 
similar to the one maintained in healthy cells (Trachootham et al, 2008). Changes 
in cellular function are dependentent on the type of the radical that is generated, 
the location of its generation and its concentration (Bayr, 2005). However, high 
levels of ROS in cancer cells are mainly produced due to increased metabolic 
activity, mitochondrial dysfunction, oncogene activity, peroxisome activity, 
increased cellular receptor signalling or increased activity of oxidases (Liou et al, 
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2010). In addition, macrophages induce the generation of ROS within tumour cells 
through secretion of various molecules, such as TNFα (Sena and Chandel, 2012). 
Within tumour cells, NADPH oxidase initiates the formation of superoxide that later 
on leads to the production of hydrogen peroxide and apoptotic cell death. This is 
the typical cellular response to stress: to leave the cell cycle and enter into G0 
(cells enter into a quiescent state, neither dividing nor preparing to divide) 
(Duronio and Xiong, 2013). In other words, continuous exposure to and/or high 
levels of ROS, can trigger apoptotic mechanisms. Therefore, novel anti-cancer 
therapeutic strategies are focusing on the development of drugs to promote ROS-
induced apoptotic signalling in cancer cells and ensure the fine tuning of 
intracellular ROS levels after treatment (Vurusaner et al, 2012). 
 
1.2.2 ROS-mediated signalling pathways 
ROS-mediated signalling pathways are elevated in many types of cancer and seem 
to affect cell growth and proliferation, glucose metabolism and cell inflammation 
(Liou and Storz, 2014). Currently, three ROS-mediated signalling pathways have 
been reported: the mitogen-activated protein (MAP) kinase/ extracellular signal-
regulated kinase (Erk) cascade, the phosphoinositide-3-kinase (PI3K)/ Protein 
kinase B (Akt)-regulated signalling cascade and the IκB kinase (IKK)/nuclear 
factor κ-B (NF-κB)-activating pathway (Liou and Storz, 2014). 
The activation of the MAPK (mitogen-activated protein kinase)/Erk1/2 
(extracellular-regulated kinase 1/2) pathway in cancer is mediated through ras 
and growth factors, such as epidermal growth factor receptor (EGFR) (Khavari and 
Rinn, 2007, Roberts and Der, 2007). In breast cancer cells, Erk1/2 is activated by 
hydrogen peroxide that is generated as a by-product during oestrogen 
 
14 
metabolism, increasing cell proliferation (Reddy and Glaros, 2007). On the other 
hand, Akt (protein kinase B) mediates cell survival through phosphorylation and 
inactivation of pro-apoptotic proteins (Bad, Bax, Bim) and transcription factors 
(FOXO) (Xin et al, 2005, Qi et al, 2006). In breast cancer, ROS generation has 
been found to activate the PI3K/Akt signaling pathway (Park et al, 2009). NF-κB, 
which is a redox-regulated sensor for oxidative stress, is mainly activated by low 
doses of hydrogen peroxide that activate the NF-κB-inducing kinase (NIK) and the 
IκB kinase (IKK) complex (Li and Karin, 1999). IKK is phosphorylated on serine 
residues, enabling its ubiquitination and degradation. Upon IKK degradation, NF-
κB is translocated to the nucleus (Karin, 2008). Then, NF-κB acts as a transcription 
factor, inducing the expression of anti-apoptotic and anti-inflammatory genes 
(Karin, 2008).  
The above pathways indicate the involvement of ROS in cancer development, by 
affecting all characters of cancer cell behaviour, including cell cycle progression, 
proliferation, DNA damage and cell death (Liou and Storz, 2014), suggesting the 
need for more detailed understanding of ROS-mediated signalling, in order to 
develop new strategies for ROS-based therapeutics against cancer cells.  
 
1.3 Epigenetics and cancer 
Epigenetics is defined as the study of heritable changes in gene activities that 
occur without changes in the DNA sequence (Schemies et al, 2009). Epigenetic 
modifications, like DNA methylation or histone acetylation and deacetylation, alter 
the gene function and can cause mutations, responsible for the development of 
diseases (Dawson and Kouzarides, 2013). In 1983, cancer was the first disease to 
be associated with epigenetics, when researchers found that there was loss of DNA 
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methylation in the diseased tissue of colorectal cancer patients, compared to the 
healthy tissue (Feinberg and Vogelstein, 1983). 
Epigenetic information is stored in DNA/protein complexes, known as chromatins. 
The fundamental unit of chromatins is the nucleosome, which consists of an 
octamer of four core histones (H3, H4, H2A, H2B) (Rivera and Bennett, 2010). 
Histones are positively charged proteins that structure DNA into nucleosomes, by 
interacting with its negatively charged phosphate groups. Histones are 
predominantly globular; however, their N-terminal tails are unstructured and 
susceptible to a large number and type of modifications (Rivera and Bennett, 
2010). Histones recruit several enzyme complexes in order to manipulate DNA. 
Thus, histone modifications have a direct effect on fundamental biological 
processes, such as gene transcription, DNA replication and DNA repair, which can 
be epigenetically inherited (Biswas and Rao, 2017). 
More specifically, eight different classes of histone modifications have been 
reported (Table 1.3.1) and seem to disrupt the levels of histones, deregulate the 
control of chromatin-based processes and ultimately lead to oncogenic 
transformation and the development of cancer (Kouzarides, 2007). 
The majority of these modifications are the result of reversible acetylation of lysine 
residues, which are clustered at the basic amino-terminal domains of histones 
(Kouzarides, 2007). Consequently, these residues interact ionically with the 
negatively charged phosphates of the DNA backbone, resulting in charge 
neutralization and separation of histones from the DNA (Kouzarides, 2007).  
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Table 1.3.1.: Different classes of modification identified on histones and function 
that they regulate (Adapted from: Kouzarides, 2007). 
 
Abbreviations: ac=Acetylation, me=Methylation, ph=Phosphorylation, ub=Ubiquitylation, 
su=Sumoylation, ar=ADP ribosylation, K=Lysine, R=Arginine, S=Serine, T=Threonine, 
E=Glutamic acid. 
The level of histone acetylation is controlled by two families of enzymes, histone 
acetyltransferases (HATs) and histone deacetylases (HDACs). Histone acetylation 
is catalysed by HATs that neutralise the charge of histone proteins, leading to DNA 
loosening (Bannister and Kouzarides, 2011). Histone acetylation is associated with 
DNA repair and proliferation, as well as with chromosomal organisation (Bannister 
and Kouzarides, 2011). On the other hand, HDACs are enzymes divided into four 
classes that enhance the ability of histones to wrap tightly around the DNA 
(Bannister and Kouzarides, 2011). HDAC overexpression can decrease the levels 
of histone acetylation and compact DNA/histone complex, in a way that gene 
transcription and differentiation can be blocked (Woan et al, 2011). 
Chromatin 
Modifications 
Residue 
Modification 
Functions Regulated 
Acetylation K-ac 
Transcription, Repair, Replication, 
Condensation 
Methylation (lysines) 
K-me1 
K-me2 
K-me3 
Transcription, Repair 
Methylation (arginines) 
R-me1 
R-me2a 
R-me2s 
Transcription 
Phosphorylation 
S-ph 
T-ph 
Transcription, Repair, 
Condensation 
Ubiquitylation K-ub Transcription, Repair 
Sumoylation K-su Transcription 
ADP ribosylation E-ar Transcription 
Deimination R > Cit Transcription 
Proline Isomerization P-cis > P-trans Transcription 
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The activity of HDACs can highly modify the chromatin structure and their 
functional importance is highlighted by the fact that their deregulation has been 
linked to the progression of cancers, such as leukaemia, colorectal and breast 
cancer (Toh et al, 2017). Therefore, identification of therapeutic targets which 
involves the ability of potential agents to inhibit HDAC activity has received much 
attention. 
 
1.3.1 HDAC inhibitors in cancer treatment 
Over the last few years, HDAC inhibitors have been considered as potential anti-
cancer therapeutic agents and nowadays, several derivatives (see Table 1.3.1.1), 
such as Vorinostat (cutaneous T cell lymphoma) and Belinostat (peripheral T cell 
lymphoma) have been approved and licensed for cancer treatment, as they were 
found to inhibit HDAC activity (Ceccacci and Minucci, 2016, Seidel et al, 2014). 
HDACs are classified based on their functional and phylogenetic criteria (Marks, 
2010). More specifically, HDACs are divided into Zn2+-dependent (Class I, II and 
IV) and Zn2+-independent, NAD-dependent (class III - sirtuins) enzymes. 
Currently, the majority of inhibitors being developed target class I, II and IV 
enzymes (Seidel et al, 2014). 
However, new evidence has shown that the class III HDACs, which are 
homologous related to yeast Silent information regulator 2 (Sir2) protein family 
and are well distributed in several cellular locations (nucleus, cytoplasm and 
mitochondria), are critical transcriptional regulators (Tang, 2016). 
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Table 1.3.1.1: HDAC inhibitors classified according to status of clinical 
advancement, targeted HDACs and chemical class (Adapted from: Valente and Mai, 
2014). 
Compound Target Class Highest phase trial 
Panobinostat (LBH-
589) 
Pan-HDAC 
inhibitor 
Hydroxamic 
acids 
Approved in 2015 
for multiple 
myeloma 
Belinostat (PXD101) Pan-HDAC 
inhibitor 
Hydroxamic 
acids 
Approved in 2014 
for PTCL 
Romidepsin 
(desipeptide-FK228) 
Pan-HDAC 
inhibitor 
Cyclic 
tetrapeptides 
Approved in 2009 
for CTCL 
SAHA(Vorinostat, 
Zolinza) 
Pan-HDAC 
inhibitor 
Hydroxamic 
acids 
Approved in 2006 
for CTCL 
 
Abbreviations: CTCL=cutaneous T-cell lymphoma, PTCL=peripheral T-cell lymphoma. 
 
The function of HDACs and their potential as therapeutic targets has become an 
area of intense investigation in cancer treatment. With regards to breast cancer, 
the first clinical study evaluating the co-administration of an HDAC inhibitor 
(vorinostat) with an anti-estrogen (tamoxifen) in advanced breast cancer patients 
was reported in 2015 (Raha et al, 2015). For the very first time, there was a 40% 
clinical benefit (19% objective response and 21% stable disease for more than 6 
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months) in patients who did not respond to earlier anti-estrogen therapies and 
chemotherapy (Raha et al, 2015). The same study demonstrated that another 
HDAC inhibitor, entinostat, can reverse hormone therapy resistance when 
combined with the aromatase inhibitor exemestane. Therefore, although the 
understanding of the mechanism that underlies HDAC effectiveness is still 
unknown, HDACs are currently among the most promising therapeutic targets for 
cancer treatment. 
 
1.4 Cancer therapeutics: use and limitations of chemotherapy 
Radiotherapy, hormone therapy, surgery and chemotherapy are existing 
treatments used for breast cancer therapy. More specifically, chemotherapy is 
used to treat different types of cancer, based on the use of anti-cancer compounds 
that are able to recognise and attack fast-dividing cells. In breast cancer, the 
drugs are provided to patients in tablet form (e.g. Cyclophosfamide) or 
intravenously (e.g. Adriamycin), depending on the dosage and application (Siden 
and Wolf, 2013). As cancer diagnosis has increased, not only due to the rise of 
cancer incidence, but also due to the improved diagnostic technologies (e.g. 
Mammograms, Magnetic Resonance Imaging, Elastograms), researchers aim to 
develop novel anti-cancer compounds and study their effects on cancer cells 
(Leong et al, 2013), in order to overcome existing limitations (i.e. 
chemoresistance) in current treatments. 
More specifically, breast cancer, depending on whether or not it develops in 
response to the hormone oestrogen, is divided in two categories: oestrogen 
dependent (ER+) and oestrogen independent (ER-) cancer (Redmond et al, 2015). 
ER+ breast cancers respond better to anti-oestrogen (endocrine) therapies, such 
as tamoxifen and exemestane, by inhibiting the effect of oestrogen and decreasing 
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the uncontrolled proliferation of breast cancer cells (Redmond et al, 2015). On the 
other hand, ER- breast cancers are more invasive and less responsive to current 
standard of care treatment regimes, such as Adrucil (fluorouracil), Ellence 
(epirubicin) and Adriamycin (doxorubicin), which do not selectively target breast 
cancer cells hence leading to severe side effects, especially when they are used in 
combination (Becorpi et al, 2014). Therefore, researchers have focused on the 
development and clinical application of novel cancer-specific therapies that will act 
on potential molecular targets. Nucleic acids are such an example of molecular 
targets, that could potentially increase the selectivity against breast cancer cells, 
reduce treatment resistance and/or adverse severe side effects (Lehmann and 
Pietenpol, 2013). 
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1.4.1 DNA binding properties of compounds with therapeutic potential 
Over the last few decades, studies in cancer chemotherapy have focused on 
derivatives being able to interact directly with nucleic acids and specifically with 
deoxyribonucleic acid (DNA) (Palchaudhuri and Hergenrother, 2005). A variety of 
small molecules, often referred to as ligands (e.g. ifosfamide), have been classified 
into three categories: compounds that bind covalently to cell DNA, such as 
alkylating agents, compounds that cause breakage of the DNA molecule (e.g. 
bleomycins), or compounds that bind to DNA either by intercalating among the 
base pairs of its double strand or by external binding to its major/minor groove 
(e.g. netropsin) (Figure 1.4.1) (Ali and Bhattacharya, 2014).  
 
Figure 1.4.1.: Chemical structures of agents that interact with DNA. 
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1.4.2 Synthesis of mononaphthalimide and bisnaphthalimide derivatives 
Naphthalimido compounds were first synthesised in 1970’s (Chen et al, 1993). A 
naphthalimido compound consists of three fused 6-membered rings with a basic 
terminal group in one of its side chains, which is critical for its cytotoxic activity 
(Porter et al, 1985). The first series of naphthalimides had variations not only on 
side chains, but ring substituents, too. More specifically, when the nitrogen atom 
in the basic side chain was separated from the ring nitrogen atom by methylene 
units, maximum growth inhibition in HeLa cervical cancer and KB epidermal 
carcinoma of the mouth cells was obtained (Brana and Ramos, 2001; Brana et al, 
2001). This showed that naphthalimido compounds were found to be highly active 
against cancer cell lines in vitro, however once clinical trials were undertaken, they 
induced multiple side effects, such as myelosupression and dementia (Llombart et 
al, 1992; Brana et al, 2001, 2004), probably due to high dose toxicity, resulting 
in considerable mortality (Lyman, 2009). 
However, the increased anti-cancer activity of naphthalimido derivatives had led 
Brana and others to design and synthetise novel symmetrical compounds, the 
bisnaphthalimides (Brana et al, 2001, Dance et al, 2005). The main characteristic 
of bisnaphthalimido compounds was a linker sequence that would join the two 
naphthalimido units together, in order to improve the therapeutic properties of 
precursor mononaphthalimides (Brana et al, 2001). Indeed, the use of polyamine 
linker sequences were found to improve the in vivo and in vitro activity of 
bisnaphthalimides and their DNA intercalating properties (Brana et al, 2001). 
Intercalating agents are able to insert themselves between DNA base pairs 
(reversible inclusion) and interfere with DNA transcription and replication. In 
addition, Brana and Ramos (2001) also proved that different pharmacophore 
substitutions (NO2 > H > NH2 > CH3CONH) and the length of linker chain could 
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improve compound cytotoxicity. However, the aqueous insolubility of 
bisnaphthalimides was a main disadvantage for their potential use as 
chemotherapeutic agents, even if there was strong evidence that 
bisnaphthalimides could be further developed to be suitable anti-cancer drugs. 
 
1.4.3 Synthesis of novel bisnaphthalimidopropyl polyamine derivatives 
In order to overcome the insolubility issues of bisnaphthalimides, Kong Thoo Lin 
and Pavlov designed and synthesised in 2000, a number of bisnaphthalimidopropyl 
derivatives (BNIPs), by incorporating natural polyamines in the bisnaphthalimide 
linker chain. Polyamines were previously proved to be promising carriers in 
delivering cytotoxic drugs into cancer cells, thus a promising target for therapeutic 
intervention in cancer research. The addition of two or more amide (NH2) groups 
in the aliphatic chain improved their aqueous solubility, as well as their biological 
activity. Cancer cells have higher polyamine levels compared to normal cells due 
to an active polyamine transporter (PAT) (Phanstiel et al, 2007). Synthesis of 
naturally occurring polyamine analogues (with a polyamine linker) that inhibit the 
polyamine synthesis metabolic pathway by targeting PAT on cancer cells could 
lead to targeted drug delivery. Kong Thoo Lin and Pavlov (2000) combined both 
the characteristics of naphthalimides and polyamines, forming the 
bisnaphthalimidopropyl polyamine derivatives (BNIPPs): Bis-naphthalimidopropyl 
putrescine (BNIPPut), spermidine (BNIPSpd), spermine (BNIPSpm) and oxa-
putrescine (BNIPOPut) were tested for their cytotoxicity and proved to be highly 
toxic anti-cancer agents (Figure 1.4.3) (Kong Thoo Lin and Pavlov, 2000).  
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Figure 1.4.3.: Chemical structures of bisnaphthalimidopropyl polyamine 
derivatives: BNIPPut, BNIPOPut, BNIPSpd, BNIPSpm and BNIPOSpm. 
 
Interestingly, the main outcome of the above studies was that the shorter the 
linker chain, the higher the cytotoxicity of the compound is and the presence of 
more heteroatoms, the better the solubility.  
In 2005, Brana et al determined that symmetry in the structure was also an 
important factor for cytotoxicity and, according to these studies, non-symmetrical 
BNIPPs were less toxic than symmetrical BNIPPs.   
Research focused on the synthesis of BNIPPs was continued by Dance et al. 
(2005), who introduced oxygen atoms into the α-position of the naphthalimido 
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ring, enhancing the solubility of previously synthesised derivatives, but decreasing 
their cytotoxicity. Oliveira et al. (2007) showed that depending on the nature of 
the polyamine linker chain and increasing length, its aqueous solubility was 
increased. Barron et al. (2010) demonstrated how modification in the central 
linker chain of BNIPs, either by removing nitrogen atoms or by substituting with 
cyclohexane rings, can result in higher cytotoxicity levels. 
However, there were still important questions about BNIPs: whether structural 
isomers possess different cytotoxic and DNA-binding properties and which 
modifications could further improve BNIP solubility, cytotoxicity and DNA 
intercalation. This has lead to the design and synthesis of more effective novel 
BNIPs which will be tested in this thesis in the context of cancer treatment in 
different in vitro models of breast cancer. 
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1.5 Aims and thesis layout 
The aims of this project were to investigate the mode of action of newly 
synthetised BNIPs in an in vitro cell system, which could be used as new 
chemotherapeutic drugs for breat cancer treatment. 
Based on previous findings (Kong Thoo Lin and Pavlov, 2000, Pavlov et al, 2001, 
Dance et al, 2005, Ralton 2006, Oliveira et al, 2007, Ralton et al, 2009, Barron et 
al, 2010), where either BNIPPs or BNIPs were found to possess cytotoxicity against 
several types of cancer cells, such as MCF-7 (breast cancer), CaCO-2 (colon 
cancer) or HL-60 (human leukaemia), the aim was to synthesise three novel BNIPs 
that would possess higher cytotoxicity towards breast cancer cells compared to 
previously synthetised BNIPs and/or anticancer drugs that are currently used in 
the clinic. After trying various chemical structure modifications on the parental 
compound Bisnaphthalimidopropyl diaminodicyclohexylmethane (BNIPDaCHM), 
questioning whether cytotoxicity differs among structural isomers, whether the 
length of the linker chain, the ring structure position or the existence of 
stereoisomers affects the cytotoxicity, the Bisnaphthalimidopropyl-
piperidylpropane (BNIPPiProp), bisnaphthalimidopropyl- ethylenedipiperidine 
dihydrobromide (BNIPPiEth) and trans,trans-4,4’-methylenebis-cyclohexylamine 
bisnaphthalimidopropyl diaminodicyclohexylmethane (trans,trans-BNIPDaCHM) 
were synthetised, characterised (Chapter 2) and tested for their DNA binding 
affinities through a number of studies, including thermal denaturation of DNA, 
EtBr displacement and UV binding studies (Chapter 3). 
Human MDA-MB-231 and SKBR-3, two highly metastatic breast cancer cell lines 
that do not respond to current chemotherapy treatments (Denkert et al, 2016, Loi 
et al, 2016), were used to test BNIPDaCHM, BNIPPiProp, BNIPPiEth and 
trans,trans-BNIPDaCHM with regards to theirs cytotoxicity, production of 
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intracellular ROS and DNA damage, confirming or not the importance of 
bisnaphthalimido moiety for biological activity (Chapter 4) and also to extend the 
knowledge on BNIP derivative cytotoxicity against different breast cancer cell 
types and their mode of action. 
Furthermore, investigations into the mode of cell death were undertaken, by 
examining the cell cycle distribution and induction of early apoptosis or autophagy, 
by treating human MDA-MB-231 and SKBR-3 cells with BNIPDaCHM, BNIPPiProp, 
BNIPPiEth and trans,trans-BNIPDaCHM (Chapter 5). 
Finally, the effect of BNIPs on HDAC activity, with emphasis on SIRT2 and cell 
stress-related proteins were studied and protein-protein interaction (PPI) network 
analysis and bioinformatic analysis were undertaken to link the proteins of interest 
for further research and validation towards the delineation of the 
mode/mechanisms of BNIPs action in breast cancer (Chapter 6). The full thesis 
layout is presented on Figure 1.5. 
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Figure 1.5.: Layout of thesis. 
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CHAPTER 2 
 
Synthesis and characterisation of novel 
bisnaphthalimidopropyl derivatives 
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2.1 Introduction 
2.1.1 Aims 
The aim of the presented experimental work in Chapter 2 was the synthesis of 
three novel BNIPs that would possess higher cytotoxicity towards breast cancer 
cells. Various chemical structure modifications of the BNIPs have been tried and 
the synthesis was based on previous methods that have been used within Robert 
Gordon University by Kong Thoo Lin and Pavlov (2000) and Barron et al (2010). 
The three BNIPs that were synthesised and characterised are 
bisnaphthalimidopropyl-piperidylpropane (BNIPPiProp), bisnaphthalimidopropyl- 
ethylenedipiperidine dihydrobromide (BNIPPiEth) and trans,trans-4,4’-
methylenebis-cyclohexylamine bisnaphthalimidopropyl 
diaminodicyclohexylmethane (trans,trans-BNIPDaCHM) (Figure 2.1.1). The first 
BNIP, BNIPPiProp is a structural isomer of BNIPDaCHM that consists of only one 
species (enantiopure). The aim of synthesising BNIPPiProp was to investigate 
whether cytotoxicity and DNA binding properties differ amongst structural isomers 
and how the position of the saturated ring structure in the linker chain affects 
cytotoxicity in breast cancer cells.  The second BNIP, BNIPPiEth, consists of one 
carbon less between the two piperidine ring structures, compared to BNIPPiProp 
and was synthesised in order to assess the effect of a shorter linker chain on 
cytotoxicity and DNA binding properties. In parallel, it is still unknown whether 
the cytotoxicity of BNIPDaCHM is associated with the existence of the three 
isomers in its structure, therefore (trans(trans))-4,4’-Methylenebis 
(cyclohexylamine), the only commercially available stereoisomer precursor 
required to synthesise trans,trans-BNIPDaCHM the latter being, the third BNIP 
used in this study. The synthesis of trans,trans-BNIPDaCHM lead to the 
investigation into the importance of this stereoisomer compared to the mixture  
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Figure 2.1.1.: Chemical structures of BNIPs: BNIPDaCHM with its three stereo 
isomers, bisnaphthalimidopropyl-piperidylpropane (BNIPPiProp), 
bisnaphthalimidopropyl- ethylenedipiperidine (BNIPPiEth) and trans,trans-
4,4’Methylenebis(cyclohexylamine) bisnaphthalimidopropyl 
diaminodicyclohexylmethane (trans,trans-BNIPDaCHM).  
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of three stereoisomers of unknown relative proportion present in BNIPDaCHM in 
relation to DNA binding affinities, cytotoxicity in breast cancer cell lines and the 
possible mode of cell death.  
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2.1.2 Synthetic method of bisnapthalimidopropyl derivatives. 
The first BNIPPs were synthesised by Kong Thoo Lin and Pavlov (2000) and the 
synthetic strategy they proposed was also used for the synthesis of BNIPPiProp, 
BNIPPiEth and trans,trans-BNIPDaCHM (Kopsida et al, 2016). 
The synthesis of the three novel BNIPs consisted of two step reactions: firstly, the 
synthesis of the common precursor N-(3-hydroxypropyl)naphthalimide, prepared 
from the reaction of 1,8-naphthalic anhydride with 3-amino-1-propanol (Figure 
2.1.2a[1]) and secondly, the synthesis of toluenesulfonyloxypropylnaphthalimide, 
prepared from N-(3-hydroxypropyl)naphthalimide with p-toluenesulfonyl chloride 
in pyridine (Figure 2.1.2a[2]).  
BNIPPiProp was obtained from the reaction between 1,3-bis-(4-piperidyl)propane 
and toluenesulfonyloxypropylnaphtalamide in tetrahydrofuran (THF) at 50 oC for 
15 minutes, fitted with a reflux condenser and in the presence of caesium 
carbonate (Cs2CO3) (Figure 2.1.2b). Synthesis of BNIPPiProp dihudrobromide salt 
was obtained upon dissolution of BNIPPiProp base in dichloromethane (DCM) and 
treatment with hydrogen bromide (HBr)/acetic acid (CH3CO2H) at room 
temperature for 2 hours to yield a precipitate. The latter was filtered off by vacuum 
filtration and washed with DCM and ether. 
BNIPPiEth was prepared upon the reaction of 4,4 Ethylenedipiperidine with 
toluenesulfonyloxypropylnaphthalimide, in the presence of caesium carbonate in 
THF overnight at 60 C (Figure 2.1.2b). Synthesis of BNIPPiEth dihydrochloride 
salt was completed upon reaction with concentrated HCl in DCM at room 
temperature for 60 minutes (Figure 2.1.2b). 
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Figure 2.1.2a.: General synthetic method for the synthesis of BNIPPs: [1] 3-
amino-1-propanol, DMF/DBU, 85°C, 5 hours [2] p-toluenesulfonyl chloride (Ts-
Cl), anhydrous pyridine, 4 °C, 12 hours.   
 
35 
 
 
 
Figure 2.1.2b.: Synthetic pathway of bisnaphthalimidopropyl-piperidylpropane 
(BNIPPiProp) and bisnaphthalimidopropyl- ethylenedipiperidine dihydrobromide 
(BNIPPiEth). 
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The synthesis of trans,trans-BNIPDaCHM was based on methods previously 
developed in our group for the synthesis of BNIPDaCHM (Kong Thoo Lin and 
Pavlov, 2000, Barron et al, 2010). Here the single isomer (trans(trans))-4,4’-
methylenebis-cyclohexylamine was used as the starting material. The synthesis of 
trans,trans-N4,N4-dimesityl-dicyclohexylmethane was carried out by reacting 
(trans(trans))-4,4’-methylenebis-cyclohexylamine with 2-mesitylenesulfonyl 
chloride (Mts-Cl) in anhydrous pyridine (Figure 2.1.2c). N-Alkylation was 
performed by reacting trans,trans-N4,N4-dimesityl-dicyclohexylmethane with 
toluenesulfonyloxypropylnaphthalimide in dimethylformamide (DMF). For the final 
step, trans,trans-bisnaphthalimido-dimesityl-dicyclohexylmethane was dissolved 
in DCM, followed by treatment with hydrobromic acid/glacial acetic acid 
(HBr/g.CH3CO2H) (Figure 2.1.2c) to obtain the novel BNIP trans,trans-
BNIPDaCHM. 
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Figure 2.1.2c.: Synthetic pathway of trans,trans-4,4’-
methylenebis(cyclohexylamine) bisnaphthalimidopropyl 
diaminodicyclohexylmethane (trans,trans-BNIPDaCHM). 
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2.1.3 Separation, identification and characterisation of BNIPs. 
Thin Layer Chromatography (TLC), Nuclear Magnetic Resonance (NMR) and Mass 
Spectrometry (MS) were the three analytical techniques that were applied for the 
characterisation of the three novel BNIPs. 
TLC is a method used for separating compounds of a mixture and determining the 
number of co-existing components in the mixture, the purity and identity of the 
final compound (Geiss, 1987). During the synthesis of all the compounds, TLC was 
used to observe the appearance or disappearance of reactants, while monitoring 
the progress of a chemical reaction.  
TLC is a sensitive, quick and low cost technique that consists of three basic steps: 
spotting, development and visualisation. The first step requires the sample to be 
dissolved in volatile solvent (5% v/v solution). By using a micro pipette, a small 
amount of this solution is transferred to one end of a TLC plate (silica gel 
aluminium plate). Once the spotting solvent evaporates, a small spot of material 
appears on the TLC plate (Stoddard et al, 2007). The next step is to place the 
bottom of the TLC place in a TLC development tank with a solvent, which moves 
upwards due to capillary action. Between the silica gel plate and the development 
solvent, there is a competition where the silica gel (polar) tries to keep the spot 
in its original place whilst the solvent moves further up the TLC plate. Once the 
solvent has almost moved to the other side of the plate, the plate is removed, the 
solvent front is marked and the TLC plate is left to dry (Figure 2.1.3). The spots 
of coloured compounds can be directly observed after the development step. 
However, most of the compounds are colourless and a visualisation method is 
required to observe the movement of material along the plate. The most common 
detection method is to observe the TLC plate under ultraviolet (UV) light, as the 
silica gel plates are permeated with fluorescent material so that every material 
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appears as a dark spot. The quantification of the material movement is expressed 
by the Rf value, which is equal to the distance of the substance divided by the 
distance of the solvent. 
 
Figure 2.1.3.: Silica gel plate and calculation of Rf value, where Rf=y/x (always 
≤1). 
 
NMR is an analytical tool used for determining and characterising the complete 
chemical structure of an organic compound. Compared to other spectroscopic 
methods, NMR is the only technique that can provide a complete elucidation of an 
unknown compound from only a few milligrams of the sample. The samples are 
prepared in NMR tubes, by dissolving the compound in deuterated solvents, such 
as chloroform-D (CDCl3). Afterwards, samples are introduced into the NMR 
instrument and processed by Bruker Topspin Software which produces the NMR 
spectrum.  
The main principle of this analytical tool is the ability to capture a phenomenon 
occurring once specific atomic nuclei (usually proton and carbon-13 nuclei) are in 
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a static magnetic field: if the nuclei possess a property called nuclear spin, then it 
is exposed to a second oscillating magnetic field (Koutcher and Burt, 1984). 1 H-
NMR and 13 C-NMR detect the signals of protons and carbons respectively and 
DEPT-135 NMR, which is another 13 C-NMR experiment, can supply further 
information on the different type of carbons present within a compound, such as 
the –CH3 and –CH signals which appear above the baseline, whilst the –CH2 signals 
appear inverted and quaternary carbons signals disappear. 1H-NMR (400.1 MHz), 
13C-NMR (100.6 MHz) and DEPT-135 NMR (100.6 MHz) are observed at different 
frequencies, as the proton nucleus processes faster than the carbon nucleus, 
requiring higher frequency radiation. 
Although NMR spectroscopy can provide important information about the entire 
chemical structure of a compound, Mass Spectrometry (MS) is an appropriate 
analytical tool that can determine and confirm the purity and molecular mass of 
the final compound (Yurek et al, 2002). For all the BNIPs that were synthesised in 
this project, MS was used to confirm their full characterisation.  
Mass spectrometers consist of three fundamental parts: the ionisation source, the 
analyser and the detector. Once the sample is introduced into the ionisation 
source, sample molecules are ionised and extracted into the analyser region. At 
that point, the charged molecules are separated according to their mass (m) to 
charge (z) ratios (m/z) (Smith et al, 1991). 
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2.2 Materials 
A list of the reagents that were used during the synthesis and characterisation of 
the novel BNIPs are presented below. All the reagents were manipulated according 
to the COSHH standards. 
1,8-naphthalic anhydride     Sigma-Aldrich, UK 
3-amino-1-propanol      Sigma-Aldrich, UK 
1,8-diazabicylo[5.4.0]undec-7-ene (DBU)   Sigma-Aldrich, UK 
Dimethylformamide (DMF)     Fisher Scientific, UK 
Pyridine (anhydrous)      Sigma-Aldrich, UK 
p-toluenesulfonyl chloride (Ts-Cl)    Sigma-Aldrich, UK 
4,4’-methylenebis(cyclohexylamine)    TCI, Japan 
2-mesitylenesulfonyl chloride (Mts)    Sigma-Aldrich, UK 
Caesium carbonate      Alfa Aescar, UK 
Hydrobromic acid/glacial acetic acid    Sigma-Aldrich, UK 
Dichloromethane (DCM)      Fisher Scientific, UK  
1,3-bis-(4-piperidyl)propane     Sigma-Aldrich, UK 
Tetrahydrofuran (THF)      Sigma-Aldrich, UK 
4,4-Ethylenedipiperidine dihydrochloride   Sigma-Aldrich, UK 
Sodium hydroxide       Sigma-Aldrich, UK 
Diethyl ether       Fisher Scientific, UK 
Ethanol        Acros Organics, Belgium 
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Hydrochloric acid       Sigma-Aldrich, UK 
Methanol       Acros Organics, Belgium 
Chloroform-D       Cambridge Isotope, USA 
Dimethylsulfoxide-d6     Cambridge Isotope, USA 
 
2.3 Instrumentation 
Thin Layer Chromatography (TLC) assays were carried out to verify the completion 
and purity of the products. TLCs were performed on 2cm×5cm silica gel 60 F254 
aluminium plates (Merck, Germany). One % (v/v) methanol in dichloromethane 
solution was used as mobile phase and the spots were visualized under UV light 
(254nm-375nm). 
Nuclear Magnetic Resonance (NMR) spectroscopy was performed on a Bruker 400 
Ultrashield spectrometer, using chloroform-D (CDCl3) or dimethyl-sulfoxide 
(DMSO-D6). 
Mass spectral analysis was undertaken at the Engineering and Physical Sciences 
Research Council National Mass Spectrometry Centre at Swansea University, 
Swansea, UK.  
Thermal melting points (MP) were defined by using the standard operating 
procedure of Griffin Melting Point Apparatus (Fisher Scientific, UK). 
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2.4 Results and Discussion: Synthesis of bisnaphthalimidopropyl-
diaminodicyclohexylmethane (BNIPDaCHM) 
2.4.1 Synthesis of N-(3-hydropropyl) naphthalimide 
 
 
Figure 2.4.1a.: Synthesis of N-(3-hydropropyl)naphthalimide. 
 
In a round bottom flask (250cm3), 1,8-naphthalic anhydride (Molecular mass (M) 
= 198.17 g mol-1, Number of moles (n) = 0.050 mol, 10 g) was dissolved in 
dimethylformamide (DMF) (140 mL) (Figure 2.4.1a). Once the 1,8-naphthalic 
anhydride was totally dissolved, 3-amino-1-propanol (M = 75.11 g mol-1, n = 
0.050 mol, 3.75 g) and 1,8-diazabicylo[5.4.0]undec-7-ene (DBU) (13 mL) were 
added. The reaction was left to stir for 5 hours at 85 °C. Reaction completion was 
monitored with TLC and once completed, the solution was poured into icy water 
(200 mL) while stirring with a glass rod to allow formation of a white precipitate. 
The precipitate was filtered off by vacuum filtration, followed by several water 
washes, and dried in a vacuum oven set at 45 °C overnight. The pure product was 
characterised using 1H-NMR. Yield was calculated as: 53.9% 
 
N-(3-hydroxypropyl) naphthalimide 1 H-NMR (CDCl3): δH 8.66 – 8.63 (2H, aromatic 
H, doublet, J=7.2 Hz), 8.29 – 8.25 (2H, aromatic H, doublet, J=8.4 Hz), 7.83 – 
7.78 (2H, aromatic H, doublet, J=8.0 Hz), 4.41-4.38 (3H, triplet, J=5.6 Hz), 3.64-
 
44 
3.59 (2H, CH2, multiplet ) 3.23 (OH,  singlet) and 2.06–2.00 (2H, CH2 multiplet) 
parts per million (ppm). 
 
Figure 1.4.1b.: Equivalent protons of N-(3-hydroxypropyl)naphthalimide.  
 
Chemical shifts corresponding to protons situated at the aromatic carbons c, a, 
and b of the naphthalimido group resonated at 8.66-8.63 ppm, 8.29, 8.25 ppm 
and 7.83-7.778 ppm respectively (Figure 2.4.1b). Integration analysis within the 
aromatic region of the spectrum showed that the signals correspond to six 
hydrogens, hence were assigned to protons a, b and c. The chemical shift of the 
solvent signal was observed at 7.26 ppm (chloroform-d). At 4.41-4.38 ppm, 
aliphatic peaks resonated for protons d, due to the deshielding effect from nitrogen 
and oxygen atoms. Signal for protons at carbon f occurred upfield, at 3.64-3.59 
ppm, for protons on carbon e at 2.06–2.00 ppm and the chemical shift 
corresponding to proton of the OH group (g) resonated at 3.23ppm. 
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2.4.2 Synthesis of toluenesulfonyloxypropylnaphthalimide 
       
Figure 2.4.2a.: Synthesis of toluenesulfonyloxypropylnaphthalimide. 
 
In a round bottom flask (150cm3), N-(3-hydropropyl)naphthalimide (M = 255.27 
g mol-1, n = 0.0196 mol, 5.0 g) was dissolved in anhydrous pyridine (70 mL), 
whilst stirring on ice. Once the N-(3-hydropropyl)naphthalimide was completely 
dissolved, p-toluenesulfonyl chloride (Ts-Cl) (M = 190.65 g mol-1, n = 0.0394 mol, 
7.51 g, 2.01 excess) was slowly added to the reaction (Figure 2.4.2a). The 
reaction was left at 4 °C overnight. It was monitored using TLC and once it was 
complete, the solution was poured into icy water (200 mL) and stirred with a glass 
rod until a precipitate was formed. After vacuum filtration and several washes with 
water, the final product was left to dry under negative pressure in a vacuum oven 
at 45°C for 3 hours. The product was recrystallised from ethanol and characterised 
by 1H-NMR. Yield was calculated as: 68.2% 
Toluenesulfonyloxypropylnaphthalimide 1H-NMR (CDCl3): δH 8.59 – 8.57 (2H, 
aromatic H, doublet, 8.2 Hz), 8.25 – 8.23 (2H, aromatic H, triplet, 7.2 Hz), 7.81– 
7.76 (2H, multiplet), 7.30 (2H, aromatic H, doublet, 1.2 Hz), 4.27-4.20 (2H, CH2, 
multiplet), 2.44 (3H, CH3 , singlet) and 2.19–2.12 (2H, CH2, multiplet) ppm. 
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Figure 2.4.2b.: Equivalent hydrogens of toluenesulfonyloxypropyl-
naphthalimide. 
 
Chemical shifts corresponding to protons situated at carbons c, a and b of the 
naphthalimido group resonated at 8.59–8.57 ppm, 8.25–8.23 ppm and 7.81–7.78 
ppm respectively (Figure 2.4.2b). Integration analysis within the aromatic region 
showed that the signals correspond to six hydrogens, hence were assigned to 
protons a, b and c respectively. The chemical shift of the solvent signal was 
observed at 7.26 ppm (chloroform-d). At 4.27-4.20 ppm, aliphatic peaks 
resonated for CH2 protons f and downfield when compared with d, since nitrogen 
atom is less electronegative (3.0) than the oxygen atom (3.5). Signal for proton i 
was detected at 2.44 ppm and the chemical shift corresponding to proton e 
resonated at 2.19-2.12 ppm. Chemical shifts for g and h resonated downfield at 
7.81–7.76 ppm, between protons a and b.  
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2.4.3 Synthesis of N4,N4-dimesityl-dicyclohexylmethane  
 
Figure 2.4.3a.: Synthesis of N4,N4-dimesityl-dicyclohexylmethane. 
 
In a round bottom flask (50cm3), 4,4’-methylenebis(cyclohexylamine) (M = 
210.36 g mol-1, n= 4.75x10-3 mol, 1.0 g) was added in anhydrous pyridine (10 
mL) and left to stir for 15 minutes. After dissolution, 2-mesitylenesulfonyl chloride 
(Mts) (M = 218.70 g mol-1; n = 9.56x10-3 mol; 2.1 g) was added (Figure 2.4.3a). 
The reaction was left to stir overnight at room temperature and TLC confirmed 
reaction completion. The solution was poured into icy water (150 mL) and stirred 
with a glass rode until the formation of a precipitate. The product was filtered off 
by vacuum filtration, left to dry in a vacuum oven set at 45 °C for 24 hours. The 
product was afterwards characterised by 1H-NMR. Yield of the reaction was 
calculated as: 43.3%. 
N4,N4-dimesityl-dicyclohexylmethane 1H-NMR (CDCl3): δH 7.30 (NH), 6.97 (4H, CH 
aromatic protons), 2.99 (4H, CH protons), 2.67-2.66 (6H, CH3-Mts protons) and 
1.73-1.49 (CH2 and cyclohexane protons) ppm. 
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Figure 2.4.3b.: Equivalent hydrogens of N4,N4-dimesityl-dicyclohexylmethane. 
 
The NMR signal for the NH proton d resonated at 7.30 ppm, due to the deshielding 
effect of the electronegative sulfonamide group (Figure 2.4.3b). Chemical shifts 
corresponding to aromatic proton b resonated at 6.97 ppm and the signal for the 
methane proton e observed further upfield at 2.99 ppm. Chemical shifts 
corresponding to methyl groups on the aromatic ring resonated at 2.67-2.66 ppm 
and 2.21 ppm respectively. Signals for protons at carbons f, g and h of the 
cyclohexane ring were detected upfield between 1.75-1.43 ppm. Chemical shift 
corresponding to methylene group i resonated further upfield at 1.04 ppm. Due to 
signals overlapping and the co-existance of three isomers in the above compound, 
the assignment of the rest signals was difficult to assign. 
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2.4.4 N-alkylation reaction  
 
Figure 2.4.4a.: Synthesis of protected bisnaphthalimidopropyl-dimesityl-
dicyclohexylmethane. 
 
In a round bottom flask (50cm3), N4,N4-dimesityl-dicyclohexylmethane (M = 
574.83 g mol-1, n = 6.968x10-4 mol, 0.4 g) and 
toluenesulfonyloxypropylnaphthalimide (M = 409.46 g mol-1; n = 1.400x10-3 mol,  
0.57 g, 2.01 excess) were dissolved in DMF (8 mL). Afterwards, excess of caesium 
carbonate (M = 325.82 g mol-1, n = 3.5x10-3 mol, 1.13 g, 2.5 excess) was added 
slowly (Figure 2.4.4a).  
The reaction was left to stir for 48 hours at 60 °C. After TLC confirmed the reaction 
was complete, the solution was poured into icy water (150 mL) to form a 
precipitate. After vacuum filtration and several washes with water, the product 
was left to dry under negative filtration in a vacuum oven at 45 °C for 3 hours. 
The product was recrystallised with pure ethanol and characterised by 1H-NMR. 
Yield was calculated as: 92.2%. 
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Protected bisnaphthalimido-dimesityl-dicyclohexylmethane 1H-NMR (CDCl3): δH 
8.50–8.47 (2H, aromatic H), 8.18–8.15 (2H, aromatic H), 7.72–7.67 (2H, 
aromatic H), 6.87 (2H, CH-Mts H), 6.55–6.53 (2H, CH-Mts H), 3.94–3.92 (2H, 
CH2), 3.12–3.10 (2H, CH2), 2.87-2.80 (2H, CH2), 2.35-2.32 (3H, CH3), 2.05-2.04 
(3H, CH3), 1.61-1.58 (H, CH), 1.61 (2H,CH2) 1.49-1.37 (2H, CH) and 1.04 (2H, 
CH2) ppm. 
13C-NMR (CDCl3): δH 163.87-162.76 (C=O), 134.36 (C aromatic), 131.40-130.74 
(C aromatic), 127.75 (C aromatic), 35.75 (CH2), 30.41 (CH2), 21.97 (CH3) and 
20.32 (CH3) ppm. 
 
Figure 2.4.4b.: Equivalent proton and carbons of bisnaphthalimido-dimesityl-
dicyclohexylmethane. 
Chemical shifts corresponding to protons situated at carbons a, b and c of the 
naphthalimide rings resonated at 8.50-7.67 ppm (Figure 2.4.4b). Integration 
analysis within the aromatic region showed that the signals correspond to six 
hydrogens, hence were assigned to protons a, b and c respectively. The chemical 
shift of the solvent signal was observed at 7.26 ppm (chloroform-d). At 6.87 ppm 
and 6.55-6.53 ppm, chemical shifts corresponded to protons that were situated 
on the N4,N4-dimesityl-dicyclohexylmethane methyl groups were detected. Signal 
for proton d was detected next upfield, due to the deshielding effect from nitrogen 
and oxygen atoms, the signal for proton f and h were observed upfield at 3.12–
3.10 ppm and 2.87-2.80 ppm, respectively. Chemical shifts corresponding to 
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protons of the methyl groups on the N4,N4-dimesityl-dicyclohexylmethane 
aromatic ring resonated at 2.35-2.04 ppm. Further upfield, the proton signal for 
carbon e was detected at 1.61-1.58 ppm and for i and j at 1.61 ppm, respectively. 
Chemical shifts corresponding to protons situated at k resonated at 1.49-1.37 ppm 
and for i at 1.04 ppm. 
For the 13C spectrum, chemical shifts corresponding to the amide carbon of the 
naphthalimido ring resonated at 163.87-162.76 ppm and for a, b and c at 134.36-
127.17 ppm. At 35.75 ppm, the chemical shift corresponded to i and j of the 
cyclohexane ring and further upfield, the chemical shift for k resonated at 30.41 
ppm. The next upfield, chemical shifts corresponded to the methyl groups of 
N4,N4-dimesityl-dicyclohexylmethane were detected at 21.97 and 20.32 ppm, 
respectively. 
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2.4.5 Deprotection reaction 
 
 
Figure 2.4.5a.: Synthesis of bisnaphthalimidopropyl-diamino-dicyclohexyl-
methane dihydro-bromide salt (BNIPDaCHM). 
 
In a round bottom flask (50cm3), bisnaphthalimido-dimesityl-
dicyclohexylmethane (M = 1049.53 g mol-1, n = 3.813x10-4 mol, 0.4 g) was 
dissolved in dichloromethane (DCM) (8 mL). Afterwards, hydrobromic acid/glacial 
acetic acid (HBr/CH3CO2H) (1 mL) was added drop wise (Figure 2.4.5a). The 
reaction was stirred overnight at room temperature. TLC was used to confirm that 
the reaction was complete. The precipitate formed, was filtered off by vacuum 
filtration and washed with DCM (15 mL) and ether (5 mL). The final product was 
dried under negative pressure in a vacuum oven set at 45 °C for 3 hours. Once 
dry, the final product was characterised by 1H-NMR (Figure 2.4.5b), 13C-NMR 
(Figure 2.4.5c) and DEPT-135 NMR. Yield was calculated as 37.5% and the relative 
molecular mass of bisnaphthalimidopropyl-diamino-dicyclohexylmethane 
(BNIPDaCHM) was confirmed by mass spectral analysis (Figure 2.4.5e). 
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Figure 2.4.5b.: 1H-NMR spectrum for BNIPDaCHM. 
 
Bisnaphthalimidopropyl-diamino-dicyclohexylmethane dihydro-bromide salt 1H-
NMR (CDCl3) (Figure 2.4.5b): δH 8.32–8.25 (2H, aromatic Hs), 7.73–7.65 (2H, 
aromatic Hs), 3.70–3.64 (2H, CH2 protons), 3.13 (2H, CH2 protons), 2.90-2.30 
(3H, CH3 protons), 2.09-2.02 (3H, CH3 protons), 1.83-1.80 (H, CH proton), 1.43-
1.33 (2H, CH2 protons) ppm. 
 
54 
 
Figure 2.4.5c.: 13C-NMR spectrum for BNIPDaCHM. 
 
13C-NMR (CDCl3) (Figure 2.4.5c): δ 163.87-162.76 (C=O), 134.36 (C aromatic), 
131.40-130.74 (C aromatic), 127.75 (C aromatic), 35.75 (CH2) and 30.41 (CH2) 
ppm. 
 
 
Figure 2.4.5d.: Equivalent protons and carbons of bisnaphthalimidopropyl-
diamino-dicyclohexylmethane dihydro-bromide salt (BNIPDaCHM). 
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Figure 2.4.5e.: High resolution mass spectrum of BNIPDaCHM: M+=630.3344. 
 
The chemical shifts for the final product BNIPDaCHM resonated on a similar way, 
as for bisnaphthalimido-dimesityl-dicyclohexylmethane (Section 2.4.5b). The 
absence of resonance signals corresponding to protons which were present from 
the methyl groups of N4,N4-dimesityl-dicyclohexylmethane confirmed that the 
reaction was complete and that BNIPDaCHM was formed. However, the aromatic 
rings could not be assigned accurately, due to the mixture of isomers (cis,cis or 
trans,trans, or trans,cis) that makes the assignment of peaks more complex.  
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2.5 Results and Discussion: Synthesis of bisnaphthalimidopropyl-
piperidylpropane (BNIPPiProp) 
2.5.1 Synthesis of bisnaphthalimidopropyl-dipiperidyl-propane base 
 
Figure 2.5.1a.: Synthesis of BNIPPiProp free base. 
 
In a round bottom flask (50cm3), 1,3-bis-(4-piperidyl)propane (M = 210.36g/mol, 
n = 1.19 x10-3mol, 0.25g) and toluenesulfonyloxypropylnaphtalamide (M = 
409.46 g mol-1, n = 2.39 x10-3mol, 0.98g) were dissolved in tetrahydrofuran 
(THF)(6 mL). Using a reflux condenser, the reaction was stirred at 50oC for 15 
minutes and after the addition of caesium carbonate (M = 325.82 g mol-1, n = 
3.069 x10-3 mol, 1 g), the reaction was left to stir overnight at 50 oC (Figure 
2.5.1a). The reaction was monitored with TLC and once complete, the solution 
was poured into icy water (100 mL). A precipitate was formed and after vacuum 
filtration, the product was dried in a vacuum oven at 45 oC overnight. The crude 
product (base of BNIPPiProp) was recrystallised in ethanol and the pure product 
was characterised by 1 H-NMR. Yield was calculated as: 64.8%. 
1 H-NMR : δH 8.53–8.51 (2H, CH aromatic protons), 8.14–8.12 (2H, CH aromatic 
protons), 7.70–7.66 (2H, CH aromatic protons), 4.17–4.14 (2, CH2 protons), 
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2.84–2.82 (2H, CH2 protons), 2.41–2.37 (2H, CH2 protons), 1.91-1.83 (2H, CH2 
protons), 1.79-1.74 (2H, CH2 protons), 1.51-1.48 (2H, CH2 protons), 1.71-1.09 
(H, CH protons) ppm.  
                       
Figure 2.5.1b.: Equivalent hydrogen of BNIPPiProp base. 
 
As expected, chemical shifts which corresponded to protons of naphthalimido 
rings, at carbons a, b and c resonated between 8.53-7.66 ppm (Figure 2.5.1b). 
Integration analysis within the aromatic region of the spectrum showed that the 
signals correspond to six hydrogens, hence were assigned to protons a, b and c, 
respectively. The chemical shift of the solvent signal was observed at 7.26 ppm 
(chloroform). At 4.17-4.14 ppm, aliphatic peaks resonated as a triplet for d, due 
to the existence of two adjacent protons on carbon e. The signal for proton e was 
detected upfield, due to the deshielding effect from nitrogen atoms and next to 
them, the chemical shifts corresponding to protons situated at carbons r, h, i, j 
and k were resonated.   
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2.5.2 Synthesis of BNIPPiProp salt 
 
 
Figure 2.5.2a.: Synthesis of BNIPPiProp salt. 
In a round bottom flask (50cm3), the base of BNIPPiProp (M = 685.05 g mol-1, n 
= 1.459 x10-3 mol, 1 g) was dissolved in DCM (20mL) and HBr/CH3CO2H (2 mL) 
was added slowly (Figure 2.5.2a). The reaction was stirred for 2 hours at room 
temperature and reaction completion was monitored by TLC yielding a precipitate. 
The precipitate was filtered off by vacuum filtration and washed with DCM (30 mL) 
and ether (10 mL). The BNIPPiProp salt was dried under negative pressure in a 
vacuum oven set at 45 oC for 2 hours and the pure product was characterised by 
1H-NMR (Figure 2.5.2b), 13C-NMR (Figure 2.5.2c) and DEPT-135 NMR. Yield was 
calculated as 72.3%. The relative molecular mass of bisnaphthalimidopropyl-
piperidylpropane was confirmed by mass spectral analysis (Figure 2.5.2e). 
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Figure 2.5.2b.: 1H-NMR spectrum for BNIPPiProp. 
1 H-NMR (CDCl3) (Figure 2.5.2b): δH 8.53–8.51 (2H, CH aromatic protons), 8.14–
8.12 (2H, CH aromatic protons), 7.70–7.66 (2H, CH aromatic protons), 4.69 (2H, 
CH2 protons), 4.17–4.14 (2H, CH2 protons), 2.84–2.82 (2H, CH2 protons), 2.41–
2.37 (2H, CH2 protons), 1.91-1.83 (2H, CH2 protons), 1.79-1.74 (2H, CH2 
protons), 1.51-1.48 (2H, CH2 protons), 1.71-1.09 (H, CH proton) ppm. 
 
Figure 2.5.2c.: 13C-NMR spectrum for BNIPPiProp. 
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13C-NMR (CDCl3) (Figure 2.5.2c): δH 164.24 (C=O), 131.87 (CH aromatic), 131.60 
(C aromatic), 131.24 (CH aromatic), 127.75 (C aromatic), 126.94 (CH aromatic), 
122.80 (C aromatic), 56.58 (CH2), 54.03 (CH2), 39.10 (CH2 aromatic), 36.77-
35.69 (CH), 32.34 (CH2), 25.33 (CH2) and 23.76 (CH2) ppm. 
               
Figure 2.5.2d.: Equivalent protons and carbons of BNIPPiProp salt. 
 
 
Figure 2.5.2e.: High resolution mass spectrum of BNIPPiProp: M+=685.3733. 
For the BNIPPiProp salt, chemical shifts resonated on a similar way, as for the 
BNIPPiProp free base, as they are structurally similar compounds. However, in its 
13C spectrum, the chemical shifts of the aliphatic carbons were weak and difficult 
to assign (Figure 2.5.2c). 
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2.6 Results and Discussion: Synthesis of bisnaphthalimidopropyl- 
ethylenedipiperidine (BNIPPiEth) 
2.6.1 Synthesis of 4,4-Ethylenedipiperidine 
 
Figure 2.6.1.: Synthesis of 4,4-Ethylenedipiperidine 
In a round bottom flask (50cm3), 4,4-Ethylenedipiperidine dihydrochloride (M = 
269.25 g mol-1, n = 7.428x10-4 mol, 0.2 g) was dissolved in distilled water (2 mL), 
Sodium hydroxide (2M, 1mL) was added until the pH of the solution was 14, 
resulting in the formation of a precipitate (Figure 2.6.1). The. The resulting 
solution was transferred into a separating funnel (100 mL) followed by extraction 
with DCM (300 mL). The organic layer was collected, dried with sodium sulfate 
and filtered. The solvent was evaporated off by a rotary film evaporator. The final 
white solid product was left to dry under negative pressure in a vacuum oven at 
45 C for 30 minutes. The synthesis of the free base was confirmed by 1H-NMR. 
Yield was calculated as 90.6%. 
 
1H-NMR (CDCl3): δ 2.98–2.95 (2H, CH2 protons), 2.52–2.45 (2H, CH2 protons), 
1.8 (NH), 1.60–1.57 (2H, CH2 protons), 1.25–1.21 (H, CH protons) and 1.19–1.16 
(2H, CH2 protons) ppm.  
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2.6.2 Synthesis of BNIPPiEth base 
 
Figure 2.6.2a.: Synthesis of BNIPPiEth base. 
In a round bottom flask (50cm3), 4,4 Ethylenedipiperidine (M = 198.25 g/mol, n 
= 5.044 x10-4 mol, 0.1 g) was reacted with toluenesulfonyloxypropyl-
naphthalamide (M = 409.46 g mol-1, n = 1.001 x10-3 mol, 0.41 g, 2.01 excess) 
(Figure 2.6.2a). Caesium carbonate (M = 325.82 g mol-1, n = 3.069 x10-3 mol, 1 
g) was added in the reaction. All the reagents were dissolved in THF (6 mL) and 
the solution refluxed overnight at 60 oC. The reaction was monitored using TLC. 
Once the reaction was complete, the solution was poured into icy water (100 mL), 
which resulting in the formation of a precipitate. The precipitate was filtered using 
a Buchner funnel and the product was left to dry under negative pressure in a 
vacuum oven at 45 C for 60 minutes. The crude product was recrystallised from 
ethanol and the pure product was characterised by 1 H-NMR. The yield of the 
reaction was calculated as 72.3%. 
1 H-NMR (CDCl3): δH 8.52–8.50 (2H, CH aromatic protons), 8.13–8.11 (2H, CH 
aromatic protons), 7,69–7.65 (2H, CH aromatic protons), 4.18–4.14 (2H, CH2 
protons), 2.83–2.80 (2H, CH2 protons), 2.40–2.36 (2H, CH2 protons), 1.90-1.83 
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(2H, CH2 protons), 1.79-1.71 (2H, CH2 protons), 1.48 (2H, CH2 protons), 1.2(H, 
CH protons) and 1.00-0.80 (2H, CH2 protons) ppm. 
                 
Figure 2.6.2b.:  Equivalent protons for BNIPPiEth. 
 
The chemical shifts corresponding to protons situated at carbons a, b and c of the 
naphthalimido rings resonated at 8.52-7.65 ppm (Figure 2.6.2b). Integration 
analysis within the aromatic region of the spectrum allowed identification between 
the signals a, b and c, respectively. At 4.18-4.14 ppm, aliphatic peaks resonated 
as a triplet for d, due to the existence of two adjacent protons. Signal for e was 
detected next, due to the shielding from nitrogen atoms and furthest upfield 
chemical shifts were the peaks protons at positions for h, i and j, respectively. 
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2.6.3 Synthesis of BNIPPiEth salt 
 
 
Figure 2.6.3.a: Synthesis of BNIPPiEth salt. 
 
In a round bottom flask (50cm3), BNIPPiEth (0.1g) was dissolved in DCM (20 mL). 
Then, HCl (1.5 mL) was added to the flask and the solution stirred at room 
temperature for 60 minutes, which resulted in the formation of a pale, blue 
precipitate (Figure 2.6.3a). The precipitate was filtered and washed with ether (50 
mL) and afterwards with ethanol (50 mL). The product was left under negative 
pressure in a vacuum oven at 45 C for 60 minutes. The final product of BNIPPiEth 
was characterised by 1 H-NMR, 13 C-NMR and DEPT-135 NMR. Yield was calculated 
as 29.5%. The relative molecular mass of BNIPPiEth was confirmed by mass 
spectral analysis (Figure 2.6.3e). 
 
65 
 
Figure 2.6.3b.: 1H-NMR spectrum for BNIPPiEth 
 
1 H-NMR (CDCl3) (Figure 2.6.3b): δH 8.42–8.38 (2H, CH aromatic protons), 7,82–
7.78 (2H, CH aromatic protons), 4.05–4.01 (2H, CH2 protons), 2.7 (2H, CH2 
protons), 2.44 – 2.43 (2H, CH2 protons), 2.05 (2H, CH2 protons), 1.70-1.67 (2H, 
CH2 protons), 1.35-1.32 (H, CH protons) and 1.090 (2H, CH2 protons) ppm. 
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Figure 2.6.3c.: 13C-NMR spectrum for BNIPPiEth. 
 
13 C-NMR (CDCl3) (Figure 2.6.3c): δH 164.10 (C=O), 134.81 (CH aromatic), 131.76 
(C aromatic), 131.18 (CH aromatic), 127.92 (C aromatic), 127.68 (CH aromatic), 
122.59 (C aromatic), 55.40 (CH2), 52.27 (CH2), 37.79 (CH), 29.43 (CH2) 23.04 
(CH2) and 22.54 (CH2) ppm. 
 
                    
Figure 2.6.3d.: Equivalent protons and carbons for BNIPPiEth salt. 
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Figure 2.6.3e.: High resolution mass spectrum of BNIPPiEth: M+=671.3572. 
 
For the BNIPPiEth salt, chemical shifts are resonated in a similar way, as that for 
BNIPPiEth free base. However, for the 13C spectrum, the aliphatic chemical shifts 
were weak and hard to be assigned, as observed with the analysis of BNIPPiProp 
salt. 
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2.7 Results and Discussion: Synthesis of trans,trans-
bisnaphthalimidopropyl diaminodicyclohexylmethane (trans,trans-
BNIPDaCHM) 
2.7.1 Synthesis of trans,trans-N4,N4-dimesityl-dicyclohexylmethane 
 
Figure 2.7.1a.: Synthesis of trans,trans-N4,N4-dimesityl-dicyclohexylmethane. 
 
In a round bottom flask (25cm3), trans,trans-4,4’-methylenebis(cyclohexylamine) 
(M = 210.37 g mol-1, n= 2.38x10-4 mol, 0.05 g) was added in anhydrous pyridine 
(1.5 mL) and left to stir for 15 minutes with warming. After dissolution, 2-
mesitylenesulfonyl chloride (Mts) (M = 218.70 g mol-1; n = 4.76x10-4 mol; 0.10 
g) was added (Figure 2.7.1a). The reaction was left to stir overnight at room 
temperature and TLC confirmed reaction completion. The solution was poured into 
icy water (10 mL) and stirred with a glass rod until the formation of a precipitate. 
The suspension was centrifuged and was washed 3 times with distilled water and 
the precipitate was left to dry under negative pressure in a vacuum oven set at 
45 °C for overnight. The product was afterwards characterised by 1H-NMR. Yield 
was calculated as: 21%. 
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N4,N4-dimesityl-dicyclohexylmethane 1H-NMR (CDCl3): δH 7.31 (NH), 6.98 (4H, CH 
aromatic protons), 3.87 (4H, CH protons), 2.67 (6H, CH3-Mts protons), 2.33 (3H, 
CH3-Mts protons), 1.84-1.82 (CH2-cyclohexane ring), 1.65-1.62 (CH2-cyclohexane 
ring), 1.16-1-10 (CH-cyclohexane ring) and 0.99-0.95 (CH2 cyclohexane protons) 
ppm. 
 
Figure 2.7.1b.: Equivalent hydrogen atoms of trans, trans-N4,N4-dimesityl-
dicyclohexylmethane. 
 
The NMR signal for proton d resonated at 7.31 ppm, due to the deshielding effect 
of the electronegative sulfur dioxide group (Figure 2.7.1b). Chemical shifts 
corresponding to aromatic proton b resonated at 6.98 ppm and the signal for e 
observed further upfield at 3.87 ppm. Chemical shifts corresponding to methyl 
protons situated at carbon c and a of the aromatic ring resonated at 2.67 ppm and 
2.33 ppm respectively. Signals for protons at carbons f, g and h of the cyclohexane 
ring were detected upfield, at 1.84-1.82 ppm, 1.65-1.62 ppm and 1.16-1.10 ppm. 
Chemical shift corresponding to i resonated further upfield at 0.99-0.95 ppm. 
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2.7.2 N-alkylation reaction  
 
Figure 2.7.2a.: Synthesis of protected trans,trans-bisnaphthalimidopropyl-
dimesityl-dicyclohexylmethane. 
 
In a round bottom flask (25cm3), trans, trans-N4,N4-dimesityl-
dicyclohexylmethane (M = 574.83 g/mol, n = 6.44x10-5 mol, 0.037 g) and 
toluenesulfonyloxypropylnaphthalimide (M = 409.46 g mol-1; n = 1.29x10-4 mol,  
0.053 g, 2.01 excess) (synthesis of toluenesulfonyloxypropylnaphthalimide has 
been detailed in Section 2.4.2) were dissolved in DMF (1 mL). Afterwards, excess 
of caesium carbonate (M = 325.82 g mol-1, n = 3.07x10-4 mol, 0.1 g, 5.0 excess) 
was added slowly (Figure 2.7.2a).  
The reaction was left to stir for 48 hours at 60 °C. After TLC confirmed the reaction 
was complete, the solution was poured into icy water (10 mL) to form a 
precipitate. The suspension was applied to centrifugation and was washed twice 
with distilled water. The product was left to dry under negative filtration in a 
vacuum oven at 45 °C for 24 hours. The crude product (59 mg, 88%) was purified 
using column chromatography and the final product (25 mg) was characterised by 
1H-NMR. Yield was calculated as: 37%. 
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Protected bisnaphthalimido-dimesityl-dicyclohexylmethane 1H-NMR (CDCl3): δH 
8.65–8.59 (2H, CH aromatic protons), 8.30–8.25 (2H, CH aromatic protons), 
7.84–7.78 (2H, CH aromatic protons), 6.65–6.60 (4H, CH-Mts protons), 4.41–
4.38 (2H, CH2 protons), 4.06–4.04 (2H, CH2 protons), 3.71-3.68 (2H, CH2 
protons), 2.68 (3H, CH3 protons), 2.46-2.44 (3H, CH3 protons), 2.34 (H, CH 
protons), 2.16-2.15 (2H,CH2 protons) 1.84 (2H, CH protons) and 1.73-1.71 (2H, 
CH2 protons) ppm. 
13C-NMR (CDCl3): δH 141.93(C=O), 138.76 (C aromatic), 135.17 (C aromatic), 
131.95 (C aromatic), 43.72 (CH2), 33.93-31.99 (CH2), 23.02 (CH3) and 20.97 
(CH3) ppm. 
 
Figure 2.7.2b.: Equivalent proton and carbons of trans,trans-bisnaphthalimido-
dimesityl-dicyclohexylmethane. 
 
Chemical shifts corresponding to protons situated at carbons a, b and c of the 
naphthalimide rings resonated at 8.65-7.78 ppm (Figure 2.7.2b). Integration 
analysis within the aromatic region showed that the signals correspond to six 
hydrogens, hence were assigned to protons a, b and c respectively. The chemical 
shift of the solvent signal was observed at 7.30 ppm (chloroform). At 6.65 ppm, 
chemical shifts corresponded to protons that were situated on the trans,trans-
N4,N4-dimesityl-dicyclohexylmethane methyl groups were detected. Signal for 
proton d was detected next upfield at 4.41-4.38 ppm, due to the deshielding effect 
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from nitrogen and oxygen atoms, the signal for proton f and h were observed 
upfield at 4.06-4.04 ppm and 3.71-3.68 ppm, respectively. Chemical shifts 
corresponding to protons of the methyl groups on the N4,N4-dimesityl-
dicyclohexylmethane aromatic ring resonated at 2.68 ppm and 2.46-2.44 ppm. 
Further upfield, the proton signal for carbon e was detected at 2.34 ppm and for i 
and j at 2.16-2.15 ppm, respectively. Chemical shifts corresponding to protons 
situated at k resonated at 1.84 ppm and for l at 1.73-1.71 ppm. 
 
From the 13C spectrum, chemical shifts corresponding to the amide carbon of the 
naphthalimido ring resonated at 141.93 ppm and for a, b and c at 138.76-131.95 
ppm. At 43.72 ppm, the chemical shift corresponded to i and j of the aromatic ring 
and further upfield, the chemical shift for k resonated at 33.93-31.99 ppm. The 
next upfield, chemical shifts corresponded to the methyl groups of trans,trans-
N4,N4-dimesityl-dicyclohexylmethane were detected at 23.02 ppm and 20.97 
ppm, respectively. 
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2.7.3 Deprotection reaction 
 
 
Figure 2.7.3a.: Synthesis of trans,trans-bisnaphthalimidopropyl-diamino-
dicyclohexylmethane dihydro-bromide salt (trans,trans-BNIPDaCHM). 
 
In a round bottom flask (10cm3), trans,trans-bisnaphthalimido-dimesityl-
dicyclohexylmethane (M = 1049.53 g mol-1, n = 2.38x10-5 mol, 25mg) was 
dissolved in dichloromethane (DCM) (1.0 mL). Afterwards, hydrobromic 
acid/glacial acetic acid (HBr/CH3CO2H) (0.2 mL) was added slowly (Figure 2.7.3a). 
The reaction was stirred overnight at room temperature. TLC was used to confirm 
that the reaction was complete. The suspension formed was transferred to 
Eppendorf tubes and centrifuged, washed with DCM (1.0 mL) and ether (1.0 mL). 
The final product was dried under negative pressure in a vacuum oven set at 45 
°C for 3 hours to give the product as a white solid (8.3 mg). Once dry, the final 
product was characterised by 1H-NMR, 13C-NMR and DEPT-135 NMR. Yield was 
calculated as 41% and the relative molecular mass of trans,trans-
bisnaphthalimidopropyl-diamino-dicyclohexylmethane (trans,trans-BNIPDaCHM) 
was confirmed by mass spectral analysis (Figure 2.7.3e). 
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Figure 2.7.3b.: 1H-NMR (DMSO-d6 solvent) spectrum for trans,trans-
BNIPDaCHM. 
 
Bisnaphthalimidopropyl-diamino-dicyclohexylmethane dihydro-bromide salt 1H-
NMR (CDCl3) (Figure 2.7.3b): δ 8.53–8.49 (2H, CH aromatic protons), 4.16–4.12 
(2H, CH aromatic protons), 3.42 (2H, CH aromatic protons) 3.04 (2H, CH2 
protons), 2.94 (2H, CH2 protons), 2.51-2.49 (3H, CH3 protons), 2.09-1.99 (3H, 
CH3 protons), 1.75-1.72 (H, CH proton), 1.31-1.28 (2H,CH2 protons) ppm. 
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Figure 2.7.3c.: 13C-NMR spectrum for trans,trans-BNIPDaCHM. 
 
13C-NMR (CDCl3) (Figure 2.7.3c): δ 164.26 (C=O), 131.82-131.23 (C aromatic), 
127.99-127.75 (C aromatic), 122.66 (C aromatic), 42.45 (CH2) and 40.61-37.61 
(CH2) ppm. 
 
Figure 2.7.3d.: Equivalent protons and carbons of trans,trans-
bisnaphthalimidopropyl-diamino-dicyclohexylmethane dihydro-bromide salt 
(trans,trans-BNIPDaCHM). 
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Figure 2.7.3e.: High resolution mass spectrum of trans,trans-BNIPDaCHM: 
M+=685.3732. 
 
The chemical shifts for BNIPDaCHM resonated on a similar way, as for 
bisnaphthalimido-dimesityl-dicyclohexylmethane (Section 2.4.7). The absence of 
chemical shifts corresponding to protons which were present on the methyl groups 
of N4,N4-dimesityl-dicyclohexylmethane confirmed that the reaction was complete 
and that trans,trans-BNIPDaCHM was formed.   
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2.8 Melting point determination 
Melting point (MP) determination is one of the analytical techniques applied to the 
characterisation of pharmaceutical drugs. A Griffin melting point apparatus (Fisher 
Scientific, UK) was switched on and allowed to heat to 10 oC below starting point. 
A compatible capillary (10 cm length, 0.8 mm internal diameter and 0.2 mm wall 
thickness), containing a small amount of each compound (4 mg: maximum weight 
that can be tested), was placed in the heating block’s closed end first and left 
there until the melting point could be identified. Each capillary tube contained a 
sufficient amount of dry powder in order to form a column (2-4 mm high): the 
powder was well packed at the bottom, after tapping the tube on a solid surface.  
For every experiment, the use of variable heat was kept constant (heat constant: 
7). Important step of the procedure was to ensure that the capillary was placed 
on the heating block 10 oC below a compound’s expected MP. At the end of the 
melt, MP range was recorded. For this method, the onset and the clear point of 
the melt were measured. 
In order to investigate the physical properties of BNIPDaCHM, BNIPPiProp, 
BNIPPiEth and trans,trans-BNIPDaCHM, measurements of their melting points 
were carried out. Table 2.8 shows the onset and clear melting point of the four 
BNIP derivatives. The derivative with the highest melting points was BNIPPiProp. 
The onset melting point for BNIPPiProp was measured at 160 oC and clear melting 
point at 170 oC. Lower melting points were determined for BNIPPiEth and 
trans,trans-BNIPDaCHM. BNIPPiEth started its melting process at 125 oC and 
reached its liquid phase at 130 oC and trans,trans-BNIPDaCHM at 120 oC and 125 
oC, respectively. The onset melting point for BNIPDaCHM was measured at 105 oC 
and clear melting point at 130 oC. 
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Previous studies have shown that MP depends on the chemical structure of a 
compound, its properties and its purity. In addition, sharp and characteristic 
melting points cannot be determined for compounds with impurities and their 
melting point range is increased, compared to compounds with less impurity 
(Lipinski et al, 2012). According to the above results, BNIPDaCHM has the widest 
melting point range amongst the four BNIP derivatives. The wide range could be 
explained by the fact that BNIPDaCHM is a mixture of isomers and as a result, the 
least pure compound. This hypothesis can be also supported by the fact that 
trans,trans-BNIPDaCHM, that consists of only one isomer, has a sharper melting 
point range, in comparison to BNIPDaCHM. 
 
Table 2.8.: Melting points of BNIPDaCHM, BNIPPiProp, BNIPPiEth and 
trans,trans-BNIPDaCHM (use of variable heat: 7). 
 
BNIPs Melting Point (oC) 
BNIPDaCHM 105-130 
BNIPPiProp 160-170 
BNIPPiEth 125-130 
trans,trans-BNIPDaCHM 120-125 
 
On the other hand, BNIPPiProp which is an enantiopure compound exhibited higher 
melting point temperatures than BNIPDaCHM. This outcome may be because 
BNIPPiProp does not consist of more than one isomer (thus better purity), together 
with the fact that it is a larger molecule with two extra carbons in the linker chain 
when compared to BNIPDaCHM. In parallel, it is an important indication that may 
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the position of the ring structure on the linker chain affects the stability of a 
compound and its DNA binding properties that will be examined later on. Similarly, 
BNIPPiEth consists of one carbon less between the two ring structures, compared 
to BNIPPiProp, showing that smaller molecules tend to melt in lower temperatures, 
due to less surface area for hydrophobic interactions. 
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2.9 Conclusion 
Three novel BNIPs, BNIPPiProp, BNIPPiEth and trans,trans-BNIPDaCHM were 
successfully synthesised and characterised. The N-alkylation reaction that has 
been used previously for the synthesis of other BNIPs in this series has been 
proved a suitable synthetic process to produce the above compounds, as apart 
from high yields, it resulted in formation of compounds without by-products (Lima 
et al, 2013).  
In addition, melting point determination revealed that BNIPs have stable 
structures due to the carbons that support their linker chains and the two 
naphthalimide rings that protect their two ending points, results that are in 
agreement with previous studies of Banerjee et al. (2013). Consequently, the 
three above derivatives were further examined, with regards to their DNA binding 
and biological affinities, structure-activity relationship and mode of action. 
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CHAPTER 3 
 
DNA binding studies on bisnaphthalimidopropyl 
derivatives. 
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3.1 Introduction 
3.1.1 Naphthalimides, bisnaphthalimides and DNA intercalation 
In 1970’s, researchers synthesised the first naphthalimide compounds, based on 
the fact that DNA is a fundamental biochemical target in the design of anti-cancer 
therapeutics (Huang et al, 2009). A naphthalimide compound consists of three 
fused 6-membered rings with a basic terminal group in one of its side chains. 
Naphthalimido compounds were found to be highly active against cervical cancer 
and leukaemia cells in vitro (Llombart et al, 1992, Brana et al, 2001), mainly due 
to the existence of nitrogen atoms. As a result, the next objective was to design 
and synthesise bisnaphthalimide compounds, by using a linker sequence that 
would join the two naphthalimide units together, in order to improve the 
therapeutic properties of their precursor form mononaphthalimides. Later on, 
polyamine linker sequences were incorporated into their structure, improving their 
stability and DNA intercalating properties. The existence of a flexible aminoalkyl 
linker chain that consisted of different numbers of amino groups was found to be 
the major parameter that bisnaphthalimide could exhibit strong DNA binding 
affinities (Brana et al, 1993, 2001).  
More specifically, it has been suggested that the mechanism of action of those 
bisnaphthalimides involves intercalation or bis-intercalation of the chromophore 
units between the DNA base pairs (Pavlov et al, 2001, Dance et al, 2005). 
Therefore, synthesis of novel bisnaphthalimides and further investigation on their 
DNA binding properties could lead to more effective and selective cancer 
treatment.  
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3.1.2 Assessment of DNA binding interactions 
Over the last decade, studies on DNA-small molecule interactions have been the 
focus of medicinal chemistry and is of importance, as these interactions are the 
basis of therapeutic, antitumour or antivirus properties of novel compounds and 
have great significance for medicine design (Wilson and Kool, 1990). The 
interaction mode between DNA and molecules can be developed via binding 
interactions with the minor and/or major grooves of DNA double helix, 
intercalation between DNA adjacent base pairs or electrostatic interactions with 
the sugar phosphate backbone (Strekowski and Wilson, 2007).  
Several methods have been developed and used for the assessment of DNA-small 
molecule interactions, such as DNA thermal denaturation, competitive 
displacement of DNA bound Ethidium Bromide (EtBr), circular dichroism, NMR 
spectroscopy and UV binding studies (Rajesh et al, 2012).  
In this study, the methods that were used to determine the physical interactions 
of the novel BNIPs and DNA were DNA thermal denaturation, competitive 
displacement of DNA bound EtBr and UV binding studies. Biological mechanisms 
of DNA, such as replication and transcription require separation of the DNA double 
helix, which is called denaturation and can be partial or total. DNA denaturation 
depends on several factors, such as DNA polymer geometry, DNA sequence 
composition and temperature (Benham, 1979, 1990, 1996). 
In DNA thermal denaturation studies, double stranded DNA (in the presence or 
absence of derivatives, i.e. BNIPs) is gradually heated, resulting in double strand 
separation (denaturation) (Figure 3.1.2.1) (Martinez and Chacon-Garcia, 2005). 
As a derivative stabilises DNA, the temperature at which denaturation takes place 
increases. 
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Figure 3.1.2.1.: Method of DNA thermal denaturation studies (Adapted from: 
Mathews and Van Holde, 1995). 
The degree of DNA binding is determined by the Tm value (Melting Temperature): 
the higher the Tm value, the stronger the derivative binds to DNA. 
To explore further the mode of action and DNA binding properties of novel BNIPs, 
a more selective diagnostic tool based on the competitive displacement of DNA 
bound EtBr, was used.  
EtBr, is a well-known DNA intercalator, which binds to DNA resulting in an increase 
of emitted fluorescence at 600 nm (Dance et al., 2005). Derivatives with higher 
binding affinities than EtBr, displace EtBr bound to DNA, that results in 
fluorescence quenching which is proportional to the amount of displaced EtBr 
(Figure 3.1.2.2) (Vardevanyan et al, 2003). 
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Figure 3.1.2.2.: Method of competitive displacement of DNA bound EtBr on 
Shimadzu RF-5301 spectrophotometer (Shimadzu, Japan). BNIPDaCHM in 
different concentrations (0-50 μΜ), resulting in fluorescence quenching after 
EtBr displacement from DNA. 
In addition, UV absorption spectroscopy was used to examine the binding strength 
and binding mode of DNA with BNIPs (Figure 3.1.2.3). The degree of binding 
strength of the DNA-BNIP complex was quantitatively determined by calculating 
the K binding constants (see Appendix 2) (Zhi-Yong et al, 2014). The stronger the 
binding, the lower the UV absorption and the higher the K binding constant value. 
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Figure 3.1.2.3.: Method of UV binding studies on Agilent 8453 UV-visible 
Spectroscopy System (GenTech, USA). A continuous decrease in UV absorption 
(from high to low peaks) was observed at 260 nm, within the range of BNIP 
concentrations (0–7 µM) investigated. 
  
 
87 
3.1.3 Aims 
The aim of the work presented in Chapter 3 was to investigate the DNA binding 
properties of three novel BNIPs and their parental compound BNIPDaCHM, based 
on synthetic methods introduced by Kong Thoo Lin and Pavlov (2000) (see 
Chapter 2).  
BNIPs were investigated for their DNA binding affinities by examination of DNA 
binding capacity and competitive displacement. 
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3.2 Materials and Instrumentation 
3.2.1 Materials 
A list of the reagents used during the DNA binding studies with BNIPs are 
presented below. All the reagents were handled according to the COSHH 
standards. 
 
Calf Thymus DNA       Sigma-Aldrich, UK 
Ethidium Bromide       Sigma-Aldrich, UK 
Saline Sodium Citrate      Sigma-Aldrich, UK 
 
3.2.2 Instrumentation 
Thermal denaturation studies were carried out using a Shimadzu UV-1650 PC UV-
Visible (Japan) spectrophotometer that was connected to a temperature controller 
and water supply. The samples were loaded in quartz glass flow cells (10 mm path 
length) (Hellma Analytics, UK). 
Fluorescence-binding studies were performed in plastic cuvettes (1 cm path 
length) (Hellma Analytics, UK) using a Shimadzu RF-5301 spectrophotometer 
(Japan). 
UV binding studies were carried out using an Agilent 8453 UV-visible Spectroscopy 
System (GenTech, USA) and a Diode array instrument. The samples were loaded 
in quartz glass flow cells (10 mm path length) (Hellma Analytics, UK). 
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3.3 Methods 
3.3.1 Thermal denaturation studies of BNIP derivatives 
BNIPDaCHM, BNIPPiProp and BNIPPiEth working solutions (100 µM) were prepared 
from their stock solutions (10 mM in 100% DMSO) and were further diluted to 10 
µM final concentration in 0.01 M SSC buffer. For the DNA working solution, Calf 
Thymus DNA (0.5 g) was dissolved in 0.01 M saline-sodium citrate (SSC buffer) 
(100 mL). The final DNA-BNIP samples were prepared by adding Calf Thymus DNA 
(500 µL), 0.01 M SSC buffer (400 µL) and BNIP solution (100 µL) in the same 
Eppendorf tube.  
After 12 hours incubation at room temperature, the DNA-test samples were 
analysed at 260 nm using a Shimadzu UV-1650 PC UV-Vis spectrophotometer 
(Section 3.2.2). The temperature was increased at a rate of 2 oC per minute 
between 40-100 oC and the thermal melting point (Tm (oC)) was determined using 
a curve of absorbance against temperature. 
 
3.3.2 EtBr Fluorescence studies 
BNIPDaCHM, BNIPPiProp, BNIPPiEth and trans,trans-BNIPDaCHM working 
solutions (100 µM) were prepared from their stock solutions (10 mM in 100% 
DMSO), and were further diluted to 50 µM final concentration in 0.01xSSC buffer 
(Table 3.3.2). Calf Thymus DNA and 0.01 M SSC buffer were prepared as described 
in Section 3.3.1. EtBr solution (200 µM) was prepared by dissolving 3.94 mg of 
EtBr in distilled water (50 mL) and was further diluted in 0.01 M SSC buffer to 
give the final concentration of 20 µM (Figure 3.3.2). 
Test solutions were prepared by adding varying volumes of SSC buffer (final 
volume 2000 μL), Calf Thymus DNA solution (200 μL), EtBr solution (20 μL) and 
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BNIP derivative solution (0-100 μL) in Eppendorf tubes (Table 3.3.2a). The final 
solutions were thoroughly mixed and analysed at 510 nm (excitation) and 520 nm 
(emission) using a Shimadzu RF-5301 spectrophotometer (Section 3.2.2). The C50 
value was determined as the concentration (µM) required to decrease the 
fluorescence of DNA bound EtBr by 50%. 
 
Table 3.3.2.: Preparation of test solutions with different BNIPs concentrations 
for EtBr Fluorescence studies. 
 
 
 
 
Sample 
 
A 
 
B 
 
C 
 
D 
 
E 
 
F 
Volume of SSC buffer (µL) 1780 1760 1740 1720 1700 1680 
Volume of DNA solution (µL) 200 200 200 200 200 200 
Volume of EtBr (µL) 20 20 20 20 20 20 
Volume of compound (µL) 0 20 40 60 80 100 
Final Volume (µL) 2000 2000 2000 2000 2000 2000 
Final drug concentration (µM) 0 0.5 1 1.5 2 2.5 
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Figure 3.3.2.: Fluorescence emission of different EtBr concentrations in presence 
of Calf Thymus DNA. Data are presented as mean ± SEM, n=3. 
 
3.3.3 UV binding studies 
BNIPDaCHM, BNIPPiProp, BNIPPiEth and trans,trans-BNIPDaCHM working 
solutions (100 µM) were prepared from their stock solutions (10 mM in 50% 
DMSO/H20), and were further diluted to 20 µM final concentration in 0.01 M SSC 
buffer. Calf Thymus DNA and 0.01 M SSC buffer were prepared as described in 
Section 3.3.2. 
Test solutions were prepared by adding 1 mL of Calf Thymus DNA solution in a 
quartz glass flow cell and by adding on top 100 µL BNIP solution. The final 
solutions were thoroughly mixed and analysed at 260 nm using an Agilent 8453 
UV-visible spectrophotometer (Section 3.2.2).  
The values of apparent binding constants (K) were calculated from the intercept 
and slope by plotting A0/(A-A0) against the BNIP derivative concentrations, where 
A0 and A correspond to the absorbance values in the absence and presence of a 
compound. 
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3.3.4 Statistical analysis 
Each data set contained a minimum of three independent experiments with two 
internal replicates, expressed as mean ± Standard Deviation (SD) or Standard 
Error of Mean (SEM). Statistical analysis was performed using GraphPad Prism 5.0 
software (GraphPad Software, San Diego, CA, USA). Data sets (means ± SD or 
SEM) were compared using one-way analysis of variance (ANOVA) followed by a 
Tukey's post-test for pair-wise comparisons. Statistically significant data were 
detailed when *p<0.05, **p<0.01, ***p<0.001, ***p<0.0001. 
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3.4 Results and Discussion 
3.4.1 Thermal denaturation studies and the effect of BNIPs on DNA 
binding 
Thermal denaturation studies on Calf Thymus DNA were conducted to examine 
the DNA binding properties of the three novel BNIPs. The thermal denaturation 
profile of each derivative was represented by the thermal denaturation curves that 
corresponded to UV absorbance (260nm) for Calf Thymus DNA incubated in the 
absence and presence of 10 µM BNIPs. The Tm values of three independent 
experiments were averaged and presented as mean ± SD in Table 3.4.1. 
According to Table 3.4.1, the melting point temperature of Calf Thymus DNA was 
53.29oC. The highest Tm value was observed with BNIPPiEth (91.05 oC), followed 
by BNIPPiProp (90.06 oC) and BNIPDaCHM (85.99 oC). The Tm value is defined as 
the temperature when half of the DNA has been dissociated. In presence of 
BNIPDaCHM, BNIPPiProp and BNIPPiEth, a significant increase by 32.70, 36.77, 
and 37.76 oC (DNA (ΔT)) in melting temperature was observed respectively 
(p<0.0001), as determined by one-way ANOVA analysis (Table 3.4.1). A ΔT value 
of 31.20 oC was previously reported for BNIPDaCHM by Barron et al. (2010), which 
was slightly lower than that observed in this study. However, discrepancies may 
have occurred due to purity differences among the synthesised compounds (Yurek 
et al, 2002).  
BNIPPiEth was identified to be the most active DNA binding member of the BNIP 
family. BNIPPiEth, which is a structural analogue of BNIPPiProp, consists of a two-
carbon linker sequence instead of a three-carbon linker sequence, as in 
BNIPPiProp. 
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Table 3.4.1.: Tm values of Calf Thymus DNA alone and in the presence of BNIPs. 
Sample 
Mean ± SD 
Tm (oC) 
Mean ± SD 
ΔT (oC) 
Calf Thymus DNA 53.29±1.6 0.0 
BNIPDaCHM 85.99±1.0 a, c, d 32.70±1.0 
BNIPPiProp 90.06±0.9 a, b 36.77±0.9 
BNIPPiEth 91.05±1.0 a, b 37.76±1.0 
 
*ΔT is the difference between the mean Tm value of each compound and the mean Tm 
value of Calf Thymus DNA. Three independent experiments for each BNIP were performed 
(n=3). Statistical analysis was performed using one-way analysis of variance (ANOVA) 
(GraphPad Prism 5.0). A p-value of <0.05 was considered statistically significant and it is 
represent by different letters: a; compared to the control, b; compared to BNIPDaCHM, c; 
compared to BNIPPiProp and d; compared to BNIPPiEth. 
Thus, the length of the linker sequence appears to affect a drug’s binding potential 
to the DNA (O’Hare et al, 2001). Therefore, it would be appropriate to test BNIPs 
at different concentrations in order to determine the impact of linker sequence 
lengths in DNA intercalation in future work. The existence of electronegative amine 
groups that increase the stability of hydrogen bonds within the DNA and its 
structure that causes strong intercalation explain the high stabilising effect of 
BNIPDaCHM and BNIPPiProp, respectively (O’Hare et al, 2001).  
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3.4.2 Competitive displacement of EtBr by BNIPs 
Competitive displacement of EtBr with BNIPs from Calf Thymus DNA was carried 
out to further investigate their DNA interactions. All three novel BNIPs 
competitively displaced EtBr from Calf Thymus DNA duplexes. For each derivative, 
a range of concentrations (0-7 μM) was tested and the corresponding C50 values 
calculated (see Appendix 1). All BNIPs displaced EtBr with C50 values ranging from 
1.1 to 5.6 μM confirming their high DNA binding affinity (Table 3.4.2). BNIPDaCHM 
was included to evaluate and compare its binding properties to the three novel 
BNIPs. 
Table 3.4.2.: Competitive displacement of EtBr from Calf Thymus DNA. 
 
BNIP derivative 
Mean ± SD 
C50 value (µM) 
Calf Thymus DNA alone - 
BNIPDaCHM 2.3±0.1 a, c, d, e 
BNIPPiProp 3.9±0.3 a, b, d, e 
BNIPPiEth 1.1±0.2 a, b, c, e 
trans,trans-BNIPDaCHM 5.6±0.2 a, b, c, d 
 
*Effect of different BNIPs concentrations (0-7 μM) on % fluorescence intensity compared 
to Calf Thymus DNA alone. C50 value: concentration of each BNIP derivative required to 
cause a 50% decrease on fluorescence intensity of DNA-EtBr complex. Data are the mean 
± SD of three independent experiments (n=3). Statistical analysis was performed using 
one-way analysis of variance (ANOVA) (GraphPad Prism 5.0). A p-value of <0.05 was 
considered statistically significant and it is represent by different letters: a; compared to 
the control, b; compared to BNIPDaCHM, c; compared to BNIPPiProp, d; compared to 
BNIPPiEth and e; compared to trans,trans-BNIPDaCHM. 
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The order of binding affinity to Calf Thymus DNA from highest to lowest was 
BNIPPiEth (1.1 ± 0.2 μM), BNIPDaCHM (2.3 ± 0.1 μM), BNIPPiProp (3.9 ± 0.3 μM) 
and trans,trans-BNIPDaCHM (5.6 ± 0.2 μM). BNIPPiEth with the shortest linker 
bearing two piperidine rings attached to an ethyl group, had the lowest C50 value. 
Therefore the shorter length of the linker chain, as well as the presence of a 
nitrogen atom within the cyclohexane ring, compared to BNIPDaCHM, resulted in 
increased binding affinity.  
Moreover, the incorporation of the nitrogen atom within the cyclohexane ring was 
not found to improve the binding properties of BNIPPiProp (3.9 ± 0.3 μM), 
compared to BNIPDaCHM and BNIPPiEth, confirming that the length of the bridging 
alkyl linkers is crucial and affects significantly BNIP binding to DNA duplexes, 
which is in agreement with the findings of Liu et al. (2016). 
The trans,trans-BNIPDaCHM, a stereoisomer of BNIPDaCHM, gave a C50 value of 
5.6 ± 0.2 μM. BNIPDaCHM, consisting of three isomers, gave a C50 value of 2.3 ± 
0.1 μM, suggested that in the absence of cis,cis or/and cis,trans, isomer 
trans,trans-BNIPDaCHM did not show as high DNA-binding interactions as with 
BNIPDaCHM. Based on the above results, the structure of BNIPDaCHM together 
with its mixture of three isomers was found to improve its interacting properties 
within the DNA base pairs, compared to trans,trans-BNIPDaCHM. This was further 
confirmed since trans,trans-BNIPDaCHM resulted in a higher C50 value compared 
to BNIPDaCHM, revealing that each of the three or more than one 
(trans,trans/cis,trans or trans,trans/cis,cis) isomers co-existing in BNIPDaCHM, 
are involved in the intramolecular complexes/interactions with DNA. By isolating 
one of its isomers (trans,trans-BNIPDaCHM), the DNA binding affinity was 
significantly decreased (p<0.0001). The above results revealed a similar DNA 
binding profile of all BNIPs, as for the thermal denaturation studies: the only 
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difference being that trans,trans-BNIPDaCHM had less DNA binding affinity to 
DNA, compared to BNIPDaCHM. The existence of three isomers on BNIPDaCHM 
structure seems to be crucial in inducing displacement of DNA bound EtBr and 
thus, enhancing the competition with EtBr in order to target more DNA 
intercalating sites. 
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3.4.3 UV binding studies and the effect of BNIPs on DNA binding 
Along with the DNA thermal denaturation and EtBr displacement studies, the 
interaction of BNIPs with Calf Thymus DNA was also studied by UV-Vis 
spectroscopy. A continuous decrease in UV absorption was observed at 260 nm, 
within increasing BNIP concentration (0 - 7μM). The strength of the binding 
interaction between a single biomolecule (DNA) to its ligand/binding partner 
(BNIP) is measured quantitatively by the binding constant (KB). The larger the KB 
value, the greater the binding affinity of the ligand for its target. This is described 
by the equilibrium binding expression shown below: 
 
DNA+BNIP⇄[DNA•BNIP] 
KB= [DNA•BNIP]/[DNA][BNIP] 
 The apparent KB binding constants for the compounds under study were 
calculated from the intercept and the slope (K=intercept/slope) by plotting A0/(A-
A0) against the inverse BNIP concentrations (Zhi-Yong et al, 2014) (see Appendix 
2), where A0 and A correspond to the absorbance values in the absence and 
presence of each BNIP compound (Figure 3.4.3a), respectively. 
Binding constant values KB for the BNIPs ranged between 3.25 x 104 M-1 - 12.23 x 
104 M-1 (Figure 3.4.3b), and show that all BNIPs interact with the DNA helix. The 
highest binding constant was observed with BNIPDaCHM (12.23 x 104 M-1), 
followed by trans,trans-BNIPDaCHM (11.38 x 104 M-1) and BNIPPiEth (10.85 x 104 
M-1). The lowest KB binding constant was observed for BNIPPiProp (3.25 x 104 M-
1). This result is in agreement with the competitive displacement of EtBr studies 
(Table 3.4.2), highlighting the importance of linker chain length in achieving 
strong DNA binding interactions.  
KB 
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In addition, the UV-Vis absorption studies revealed that trans,trans-BNIPDaCHM, 
to be the least effective BNIP, obtaining a binding constant of 11.38 x 104 M-1, 
compared to BNIPDaCHM (12.23 x 104 M-1: highest KB binding constant). This 
suggests that trans,trans-BNIPDaCHM exhibits a lower intercalation capacity than 
when in combination with other two isomers present in BNIPDaCHM.  
Previous molecular modelling studies have revealed that for the most stable 
conformation of bis-1,8-naphthalimide in presence of DNA, the naphthalimide 
rings obtain an antiparallel orientation and are detected in the major groove 
(Brana et al, 2004). Furthermore, naphthalimide rings have been reported to 
induce strand cleavage, allowing the electron transfer and formation of hydrogen 
bonding between the nitrogen atoms and the nucleobases (excluding guanine) of 
the minor groove (Bailly et al, 2003), suggesting that the relatively high KB binding 
constant of trans,trans-BNIPDaCHM was obtained not only via intercalation, but 
also via binding on the major and/or minor groove of DNA. 
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BNIPs  
Corresponding value of KB 
constant (M-1) 
BNIPDaCHM 12.23 x 104 
BNIPPiProp 3.25 x 104 
BNIPPiEth 10.85 x 104 
trans,trans-BNIPDaCHM 11.38 x 104 
 
Figure 3.4.3.: a) Interaction between BNIPs and Calf Thymus DNA by UV 
spectroscopy. Plot of A0/ (A-A0) versus 1/CBNIP of the interaction between BNIPs and Calf 
Thymus DNA. b) KB constant values of BNIPs after UV binding studies. 
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3.5 Conclusion 
In Chapter 3, physical properties of three novel BNIPs, BNIPPiProp, BNIPPiEth and 
trans,trans BNIPDaCHM were further investigated. Their DNA binding affinities 
were assessed by using different in vitro techniques, such as thermal denaturation 
studies, EtBr competitive displacement and UV binding studies. BNIPDaCHM, 
which is the parental BNIP, was tested alongside each of the other novel BNIPs. 
Thermal denaturation studies have shown that BNIPPiProp and BNIPPiEth can 
intercalate and stabilize the double helix of Calf Thymus DNA that was confirmed 
by their increased Tm values compared to Calf Thymus DNA alone. BNIPPiEth was 
identified as the most active DNA binding member of the BNIPs. 
Studies on competitive displacement of EtBr by BNIPs were performed to further 
evaluate their DNA binding affinity. Each novel BNIP can competitively displace 
EtBr from DNA in a dose dependent manner, confirming the hypothesis of DNA 
intercalation being responsible for their mode of action. BNIPs displaced EtBr with 
C50 values ranging among 1.1-5.6 µM, with BNIPPiEth showing the strongest 
binding affinity (1.1 µM). In parallel, by UV binding studies, strong K binding 
constants in the range of 3.25 x 104 M-1 - 12.23 x 104 M-1 were found for the three 
novel BNIPs. 
This study confirmed that BNIPPiProp, BNIPPiEth and trans,trans-BNIPDaCHM 
have the ability to interact with DNA, by intercalating into its double helix and 
have been shown to exhibit strong in vitro DNA binding properties, suggesting 
that DNA is the main target for BNIPs (Figure 3.5).  
Therefore, further DNA-associated processes and modes of cell death were 
investigated to determine the prospective of BNIPs as potential anti-cancer 
agents. 
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Figure 3.5.: Summary of DNA binding studies (Picture of DNA from: National Human 
Genome Research Institute, www.genome.gov). 
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CHAPTER 4 
 
Cytotoxicity, reactive oxygen species and DNA damage 
studies 
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4.1 Introduction 
4.1.1 Anti-cancer drugs and in vitro cytotoxicity 
Drug-mediated inhibition of cell growth and proliferation is one of the first 
preclinical screenings to be carried out for potential anti-cancer drugs (Dobbelstein 
and Moll, 2014). Cytotoxic or antineoplastic drugs are a type of medicines that 
contain certain chemicals, which are toxic to the cells. More specifically, cytotoxic 
drugs have the ability to interfere with intracellular and extracellular regulatory 
processes such as cell division, replication or cell membrane integrity, induce DNA 
damage and cause cell death (Aydinlik et al, 2016). 
Nowadays, various assays have been developed for in vitro cytotoxicity tests. Most 
of them are based on different cell functions such as cell adherence, cell 
membrane permeability, enzyme activity, adenosine Triphosphate (ATP) 
production or nucleotide uptake activity (Adan et al, 2016). As a result, the use of 
pre-treatment chemosensitivity assays (measurement of tumour cells that have 
been removed from the body and killed after chemotherapy treatment) promotes 
the selection of anti-cancer drugs with the greatest likelihood for clinical 
effectiveness and the exclusion of ineffective therapy. 
The most common method to determine cytotoxicity is by assessing cell viability 
through the use of vital dyes (i.e. formazan dyes). The formazan dyes are 
chromogenic products formed by the reduction of tetrazolium salts by 
dehydrogenases (Figure 4.1.1.1) (McCluskey et al, 2005). Reductases and lactate 
dehydrogenase (LDH) are the main dehydrogenases that are released during cell 
death (Sobhani et al, 2016).   
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Figure 4.1.1.1.: Structure of tetrazolium and formazan salt. 
 
Major tetrazolium salts that are commonly used in clinical biochemistry and cell 
biology include INT (2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2H-tetrazolium 
chloride), MTT (3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium 
bromide), MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium), XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-
2H-tetrazolium-5-carboxanilide) and NBT (2,2′-bis(4-Nitrophenyl)-5,5′-diphenyl-
3,3′-(3,3′-dimethoxy-4,4′-diphenylene)ditetrazolium chloride 3,3′-(3,3′-
Dimethoxy-4,4′-biphenylene)bis[2-(4-nitrophenyl)-5-phenyl-2H-tetrazolium 
chloride]) (McCluskey et al, 2005). 
In this study, cytotoxicity of BNIPs in two breast cancer cell lines, MDA-MB-231 
and SKBR-3 cells, was determined by MTT assay. The MTT assay is a colourimetric 
assay that measures reduction in cell viability, when metabolic events lead to cell 
death (i.e. apoptosis or necrosis) and was first developed and introduced by 
Mosmann in 1983 (Mosmann, 1983). The main advantages of MTT assay 
compared to other methods, are its sensitivity and rapidity, excluding the use of 
radioisotopes (51Cr) or radiolabelled biochemical ([3H]-thymidine) that could be 
proved harmful for the working environment (Riss et al, 2016). The yellow, water-
soluble, tetrazolium MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium 
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bromide) is reduced by metabolically active viable cells that activate several 
dehydrogenase enzymes (Figure 4.1.1.2) (Mosmann, 1983).  
 
Figure 4.1.1.2.: A microtiter 96 well plate after an MTT assay. Yellow tetrazole was 
reduced to purple formazan (wells A-C) in living MDA-MB-231 cells. Wells C-H show MDA-
MB-231 cells treated with 1.25-10 uM BNIPDaCHM for 24 hours. Dimethyl sulphoxide 
(DMSO) was added to dissolve the insoluble purple formazan product into a coloured 
solution. 
This metabolic process forms reducing equivalents, such as NADH and NADPH that 
result in intracellular purple formazan. The formazan crystals are transported to 
the cell surface by exocytosis and after solubilisation with dimethyl sulfoxide or 
acidified ethanol solution, the absorbance of this coloured solution can be 
quantified at a specific wavelength (560 nm) by a spectrophotometer (Lü et al, 
2012). 
MDA-MB-231 and SKBR-3 cell lines have distinguishing features on gene 
expression profiling and also different responses to adjuvant therapy and different 
patterns of metastatic recurrence (Currey et al, 2006). More specifically, MDA-
MB-231 cells are triple negative breast cancer cells (TNBC) (oestrogen receptor 
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negative (ER-), progesterone receptor negative (PR-), human epidermal growth 
factor receptor 2 negative (HER2-) with four gene mutations being reported 
(BRAF, CDKN2A, KRAS and TP53) and a fast-growing basal B tumour classification 
(49.5% proliferation index rate) (Kenny et al, 2007), which makes them less 
responsive to anti-cancer treatments, such as docetaxel or carboplatin, compared 
to cells that are hormone receptor positive, such as SKBR-3 cells (Kenny et al, 
2007). SKBR-3 cells are double negative breast cancer cells (DNBC) (ER-, PR-, 
HER2+) without gene mutations and with a luminal tumour classification (35.2% 
proliferation index rate), resulting in a better response to anti-cancer treatments 
compared to TNBC, however, patients still have poor survival rates (Kenny et al, 
2007). Both cells lines demonstrate invasive phenotype in vitro, without losing the 
complex inter-relationships that exist between cells in vivo, once the cell lines are 
cultured on plastic in two dimensions. In addition, MDA-MB-231 and SKBR-3 cells 
are not sensitive to culture conditions, such as the inclusion of growth factors, 
which has been found to alter the cell phenotype and cause inappropriate pathway 
activation or differentiation (Holliday and Speirs, 2011). By using two cell lines 
which are either unresponsive or partially responsive to currently available anti-
cancer regimes, it is possible to extend the understanding on the cytotoxicity of 
BNIPs against different breast cancer cells types and to gain more information 
about their mode of action.  
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4.1.2 ROS levels in cancer cells 
ROS are free radicals, molecules or ions that are derived from molecular oxygen 
(Bayr, 2005). Atomic oxygen has two unpaired electrons in separate orbits in its 
outer electron shell. This electron structure makes oxygen susceptible to radical 
formation (Apel and Hirt, 2004). On the other hand, ROS are highly reactive, as 
they have a single unpaired electron in their outermost shell of electrons (Figure 
4.1.2.1) (Bayr, 2005). Thus, the addition of electrons leads to sequential reduction 
of oxygen and the formation of ROS.   
ROS can be categorized into two groups: free oxygen radicals, such as superoxide 
(O2•−), hydroxyl radical (•OH), nitric oxide (NO•), organic radicals (R•), peroxyl 
radicals (ROO•), alkoxyl radicals (RO•), thiyl radicals (RS•), sulfonyl radicals 
(ROS•), thiyl peroxyl radicals (RSOO•), disulfides (RSSR) and non-radical ROS, 
such as hydrogen peroxide (H2O2), singlet oxygen (1O2), ozone/trioxygen (O3), 
organic hydroperoxides (ROOH), hypochloride (HOCl), peroxynitrite (ONO−), 
nitrosoperoxycarbonate anion (O=NOOCO2−), nitrocarbonate anion (O2NOCO2−), 
dinitrogen dioxide (N2O2), and nitronium (NO2+), respectively (Ray et al, 2012). 
The most well studied ROS in cancer are superoxide, hydrogen peroxide and 
hydroxyl radicals (Ray et al, 2012). 
 
Figure 4.1.2.1.: Electron structures of common reactive oxygen species. 
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At the cellular level, specific ROS can be individually measured in tissue culture 
(Ameziane-El-Hassani and Dupuy, 2016). So far, several methods for the 
detection and quantification of ROS in aqueous solution have been developed. 
The most common methods are based on probes that react with ROS and produce 
detectable products. Chemiluminescent probes, such as luminol, 2-methyl-6-(p-
methoxyphenyl)-3,7-dihydroimidazo[1,2-a]pyrazine-3-one (MCLA), and 
coelenterazine, fluorescent probes, such as dihydroethidium, mitoSOX, 
dichlorodihydrofluorescein diacetate or N-acetyl-3,7-dihydroxyphenoxazine and 
Ferricytochrome C reduction were the first, accurate methods for detecting ROS 
levels (Aitken et al, 2013). More recently, new, rapid and cost effective methods 
for the assessment of ROS levels were introduced: immune-spin trapping, 
boronate-based fluorescent probes, fluorescent protein-based redox probes and 
X- and L-Band ESR Spectroscopy are some of them (Wang, 2016). The 
development of novel tools for detecting, measuring and studying ROS in 
biological samples underlies their critical role in cell signalling and function, 
physiology and pathophysiology and nowadays, it is commonly accepted that free 
radicals are not strictly confined to the fields of chemistry and physics as in the 
past.  
Assessment of ROS levels after treatment with BNIPs in the two breast cancer cell 
lines of interest, MDA-MB-231 and SKBR-3 cells, was determined by flow 
cytometry. Chloromethyl derivative of 2′,7′-Dichlorodihydrofluorescein diacetate 
probe (CM-H2DCFDA), was used as an indicator of ROS levels in breast cancer cells 
(Oparka et al, 2016). CM-H2DCFDA diffuses into cells, where its acetate groups 
are cleaved by intracellular esterases and its thiol-reactive chloromethyl group 
reacts with intracellular glutathione and other thiols (Gomes et al, 2005) (Figure 
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4.1.2.2). Esterase cleavage of the lipophilic blocking groups yields a charged form 
of the dye that is retained by cells (Gomes et al, 2005).   
Oxidation of the probes can be detected by monitoring the increase in fluorescence 
within each cells by using flow cytometry, using excitation sources and filters 
appropriate for fluorescein (FITC) (Excitation: 490 nm- Emission:525 nm) (Wang 
et al, 2016).  
 
Figure 4.1.2.2.: Chemical structure of CM-H2DCFDA probe. 
 
4.1.3 DNA damage in cancer cells 
Human cells are constantly subjected to external and internal stresses that cause 
damage to their DNA (Boveri, 2008). DNA damage can be harmful to the overall 
integrity of the cell as it can have a negative impact on vital cellular processes, 
like replication (Hoeijmakers, 2009). DNA damaging sources may be endogenous 
or environmental. Endogenous agents that promote DNA damage include ROS and 
nitrogen (N) OS that are produced by macrophages and neutrophils at sites of 
infection or inflammation (Trichopoulos and Petridou, 1994). ROS and NOS attack 
DNA and alter basepairing, block DNA replication/transcription or cause DNA single 
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strand breaks. These spontaneous alterations in DNA contribute to endogenous 
DNA damage. Environmental DNA-damaging agents, such as ultraviolet radiation 
(A and B), ionising radiation (X and γ) or chemical agents (alkylating anti-cancer 
drugs) can also generate various forms of DNA damage and double strand DNA 
breaks (DSBs) (Rastogi et al, 2010). 
DNA strand breaks after exposure to environmental carcinogens occur once 
topoisomerase activity is aborted (Pourquier et al, 1997). Topoisomerase I and II 
are the two main enzymes that control the synthesis of proteins and facilitate 
replication by winding and unwinding of the DNA. Once this action is disrupted and 
cannot be repaired, cell cycle arrest and cell death occur (Pourquier et al, 1997). 
Based on the importance of DNA integrity in maintaining cell viability and function, 
therapeutic strategies are focused on the synthesis of novel compounds that are 
able to inflict DNA damage and induce cell death in several groups of 
diseases/disorders, like cancer. One example of this is Etoposide, a 
chemotherapeutic agent (commercially available since 1983), which forms a 
complex with the Topoisomerase II enzyme in order to prevent the supercoiling 
of the DNA strands, causing errors in DNA (i.e. DNA mismatch) synthesis and 
apoptosis (Veuger and Curtin, 2014). Etoposide has been used as treatment 
against various types of cancer, including lung cancer, ovarian cancer, testicular 
cancer, leukaemia and lymphoma, proving that DNA is a viable target for cancer 
therapeutics also demonstrating the importance of drugs that are able to inflict its 
damage (Greco, 1998). Therefore, in breast cancer treatment, most currently 
used anti-cancer drugs, such as Camptothecin, Cisplatin, Doxorubicin and 
Etoposide were developed to induce DNA damage, by inflicting DNA double-strand 
break (DSB) (Li-Weber, 2013). 
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In the last decades, several methods for the assessment of DNA damage within 
mammalian cells have been developed, including immunological assays, high 
performance liquid or gas chromatography and neutral or alkali comet assays. In 
this study, DNA damage in MDA-MB-231 and SKBR-3 cells was assessed using 
alkali single cell gel electrophoresis, known as comet assay (Kumari et al, 2008). 
Microgel electrophoresis was first introduced by Ostling and Johanson, in order to 
measure DNA single-strand breaks (SSBs) that were responsible for DNA 
supercoils relaxation (Ostling and Johanson, 1984). A few years later, Singh and 
colleagues (1988) published an improved protocol which used alkaline conditions 
that allowed DNA unwinding and maximum exposure of SSBs (Singh et al, 1988). 
This new method allowed visualising the migration of DNA strands from individual 
agarose-embedded cells by combining DNA gel electrophoresis with fluorescence 
microscopy.  
In 1990, a new modification of the original method of Ostling and Johanson took 
place and was then introduced as the “comet assay”, which is based on the 
quantification of DNA damage within an individual cell after staining with DNA 
binding fluorescent dye (4',6-diamidino-2-phenylindole (DAPI)) (Olive et al, 
1990). The visualisation method was validated in 1998, by Duthie and Hawdon 
(1998) and has been broadly used in DNA damage studies since then. The high-
molecular-weight DNA is located at the comet head and the leading ends of 
migrating fragments are located at the comet-tail, respectively (Duthie and 
Hawdon, 1998) (Figure 4.1.3). The relative fluorescence of the comet-head and 
the length of the comet-tail correspond to the exerted DNA damage, which is 
represented by DNA strands breaks (Duthie and Hawdon, 1998). The comet assay 
is versatile, relatively simple to perform and sensitive method that proved suitable 
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for studying DNA damage in MDA-MB-231 and SKBR-3 cells after treatment with 
novel BNIPs. 
 
 
Figure 4.1.3.: DNA damage in MDA-MB-231 cells as determined by comet assay. 
Cells were visualised using a Leica DMRB fluorescence microscope with D filter (excitation 
bandpass (violet); 355 – 425 nm; emission longpass (green); 470 nm) following staining 
with DAPI (minimum (A: score 0) and maximum (B: score 4) DNA damage). Magnification 
x40. 
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4.1.4 Aims 
In Chapter 4, the ability of BNIPDaCHM, BNIPPiProp, BNIPPiEth and trans,trans-
BNIPDaCHM to affect metabolism in breast cancer MDA-MB-231 and SKBR-3 cells 
will be assessed to determine the cytotoxicity of the novel derivatives. Moreover, 
the effect of the four BNIPs on the levels of intracellular ROS and the extent of 
DNA damage induced by BNIPs in MDA-MB-231 and SKBR-3 cells treated with the 
above intercalating agents will be investigated. 
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4.2 Materials 
A list of the reagents that were used for cell maintenance, cytotoxicity, ROS and 
DNA damage studies are presented below. All reagents were handled according to 
the COSHH standards and were used without purification. 
 
4.2.1 Cell culture maintenance of MDA-MB-231 and SKBR-3 cells. 
RPMI-1640 medium GlutaMAXTM-1 with 25Mm   HEPES Gibco, UK 
Trypsin-EDTA       Sigma-Aldrich, UK 
Phosphate buffered saline     Sigma-Aldrich, UK 
Penicillin/Streptomycin      Invitrogen, UK 
Fetal Bovine Serum      Sigma-Aldrich, UK 
 
4.2.2  Colourimetric 3-(4, 5-Dimethylthiazol-2-yl)-2, 5 
diphenyltetrazodium bromide (MTT) assay. 
Methylthiazolyldiphenyl-tetrazolium bromide   Sigma-Aldrich, UK 
Dimethyl Sulfoxide       Aldrich, UK 
 
4.2.3 ROS Level Detection 
CM-H2DCFDA (General Oxidative Stress Indicator)  ThermoFisher, UK 
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4.2.4 COMET assay  
Ethylenediaminetetraacetic acid (EDTA)   Sigma-Aldrich, UK 
Sodium Hydroxide        Fisherbrand, UK  
Tris Base         Fisherbrand, UK  
Sodium Chloride       Fisherbrand, UK  
Triton X-100        Sigma-Aldrich, UK 
Agarose (1% w/v)       Sigma-Aldrich, UK 
Low Melting Point Agarose (1% w/v)    Sigma-Aldrich, UK 
Hydrogen Peroxide       Sigma, UK 
4', 6-Diamidino-2-Phenylindole, Dihydrochloride  Sigma-Aldrich, UK 
 
4.2.5 Instrumentation 
HERASafe Class II Safety Cabinet Thermo Electron Corporation, 
Germany 
HERACell incubator Heraeus, Germany 
Centaur 2 centrifuge MSE, UK 
Neubauer Haemocytometer Assitent, Germany 
Leica DMIL light microscope Leica Microsystems, UK 
96-well plate reader  Synergy/HT, BIOTEK 
Polymax 1040 Platform Shaker Heidolph, USA 
ALC Multispeed Refrigerated Centrifuge Thomson Scientific,UK 
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Coulter Epics XL-MCL flow cytometer  Beckman Coulter, UK 
Horizon 20.25 horizontal gel electrophoresis tank Gibco, UK 
Leica DMRB fluorescence microscope D filter  Leica Microsystems,UK 
(excitation bandpass (colour violet): 355-425 nm, emission longpass (colour 
green):470 nm) 
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4.3 Methods 
4.3.1 Cell culture maintenance of MDA-MB-231 and SKBR-3 cells. 
MDA-MB-231 (ECACC, Public Health England, UK, 92020424) and SKBR-3 (ATCC, 
HTB-30) cells were maintained in Roswell Park Memorial Institute 1640 medium 
(RPMI-1640) (containing GlutaMAXTM-1 with 25Mm HEPES), supplemented with 
10% (v/v) Fetal Bovine Serum (FBS) and 1% Penicillin/(10,000 µg/mL) 
Streptomycin. Aseptic cell culture procedures were carried out within HERASafe 
Class II Safety Cabinet. 
MDA-MB-231 and SKBR-3 cells were grown at 37 oC (5% CO2) within a HERACell 
incubator, sub-cultured once they reached 80% confluence, washed twice with 5 
mL of Phosphate Buffered Saline (PBS) and detached after incubating the flask at 
37 oC (5% CO2) for 2 minutes with 2 mL of Trypsin-EDTA (0.25%) solution. The 
cell mixture was transferred into a falcon tube and centrifuged at 1,000 xg for 5 
minutes, using a Centaur 2 centrifuge. After pouring off the supernatant and re-
suspending the cell pellet in 8 mL of fresh medium, cells were counted by using a 
Neubauer Haemocytometer. For routine cell maintenance, 1 x 106 cells/15 mL of 
RPMI-1640 were seeded into 75 cm2 tissue culture flasks.  
Ten μL of cell suspension were placed on the chamber and only the cells that were 
located in the four sections of the grid (A, B, C and D) were counted, under the 
microscope (Figure 4.3.1). The final concentration of cells in solution was 
calculated by the following equation: [(A+B+C+D)/4] x 104 = cells/mL. 
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Figure 4.3.1.: Counting areas on Neubauer Haemocytometer. 
 
4.3.2  Colourimetric 3-(4, 5-Dimethylthiazol-2-yl)-2, 5 
diphenyltetrazodium bromide (MTT) assay. 
Cytotoxicity testing of the novel BNIPs was performed by using a colourimetric 
MTT assay. MDA-MB-231 and SKBR-3 cells (7.5 x 103 cells/100 μL/well) were 
seeded in 96-well plates and after 24 hours were treated with different 
concentrations (0-10 μM) of BNIPDaCHM, BNIPPiProp, BNIPPiEth or trans,trans-
BNIPDaCHM. Stock solutions (10 mM in 50% DMSO/H20) of BNIP derivatives were 
diluted to the desired final concentrations with RPMI-1640 medium. In order to 
ensure that DMSO was not affecting MDA-MB-231 and SKBR-3 cells viability, a 
50% DMSO/H20 solution was added to one of the columns as a vehicle control. 
BNIPs were dissolved in RPMI before addition to the cells. After various treatment 
times (24 to 96 hours), the cell culture medium was removed and 100 μL of sterile-
filtered MTT solution (1 mg/mL) was added to each well and the plate returned to 
the incubator. After 4 hour incubation at 37 oC (5% CO2), in the dark, the MTT 
solution was removed and replaced by 200μL of DMSO. The 96-well plates were 
shaken for 20 minutes at room temperature, in the dark, and the absorbance was 
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measured at 560 nm on a 96-well plate reader. For each compound, three 
independent experiments were carried out and each treatment consisted of six 
replicates per plate. Curves were used for the representation of the percentage 
growth inhibition of MDA-MB-231 and SKBR-3 cells treated with BNIPs, with DMSO 
control representing 100% cell viability (see Appendix 3).  
 
4.3.3 ROS Level Detection 
MDA-MB-231 and SKBR-3 cells (1 x 106 cells/ T25 cm2 flask) were incubated for 
24 hours before treatment. Then, BNIPs (IC25 concentrations) were added and 
cells were incubated for 4 hours. After 4 hours of treatment, MDA-MB-321 and 
SKBR-3 cells were washed twice with PBS (2 mL), and fresh medium (5 mL) and 
ROS dye (5 µL) were added to each flask.  
The cells were incubated for 45 minutes at 37 °C. After the desired incubation 
time, the cells were removed from the culture flasks by adding trypsin (1 mL) and 
centrifuged at 500 xg for 5 minutes at 4 °C. The supernatant of each sample was 
discarded and the pellet was resuspended in PBS (1 mL) and transferred to an 
Eppendorf tube. The cells were centrifuged at 500 xg for 5 minutes at 4 °C, the 
supernatant was discarded and the pellet was resuspended in fresh PBS (500 µL).  
The samples were analysed by flow cytometry, on a Coulter Epics XL-MCL flow 
cytometer. EXPO-32 software was used to record and analyse 10,000 single 
events. The percentage of ROS production was calculated from FL-1 plots. An 
example of the gated region in control and BNIPDaCHM treated samples is 
provided in Figure 4.3.3. The markers are linked and represent the gated region 
where a shift of fluorescent is observed when ROS is produced. The markers were 
placed in the same position for all the ROS experiments undertaken.  
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Figure 4.3.3.: ROS levels in MDA-MB-231 cells before (left) and after 8 hour 
treatment with BNIPDaCHM IC25 (right). For ROS studies, 10,000 events were 
recorded and images are representative of the results obtained using EXPO32 ADC analysis 
software. 
 
4.3.4 COMET assay 
MDA-MB-231 and SKBR-3 cells (16 x 104 cells/2 mL/well) were seeded in a 12 
well plate and incubated for 24 hours before treatment. BNIPs (IC25 
concentrations) were added and cells were incubated for 24 hours. After 24 hours 
of treatment, MDA-MB-231 and SKBR-3 cells were washed with PBS and 500 µL 
trypsin were added in each well. After trypsinisation, 500 µL of medium were 
added on top and the cell solution was collected in sterile Eppendorf tubes. The 
samples were centrifuged at 400 xg for 5 minutes at 10 oC and the supernatant 
was discarded. In each tube, 85 µL of 1% LMP agarose in PBS were added and 
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mixed with the cell pellet. In parallel, 85 µL of agarose were placed on fully frosted 
microscope slides, covered with 18 x 18 mm cover slips and left at 4 oC to set. 
The cells/LMP agarose mixture was placed on the pre-coated microscope slides, 
after removing the 18 x 18 mm cover slips. The gels were covered with new 18 x 
18 mm cover slips and left for 10 minutes at 4 oC. Then the slides were placed in 
a black staining jar, filled with 200 mL of lysis solution (2.5 M NaCl, 0.1 M EDTA, 
10 mM Tris Base, 1% (v/v) Triton X-100, NaOH pH=10) and incubated for 60 
minutes at 4 oC. Slides were placed horizontally in an electrophoresis tank filled 
with 1.5 L of electrophoresis buffered (0.3 M NaOH, 1mM EDTA, pH 13) that was 
cooled before use. After 40 minutes incubation at 4 oC, electrophoresis was carried 
out at 25 V for 30 minutes at 4 oC. Then the slides were placed in black staining 
jars, adding 200 mL neutralising buffer (0.4 M Tris, HCl pH 7.8) on top of them. 
After three 5-minute washes, the slides were left at 4 oC until comet scoring. 
The quantification of DNA damage was carried out by using DAPI. After removing 
the cover slips from each slide, 20 µL of DAPI were added on top of the gel and 
covered with 22 x 22 mm cover slips. One hundred comets per gel were scored 
using a fluorescence microscope, with scores between 0-4 (0: no damage, 4: 
maximum damage). The final score per sample ranged between 0 (no damaged 
cells) to 400 (totally damaged cells). 
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4.3.5 Statistical Analysis 
Three independent experiments were conducted and each experiment was 
comprised of at least two internal replicates, unless otherwise stated. Data are 
presented as mean ± SD or ± SEM. Statistical analysis was performed using 
GraphPad Prism 5.0 software (GraphPad Software, San Diego, CA, USA). Data 
sets (means ± SD or SEM) were compared using one-way analysis of variance 
(ANOVA) followed by a Tukey's post-test for pair-wise comparisons. Statistically 
significant data were detailed when *p<0.05, **p<0.01, ***p<0.001, 
***p<0.0001. 
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4.4 Results and Discussion 
4.4.1 Cytotoxicity 
The level of cytotoxicity induced by BNIPDaCHM, BNIPPiProp, BNIPPiEth and 
trans,trans-BNIPDaCHM in MDA-MB-231 and SKBR-3 cells was assessed by MTT 
assay (Mosmann, 1983).  
Figure 4.4.1a represents the percentage of cell viability in MDA-MB-231 cells after 
treatment with BNIPDaCHM for 24, 48, 72 and 96 hours (Figure 4.4.1). Similar 
procedure was followed for all BNIPs in both MDA-MB-231 and SKBR-3 cells line 
and similar diagrams were obtained. 
 
 
Figure 4.4.1.: The growth inhibition curve of BNIPDaCHM in MDA-MB-231 cells 
after 24, 48, 72 and 96 hours. Cytotoxicity was determined by MTT Assay. The curves 
are representative of all BNIP derivatives analysed within MDA-MB-231 and SKBR-3 cells. 
Data presented as mean ± SEM of 3 independent experiments (n=3). 
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In addition, the IC50 values of the newly synthesised BNIPs were calculated and 
compared with the previously synthesised parental compound, BNIPDaCHM 
(Barron et al, 2010). The IC50 value was defined as the BNIP concentration that 
causes 50% reduction in cell viability, compared to that of untreated cells. The 
IC50 was calculated according to the most widely used method of calculation as 
seen in the literature to date (Barron et al, 2010). Later, it was suggested that 
IC50 can also be analysed to fit a 4 parameter Hill equation instead of the 
polynomial analysis used. However, due to the limited range of concentrations 
tested, the first method of analysis was more applicable for the data observed. 
This was due to the fact that the 4 parameter Hill equation requires a much wider 
range of concentrations for a sufficiently accurate calculation of IC50 (see Appendix 
4). 
After 24 hours treatment, all novel BNIPs, exhibited strong cytotoxicity with IC50 
values ranging from 1.4 μM to 3.3 μM in MDA-MB-231 cells (Table 4.4.1), 
compared to previously synthesised BNIPs or DNA intercalating drugs 
(Doxorubicin) that have been tested against the same cell line, with IC50 values 
ranging from 4.9 μM to 12.7 μM (Barron et al, 2010). In particular, trans,trans-
BNIPDaCHM exhibited the lowest IC50 value of 1.4 μM, BNIPPiEth an IC50 of 1.8 
μM and BNIPPiProp an IC50 of 3.3 μM, compared to the parental compound. A 
similar pattern of cytotoxicity was found for SKBR-3 cells, although the IC50 values 
were between 0.2 - 0.7 μM (Table 4.4.1). 
trans,trans-BNIPDaCHM (1.4 μM) was more active (p<0.01) than BNIPDaCHM 
(2.3 μM) in MDA-MB-231 cells, showing that the existence of a single isomer in 
the linker sequence results in a more cytotoxic compound, compared to a 
compound which contains a mixture of isomers. BNIPPiEth was more cytotoxic 
(p<0.05) than BNIPDaCHM, suggesting that the shorter length of the linker chain, 
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as well as the incorporation of the nitrogen atom within the cyclohexane ring, not 
only improved the binding properties of BNIPPiEth, but enhanced significantly its 
in vitro cytotoxicity too. Regarding BNIPPiProp, the derivative with the longest 
linker sequence and the highest IC50 value, it was found that the linker chain 
length plays an important role in the functionality and effectiveness of a BNIP. In 
addition, all the derivatives followed a similar pattern of cytotoxicity in both cell 
lines, however, they appeared more cytotoxic against SKBR-3 cells. This may be 
due to the different mutational and tumorigenic statuses (Kao et al, 2009), as that 
have been discussed in detail in Section 4.1.2.  
Moreover, compared to previously synthetised bisnaphthalimides, the three novel 
BNIPs exhibited low IC50 values in MDA-MB-231 and SKBR-3 cells. More 
specifically, Amonafide, which significantly inhibits the growth of HT-29, HeLa 
(cervical cancer cells), and PC3 (prostate cancer) cells, exhibited IC50 of 4.67 μM, 
2.73 μM, and 6.38 μM, respectively (Brana et al, 2004). BNIPOSpm, which has 
been tested against CaCO-2 (human colon adenocarcinoma cells), HT-29 (human 
colon adenocarcinoma cells) and MCF-7 cells (human colon adenocarcinoma cells), 
exhibited IC50 values>50 μM (Ralton, 2006, Oliveira et al, 2007).  
Thus, the structural modifications on the parental compound BNIPDaCHM, 
successfully improved the cytotoxicity of the three novel BNIPs, not only compared 
to previous BNIPs but also compared to anti-cancer drugs that are currently used 
in clinics (e.g. Doxorubicin), making BNIPPiProp, BNIPPiEth and trans,trans-
BNIPDaCHM promising agents in breast cancer therapy. 
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Table 4.4.1.: MDA-MB-231 and SKBR-3 cells were treated with different BNIPs 
concentrations (0-10 μM) for 24 hours at 37 °C.   
BNIPs  
IC
50
 values (µM)  (Mean ± SEM) 
MDA-MB-231           SKBR-3 
BNIPDaCHM 2.3± 0.1                  0.4±0.1 
BNIPPiProp 3.3± 0.1 **             0.7±0.1 * 
BNIPPiEth 1.8±0.1  *               0.3±0.1 * 
trans,trans-BNIPDaCHM 
1.4± 0.1 **             0.2±0.0 * 
 
*IC50 values correspond to the concentration required to reduce cell growth by 50% 
compared to control cells. Data presented as mean ± SEM of 3 independent experiments 
(n=3). *p<0.05, **p<0.01, compared to BNIPDaCHM. 
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4.4.2 ROS levels 
Intracellular ROS generation in MDA-MB-231 and SKBR-3 cells was detected using 
CM-H2DCFDA dye and ROS positive cells were measured by flow cytometry.  
Cells were treated with concentrations corresponding to IC25 values of BNIPs, in 
order to avoid loss of cell population during the assessment of ROS production 
(Table 4.4.2).  
A time-course experiment with treatment times of 4, 8 and 12 hours in MDA-MB-
231 (Figure 4.4.2.1a) and SKBR-3 cells (Figure 4.4.2.1b) with one novel 
compound, BNIPPiProp (higher IC25 value) were carried out and revealed that ROS 
levels in MDA-MB-231 cells were significantly increased after 4 hours treatment 
compared to untreated cells, but not in SKBR-3 cells (p<0.01). However, after 8 
hours treatment, ROS production was significantly increased in both cell lines 
(p<0.001), while 12 hour treatment showed a significant increase in ROS levels 
(p<0.001) but to a lower extent, compared to 8 hour treatment. The decrease in 
ROS that was observed after 12 hours, could be attributed to antioxidant 
responses and cellular adjustments that BNIP treatment might have triggered in 
that specific timepoint. 
Based on the time-course results, all the compounds were tested after 8 hour 
treatment in MDA-MB-231 and SKBR-3 cells, in order to compare the levels of 
intracellular ROS generation between the two different cell lines.  
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Table 4.4.2.: MDA-MB-231 and SKBR-3 cells were treated with BNIPs (IC25 
concentrations) for 24 hours at 37 °C.   
 
BNIPs  
IC
25
 values (µM)  (Mean ± SEM) 
MDA-MB-231           SKBR-3 
BNIPDaCHM     1.00± 0.06           0.2±0.00 
BNIPPiProp     1.50± 0.06*         0.5±0.01 ** 
BNIPPiEth     0.80±0.03            0.15±0.00 ** 
trans,trans-BNIPDaCHM 
    1.00± 0.03          0.11±0.01 ** 
 
*IC25 values correspond to the concentration required to reduce cell viability by 25% 
compared to control cells. Data presented as mean ± SEM of 3 independent experiments 
(n=3). *p<0.05, **p<0.01, compared to BNIPDaCHM.  
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Figure 4.4.2.1.: Quantification of ROS levels by flow cytometry following ROS dye 
staining after 4, 8 and 12 hours treatment with BNIPPiProp (IC25) in (a) MDA-
MB-231 and (b) SKBR-3 cells. DMSO/H2O was used as positive control. The percentage 
of ROS production was calculated from FL-1 plots (10,000 events). Data presented as 
mean ±SD (n=4). **p<0.01, ***p<0.001, compared to untreated MDA-MB-231 and 
SKBR-3 cells, respectively. 
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In MDA-MB-231 cells, after 8 hours treatment with BNIPDaCHM, ROS levels were 
significantly increased by 48.4% (p<0.05), compared to control cells (Figure 
4.4.2.2a). After treatment with BNIPPiProp, ROS production was significantly 
increased by 35.1% (p<0.05). ROS levels after treatment with BNIPPiEth and 
trans,trans-BNIPDaCHM were increased by 43.2% and 25%, compared to 
untreated cells, respectively. The above results indicate that the three novel BNIPs 
and their parental compound BNIPDaCHM, induce the production of endogenous 
ROS. BNIPDaCHM is the derivative that caused the highest increase of ROS levels 
in MDA-MB-231 cells, followed by BNIPPiEth, BNIPPiProp and trans,trans-
BNIPDaCHM was the derivative that cause the lowest increase of ROS levels. 
Moreover, according to statistical analysis, no significance difference was found in 
MDA-MB-231 cells after treatment with BNIPDaCHM, BNIPPiProp, BNIPPiEth and 
trans,trans-BNIPDaCHM, compared to each other. 
In SKBR-3 cells, after 8 hours treatment with BNIPDaCHM, ROS levels were 
significantly increased by 362.4% (p<0.05) (Figure 4.4.2.2b). After treatment 
with BNIPPiProp, ROS production was significantly increased by 451.5% (p<0.05). 
ROS levels after treatment with BNIPPiEth and trans,trans-BNIPDaCHM were 
significantly increased by 355.5% (p<0.05) and 184.1% (p<0.05), compared to 
untreated cells, respectively. BNIPs were found to induce the production of 
endogenous ROS in SKBR-3 cells to a greater extend compared to MDA-MB-231 
cells.  
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Figure 4.4.2.2.: Quantification of ROS levels by flow cytometry following ROS dye 
staining after 8 hours treatment with BNIPDaCHM, BNIPPiProp, BNIPPiEth and 
trans,trans-BNIPDaCHM in (a) MDA-MB-231 and (b) SKBR-3 cells, respectively. 
DMSO/H2O was used as positive control. The percentage of ROS production was calculated 
from FL-1 plots (10,000 events). Data presented as mean ±SD (n=3). *p<0.05, compared 
to untreated MDA-MB-231 and SKBR-3 cells, respectively. 
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BNIPPiProp is the derivative that caused the highest increase of ROS levels in 
SKBR-3 cells, followed by BNIPDaCHM, BNIPPiEth, and trans,trans-BNIPDaCHM 
was the derivative that cause the lowest increase of ROS levels. According to 
statistical analysis, no significance difference was found in SKBR-3 cells after 
treatment with BNIPDaCHM, BNIPPiProp, BNIPPiEth and trans,trans-BNIPDaCHM, 
compared to each other. 
A similar pattern of ROS production was found for MDA-MB-231 and SKBR-3 cells, 
in relation to treatment with individual BNIPs. However, the increase in ROS levels 
does not seem to parallel the cytotoxicity values determined by MTT assay after 
24 hours (see Section 4.4.1) for each compound in the two cell lines. For example, 
although trans,trans-BNIPDaCHM was the most cytotoxic BNIP derivative in both 
MDA-MB-231 and SKBR-3 cells compared to BNIPDaCHM, it was not responsible 
for the highest increase of ROS levels. According to the above results, ROS levels 
were increased after treatment with BNIPs. Moreover, for less cytotoxic 
compounds, such as BNIPPiProp compared to trans,trans-BNIPDaCHM, higher 
concentration of compounds was used to achieve IC25, resulting in higher levels of 
ROS being detected. Moreover, higher BNIP dose treatment in SKBR-3 cells 
resulted in higher levels of ROS compared to MDA-MB-231 cells. Thus, higher dose 
treatment seem to be linked with higher ROS level production, as it has been 
reported in a previous study, where Calu-6 lung cancer cells were treated with 
different doses of Antimycin A and ROS levels were only induced after treatment 
with the highest dose (100 µM) (Han and Park, 2009), which was a much higher 
concentration compared to BNIP treatments tested in this study. Similar studies 
have been undertaken for anti-cancer drugs that are currently used for breast 
cancer treatment in the clinic, such as Tamoxifen. Tamoxifen has been also found 
to promote ROS generation after 4 days treatment (10 µM) in MCF-7 breast cancer 
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cells (Lee et al, 2014). Thus, BNIPs seem to be promising candidates for breast 
cancer treatment, as they follow similar mode of action compared to current anti-
cancer drugs (e.g. Tamoxifen) and their ability to induce ROS levels increase their 
potential of being clinically relevant. 
The lower production of ROS after treatment with trans,trans-BNIPDaCHM 
compared to the other BNIPs, seem to be linked with the melting points and DNA 
binding studies that were presented in Chapter 3. The more stable the chemical 
structure (existence of one isomer) is, the more difficult for the agent to undergo 
oxidation by electron transfer hydrogen abstraction (Davasagaya et al, 2004). As 
a result, the possible sites of attack for free radical oxidants (Davasagaya et al, 
2004) and trans,trans-BNIPDaCHM are decreased compared to BNIPDaCHM, 
which may be due to its structure and the existence of three stereoisomers retains 
its rotational freedom (see Chapter 3). 
In addition, SKBR-3 cells (hormone receptor positive) have a better response to 
BNIP treatments compared to MDA-MB-231 cells, which is in agreement with the 
cytotoxicity findings. For example, after treatment with concentrations 
corresponding to IC25 values for BNIPs, in SKBR-3 cells an increase of 355.5% in 
ROS levels after treatment with BNIPPiEth was detected, when for MDA-MB-231 
cells the increase was 43.2%. In both cases, it has to be investigated whether the 
elevated ROS levels after treatment with BNIPs in breast cancer cells induce DNA 
damage and intracellular DNA stability, as a mechanistic link between these two 
pathways has not been clearly elucidated. 
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4.4.3 DNA damage studies 
In order to assess DNA damage induced by BNIPs within the two breast cancer 
cell lines, comet assay was used. Cells were treated with concentrations 
corresponding to IC25 values of BNIPs, in order to avoid loss of cell population 
during the assessment of DNA damage (similarly as in ROS levels detection in 
Section 4.4.2). 
BNIPs induced a significant increase in DNA strand breaks compared to 
endogenous levels, after 24 hours treatment in MDA-MB-231 and SKBR-3 cells. In 
MDA-MB-231 cells (Figure 4.4.3a), significant change in the number of DNA strand 
breaks was observed for all BNIPs. In particular, BNIPDaCHM caused an increase 
of 221.9 (p<0.0001) strand breaks compared to untreated cells, BNIPPiProp an 
increase of 262.8 (p<0.0001) strand breaks, BNIPPiEth an increase of 250.8 
(p<0.0001) strand breaks and trans,trans-BNIPDaCHM an increase of 205.0 
(p<0.0001) strand breaks. H2O2 was used as a positive control and after 10 
minutes treatment (200 μM concentration), significantly increased the DNA strand 
breaks by 326.7 (p<0.0001). Moreover, BNIPPiEth and trans,trans-BNIPDaCHM 
caused an increase in strand breaks compared to BNIPDaCHM. However, 
according to statistical analysis, no significance difference in the number of DNA 
strand breaks was found in MDA-MB-231 cells after treatment with BNIPPiEth and 
trans,trans-BNIPDaCHM, compared to BNIPDaCHM. 
In SKBR-3 cells (Figure 4.4.3b), significant changes in the number of DNA strand 
breaks were observed for all BNIPs. In particular, BNIPDaCHM caused an increase 
of 98.4 (p<0.0001) strand breaks compared to untreated cells, BNIPPiProp an 
increase of 97.3 (p<0.0001) strand breaks, BNIPPiEth an increase of 176.1 
(p<0.0001) strand breaks and trans,trans-BNIPDaCHM an increase of 130.0 
(p<0.0001) strand breaks. Moreover, after 10 minutes treatment with 200 μM 
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H2O2 (used as a positive control), significantly increased the DNA strand breaks 
by 308.0 (p<0.0001). BNIPPiProp, BNIPPiEth and trans,trans-BNIPDaCHM caused 
a significant increase in strand breaks compared to BNIPDaCHM (p<0.0001) in 
SKBR-3 cells. According to statistical analysis, significance difference in the 
number of DNA strand breaks was found in SKBR-3 cells after treatment with 
BNIPPiProp, BNIPPiEth and trans,trans-BNIPDaCHM, compared to BNIPDaCHM 
(p<0.0001), similarly to MDA-MB-231 cells. 
The above results indicate that all BNIPs induced DNA damage in MDA-MB-231 
cells and with regard to BNIPDaCHM (parental compound), this study is in 
agreement with the findings of Barron et al. (2015). In MDA-MB-231 cells, 
BNIPPiProp induced a greater level of DNA strand breaks compared to endogenous 
levels, followed by BNIPPiEth, BNIPDaCHM and trans,trans-BNIPDaCHM. In SKBR-
3 cells, BNIPPiEth induced a greater level of DNA strand breaks compared to 
endogenous levels and BNIPDaCHM, followed by trans,trans-BNIPDaCHM, 
BNIPDaCHM and BNIPPiProp. 
Interestingly, a higher number of DNA strand breaks after treatment with BNIPs 
was observed in MDA-MB-231 cells, compared to SKBR-3 cells. MDA-MB-231 cells 
were found to be more susceptible to DNA instability after treatment with BNIPs, 
which appears to relate to different proliferation index rates between the two cells 
lines. As mentioned in Section 4.4.1, the proliferation index rate among the two 
cell lines differs: MDA-MB-231 cells proliferate at a 49.5% rate and SKBR-3 cells 
at 35.2% (Kenny et al, 2007). Thus, the faster the cells proliferate, the higher the 
DNA damage is caused over time. In this study, BNIPPiEth seem to be the best 
candidate out of the three novel compounds. BNIPPiEth was found to be the 
second most cytotoxic compound in MDA-MB-231 cells and SKBR-3 cells (after 
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trans,trans-BNIPDaCHM), a highly ROS-inducing compound (Section 4.4.2) and a 
strong intercalating BNIP (Chapter 3).  
The above characteristics are in agreement with the findings observed in DNA 
damage studies. In addition, an important factor that may induce the DNA damage 
potential of BNIPPiEth is its structure. BNIPPiEth is the smallest molecule of all 
BNIPs and it seems that a short linker sequence enhances its activity (better 
cytotoxicity, more DNA strand breaks). 
Similar studies have been undertaken for anti-cancer drugs that are currently used 
for breast cancer treatment in the clinic, such as Doxorubicin. The latter, a first-
line chemotherapeutic for breast cancer, has been also found to induce DNA 
damage in triple-negative breast cancer cells (Staedler et al, 2011). However, 
Doxorubicin is associated with severe side effects to non-tumoral tissues, due to 
high dose treatments (10-50 mg per week) (Staedler et al, 2011). The induction 
of DNA damage is an additional similar mode of action between BNIPs and current 
anti-cancer drugs (e.g. Doxorubicin), suggesting their potential of being clinically 
relevant as novel breast cancer treatment. In Section 4.1.1, BNIPs were found to 
exhibit strong cytotoxicity (IC50 values ranging from 1.4 μM to 3.3 μM) compared 
to Doxorubicin (IC50 values ranging from 4.9 μM to 12.7 μM) in MDA-MB-231 cells, 
which suggests that lower dose treatments of BNIPs could be potentially more 
effective compared to Doxorubicin treatment within breast cancer patients, 
especially in case that BNIP treatment would not be accompanied by severe side 
effects as well. 
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Figure 4.4.3.: DNA strand breaks in (a) MDA-MB-231 and (b) SKBR-3 cells after 
24 hours treatment determined by comet assay. Data obtained after treating 
MDA-MB-231 and SKBR-3 cells with BNIPs (IC25) for 24 hours. DNA damage in H2O2 
(200 μM) treated cells were used as a positive control. Data are mean ± SEM of 8 replicates 
and two independent experiment (n = 2). A p-value of <0.05 was considered statistically 
significant and it is represent by different letters: a; compared to the control, b; compared 
to BNIPDaCHM, c; compared to BNIPPiProp, d; compared to BNIPPiEth, e; compared to 
trans,trans-BNIPDaCHM and f; compared to H2O2.  
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4.5 Conclusion 
The three novel BNIPs, BNIPPiProp, BNIPPiEth and trans,trans-BNIPDaCHM and 
their parental compound, BNIPDaCHM, were screened for biological activity in 
breast cancer MDA-MB-231 and SKBR-3 cells (Figure 4.5). After 24 hours 
treatment, all novel BNIPs exhibited strong cytotoxicity with IC50 values ranging 
from 1.4 μM to 3.3 μM in MDA-MB-231 cells and 0.2 - 0.7 μM in SKBR-3 cells, 
confirming the importance of bisnaphthalimidopropyl functionality. More 
specifically, linker sequence modifications showed stronger cytotoxic effects 
against MDA-MB-231 and SKBR-3 cells, compared to the parental compound 
BNIPDaCHM. The lower IC50 value range shows that SKBR-3 cells are more 
susceptible to BNIP treatment, compared to MDA-MB-231 (triple negative breast 
cancer cells).  
BNIPDaCHM was the derivative that caused the highest increase of ROS levels in 
MDA-MB-231 cells, followed by BNIPPiEth, BNIPPiProp and trans,trans-
BNIPDaCHM was the derivative that caused the lowest increase of ROS levels. In 
SKBR-3 cells, BNIPPiProp caused the highest increase of ROS levels, followed by 
BNIPDaCHM, BNIPPiEth, and trans,trans-BNIPDaCHM was the derivative that 
caused the lowest increase of ROS levels, showing that BNIPs induce the 
production of endogenous ROS in SKBR-3 cells in a greater extent compared to 
MDA-MB-231 cells. 
DNA damage studies revealed that BNIPs induced a significant increase in DNA 
strand breaks compared to endogenous levels, after 24 hours treatment in MDA-
MB-231 and SKBR-3 cells. Higher number of DNA strand breaks after treatment 
with BNIPs was observed in MDA-MB-231 cells, compared to SKBR-3 cells. 
BNIPPiEth and BNIPPiProp were the BNIP candidates with the highest DNA damage 
potential in MDA-MB-231 and SKBR-3 cells lines, respectively.  
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The above findings suggest a potential of BNIPs being clinically relevant as novel 
breast cancer treatment, as they combine similar modes of action (e.g. ROS 
production, DNA damage) of current drugs used in clinics (such as Tamoxifen and 
Doxorubicin) in lower dose treatments that could potentially reduce the occurrence 
of severe side effects in patients. 
In Chapter 5, BNIPs will be investigated further in order to assess their impact on 
cell cycle distribution and their mode of cell death. 
 
 
Figure 4.5.: Summary of cytotoxicity, ROS levels and DNA damage studies.   
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CHAPTER 5 
 
Effect of novel bisnaphthalimidopropyl derivatives on 
cell cycle distribution and cell death 
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5.1 Introduction 
5.1.1 Cell cycle and cancer 
Cell cycle is a series of coordinated events that control DNA replication and division 
of a cell (Kastan and Bartek, 2004). Cell cycle progression consists of four phases: 
Gap phase 1 (G1), DNA synthesis (S), Gap 2 phase (G2 or interphase) and mitosis 
(M) (Figure 5.1.1) (Meeran and Katiyar, 2008). G1 and G2 phases are intervals of 
growth and reorganisation. Once cells stop cycling after their division, they enter 
a state of quiescence, also known as G0 (Dhawan and Laxman, 2015).  
 
 
 
 
 
 
 
Figure 5.1.1.: Schematic representation of the cell cycle (Adapted from: The 
Biology Project- University of Arizona). 
 
The above series of events are controlled by two types of cell cycle control 
mechanisms: (i) a set of checkpoints that monitors the successful completion of 
each phase and (ii) a cascade of proteins (cyclins) that regulate the cell transition 
from one stage to the next (Rao and Johnson, 1970, Murray, 1991, Murray, 1994). 
There are three main checkpoints that control cell cycle progression: the G1 
checkpoint (between the G1-S transition), the G2 checkpoint (between the G2-M 
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transition) and the spindle checkpoint (during the anaphase where replicated 
chromosomes divide and daughter chromatids move to opposite poles) (Kastan 
and Bartek, 2004).  
The second type of cell cycle control is regulation by cyclin/cyclin dependent kinase 
complexes (CDKs) (Grana and Reddy, 1995, Michalides, 1999). CDKs are formed 
and activated during the several stages of cell division and are mainly involved in 
DNA synthesis and mitosis (Hartwell and Kastan, 1994). CDKs consist of a catalytic 
domain that is not active when monomeric and unphosphorylated (Malumbres and 
Barbacid, 2001). Once CDKs are associated with a cyclin partner, they form 
heterodimeric complexes that are activated after 
phosphorylation/dephosphorylation of specific residues (for example, cyclins A1 
and B2 interact and activate CDK1). However, CDK activity can be dysregulated 
by CDK inhibitors (CDKIs), leading to cell cycle arrest in response to cell cycle 
checkpoint machinery (Malumbres and Barbacid, 2004). Such an example is the 
dysregulation of the cyclin D1:CDK4/6 complex which is associated to different 
types of breast cancer, as according to Arnold et al. (2005), cyclin D1 is 
overexpressed in human tumours. 
Alterations to the controlled and successful progression of the cell cycle can result 
in inappropriate cell proliferation and in an increase in genomic instability, leading 
to the development of diseases, such as cancer (Sherr and Roberts, 2004). 
Therefore, it is important to understand cell cycle in cancer research, as this would 
allow researchers to synthesise drugs that would attack cancer cells in particular 
phases (G1, S, G2) of the cell cycle and become more effective than radiotherapy, 
the latter targeting only cells that undergo cell division (M phase). 
In this study, cell cycle distribution by quantitation of DNA content was assessed 
by flow cytometry following staining with propidium iodide (PI). PI is a DNA 
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intercalator and fluorescent molecule that binds to DNA, after the loss of plasma 
membrane integrity (Nicoletti et al, 1991). DNA content is proportional to the 
amount of PI bound to DNA thus, indicating the percentage of cells in each phase 
of the cell cycle. For example, in G1 phase the DNA content is 2n (diploid), DNA 
content doubles to 4n in S phase and remains at 4n during G2 phase (Crowley et 
al, 2016). When the DNA content is less than 2n, cells belong to the sub-G1 
population, which is a hallmark of apoptotic cells (low DNA content) (Crowley et 
al, 2016). 
 
5.1.2 Cell death and cancer 
One of the most widely-studied area in cancer research is cell death, particularly 
apoptosis. The main reason is that better understanding of apoptotic mechanisms 
can give insights into the pathogenesis of cancer or clues about its treatment 
(Merkle, 2009). 
Apoptosis is a biological phenomenon that was first discovered back in 70’s, by 
Kerr et al. (1972). Apoptosis is derived from the Ancient Greek ἀπόπτωσις, which 
means "falling off” (Kerr et al, 1972). Nowadays, apoptosis is defined as a 
programmed sequence of events that eliminate cells that are a threat or no longer 
needed by a tightly regulated process of cell suicide process. At a morphological 
level apoptosis involves rounding-up of the cell, cell shrinkage, reduction of 
cellular volume (pyknosis), chromatin condensation, nuclear fragmentation, 
plasma membrane and cytoplasmic blebbing, and engulfment by resident 
phagocytes (Figure 5.1.2.1) (Krysco et al, 2008). 
Apart from the morphological alterations that affect both the nucleus and 
cytoplasm, apoptosis is regulated by several pathways and biochemical mediators 
(Hacker, 2000). Caspases are central to the mechanism of apoptosis and can get 
 
145 
activated through the intrinsic (or mitochondrial) pathway (activation of pro-
apoptotic proteins, such as Bax, Bak, Bad, Bcl-Xs, Bid, and anti-apoptotic proteins, 
such as Bcl-2, Bcl-XL, Bcl-W), the extrinsic (or death receptor) pathway (activation 
of death receptors, such as TNF, CD95 and DISC complex), or the intrinsic 
endoplasmic reticulum pathway (Youle and Strasser, 2008). 
 
 
Figure 5.1.2.1.: Cytology of apoptosis (From: Abou-Ghali and Stiban, 2015). 
 
Numerous methods have been developed in order to assess apoptotic cell death. 
These methods are based on major cell death parameters, such as morphology 
(time-lapse microscopy, flow cytometry and transmission electron microscopy), 
cell surface markers phosphatidylserine (PS) exposure versus membrane 
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permeability by flow cytometry), intracellular markers (oligonucleosomal DNA 
fragmentation, caspase activation, cytochrome c release or Bid cleavage) and 
extracellular markers in the supernatant (release of cytokeratin 18) (Krysco et al, 
2008). 
In this study, Annexin V-FITC/7-AAD staining, detected by flow cytometry, was 
used to study apoptosis in MDA-MB-231 and SKBR-3 breast cancer cells. 
Translocation of membrane PS from the inner side to the surface of the plasma 
membrane is one of the earliest events of apoptosis (Koopman et al, 1994). 
Annexin V, which is a Ca2+-dependent phospholipid-binding protein conjugated to 
fluorescein isothiocyanate, binds to PS residues reversibly, serving as a sensitive 
probe for flow cytometry analysis of cells undergoing apoptosis (Figure 5.1.2.2). 
On the other hand, 7-AAD is a fluorescent dye that labels cells that have lost their 
plasma membrane integrity (necrotic cells) (Koopman et al, 1994, Van Engeland 
et al, 1998). 
 
Figure 5.1.2.2.: Translocation of membrane PS from the inner side to the surface 
of the plasma membrane in apoptotic cell (BioLegend, www.biolegend.com). 
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5.1.3 Crosstalk between cell death machineries 
Several studies have shown that in some cases, apoptotic signalling pathways can 
trigger more than one mode of cell death (Fiers et al, 1999). More specifically, a 
functional relationship between apoptosis (self-killing) and autophagy has been 
reported (Nikoletopoulou et al, 2013), showing that the two machineries share 
common pathways and that crosstalk between them exists.  
Autophagy (from the Ancient Greek αὐτόφαγος, meaning "self-devouring”) is a 
cytoprotective process that allows the degradation and recycling of unnecessary 
or dysfunctional components (Suman et al, 2014). More specifically, autophagy is 
involved in removing misfolded proteins, damaged organelles, (mitochondria, 
peroxisomes, endoplasmic reticulum) and intracellular pathogens (Suman et al, 
2014). Recent studies have also shown that autophagy promotes cancer cell 
survival, by protecting cancer cells from starvation, oxidative stress or hypoxia 
and causing tumour chemoresistance (Kroemer and Jaattela, 2005). For example, 
autophagy-mediated chemoresistance has been reported in colon and lung cancer 
cells after treatment with cisplatin and breast cancer cells after treatment with 
camptothecin (Li et al, 2010, Ren et al, 2010, Abedin et al, 2007). On the other 
hand, after treatment with temozolomide and dexamethasone anti-cancer agents 
autophagy is induced, promoting growth arrest in cancer cells (Kanzawa et al, 
2004, Laane et al, 2009). However, although the role of autophagy in cancer 
seems to be pivotal, the mechanism that dictates autophagy-mediated cell 
death/survival and its interaction with other cell death machineries is unknown. 
Recently, caspases were found to participate as crosstalk regulators between 
autophagy and apoptosis (Wu et al, 2014), acting either as initiators or effectors 
that are involved in apoptotic cascades (Figure 5.1.3). For example, several pro-
apoptotic pathways induce caspases to trigger apoptosis, but in parallel, some of 
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the activated caspases break down or cleave critical autophagic proteins, like 
Beclin-1 and inactivate autophagic functions (Matsuzawa et al, 2015, Pagliarini et 
al, 2012). 
 
Figure 5.1.3.: The relationship between apoptosis and autophagy. 
 
Recent findings have revealed that there is a differential activation of caspases 
among several types of cancer and they seem to trigger specific modes of cell 
death. For example, in the absence of Caspase-2 activity in mice neurons, 
apoptosis cannot occur, while autophagy is activated (Dorstyn and Kumar, 2009). 
In addition, Karna et al (2010) found the tubulin-binding noscapine analogue Red-
Br-nos to induce autophagy followed by caspase-independent apoptotic cell death 
(CICD) in human prostate cancer PC-3 cells (Tait and Green, 2008). 
The above findings suggest that further research on the multiple molecular 
mechanisms that coordinate autophagy and apoptosis or the role of proteins 
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involved in this crosstalk in cancer would be beneficial for the rational design of 
successful anti-cancer therapeutics. 
In this study, induction of apoptosis was assessed via a Caspase-3 activity 
colourimetric assay. Caspase-3 is an effector caspase that is associated with the 
initiation of the “death cascade” (Porter and Janickle, 1999). Thus, Caspase-3 has 
been considered as an important marker of a cell’s entry into the apoptotic 
signalling pathway. In addition, Caspase-3 is activated by the upstream Caspase-
8 and Caspase-9 and is involved in different signalling pathways (Doonan et al, 
2003). Therefore, measurement of its activity is well suited as a read-out in an 
apoptosis assay. Furthermore, autophagy as a potential mode of cell death was 
also investigated via an autophagy microplate assay. 
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5.1.4 Aims 
In cancer research, drug discovery in the pharmaceutical industry has focused into 
targeting molecular mechanisms (linked to cell cycle and cell death) in order to 
disrupt their pathways. This approach has led to the development of cell cycle-
based, mechanism-targeted cancer therapies that mimic the natural processes of 
the human organism in order to inhibit cancer cell proliferation, by inducing cell 
cycle arrest. Flavopiridol and Silibinin are two examples of anti-cancer drugs that 
target CDK activation and cause cell cycle arrest, resulting in growth inhibition and 
apoptosis in cancer cells (Deep and Agarwal, 2012). Therefore, as a consequence 
of their ability to intercalate with DNA and cause DNA strand breaks, it was crucial 
to investigate whether the novel BNIPs have the potential to induce cell cycle 
arrest and apoptotic cell death. 
The aim of the work presented in Chapter 5 was to assess the ability of novel 
BNIPs to induce cell death. The objectives of the experimental work was to 
determine the effect of BNIPDaCHM, BNIPPiProp, BNIPPiEth and trans,trans-
BNIPDaCHM on the cell cycle distribution and inducement of apoptosis (i.e. 
Caspase 3) or autophagy in breast cancer MDA-MB-231 and SKBR-3 cells. 
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5.2 Materials  
A list of reagents that were used for cell cycle, Annexin V- FITC/7-AAD, Caspase 
3 and autophagy studies are presented below. All reagents were handled 
according to the COSHH standards and were used without purification. 
 
5.2.1 Cell cycle analysis/ propidium iodide (PI) staining 
Disodium phosphate      Sigma-Aldrich, UK 
Citric acid       Sigma-Aldrich, UK 
Ribonuclease A      Sigma-Aldrich, UK 
Propidium iodide      Sigma-Aldrich, UK 
 
5.2.2 Annexin V-FITC/7-AAD Staining 
Annexin V-FITC 
Kit System for Detection of Apoptosis    Beckman Coulter, UK 
 
5.2.3 Caspase-3 colourimetric assay 
Caspase 3 colourimetric assay kit    R&D Systems Inc., UK 
 
5.2.4 Autophagy microplate assay 
CYTO-ID Autophagy Detection Kit     Enzo, UK 
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5.2.5 Instrumentation  
ALC Multispeed Refrigerated Centrifuge  Thomson Scientific, UK 
Coulter Epics XL-MCL flow cytometer   Beckman Coulter, UK 
96-well plate reader       Synergy/HT, BIOTEK  
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5.3 Methods  
5.3.1 Cell cycle analysis  
MDA-MB-231 and SKBR-3 cells (1 x 106 cells/T25 flask) were washed twice with 
PBS and serum free medium was added in order to achieve cell synchrony (Langan 
and Chou, 2011). The cells were incubated in serum free medium for 24 hours. 
BNIPs (IC25 concentrations) were then added and the cells were incubated for a 
further 24 hours, at 37 °C. The medium was removed and collected. The cells 
were washed twice with PBS (2 mL). Both washes were collected and the cells 
trypsinised, mixed with the collected washes and centrifuged at 500 xg for 5 
minutes at 4 °C. The supernatant was discarded, the pellet resuspended in PBS 
(1 mL) and centrifuged as before, the supernatant was discarded again and the 
pellet resuspended in PBS (100 µL). To fix the cells, 70% (v/v) ice-cold ethanol 
(900 µL) was added and samples incubated for 2 hours at -20 °C. The cells were 
centrifuged at 3,000 xg for 5 minutes at 4 °C, the supernatant was discarded, the 
pellet resuspended in PBS (500 µL) and DNA extraction buffer (0.2 M Na2HPO4, 4 
mM citric acid, pH 7.8, 500 µL) and incubated for 5 minutes at room temperature. 
The samples were centrifuged at 500 xg for 5 minutes at 4 °C, the supernatant 
removed and the pellets resuspended in DNA staining solution (0.2 mg/mL 
Ribonuclease A (DNAse-free) and 20 µg/mL PI in PBS). The samples were 
incubated for 30 minutes at 4°C in the dark and examined by flow cytometry. For 
cell cycle analysis, EXPO32 ADC analysis software was used to record and analyse 
10,000 single events. The percentage of cells with DNA content in sub-G1, G1, S 
and G2/M phases was calculated from histograms of linear FL-2 plots (575 nm) in 
the gated region (Figure 5.3.1).  
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Figure 5.3.1.: Cell cycle distribution of MDA-MB-231 cells before (left) and after 
24 hours treatment with BNIPDaCHM IC25 (right). Cells were stained with PI and 
analysed by flow cytometry (10,000 events were recorded). Line markers indicate the 
regions of the cell cycle: sub-G1, G1, S and G2/M phases (left-right). Images are 
representative of the results obtained using EXPO32 ADC analysis software. 
In cell cycle analysis, doublet exclusion ensures the count of single cells and the 
exclusion of cell doublets. Doublets can be discriminated by using two parameter 
measurements plotting pulsed-height (FL-H) against pulsed-area (FL-A), which is 
not available in every instrument though (Coulter Epics XL-MCL flow cytometer). 
Doublets form when cells in close proximity are identified by the flow cytometer 
as a single event (eg. cell coincidence or clumping during data acquisition). As a 
result, a doublet may be falsely identified as a single tetraploid cell in G2/M-phase 
(Nunez, 2001). If a sample contains many doublets, which could mistakenly 
increase the relative number of cells in the G2/M-phase of the cell cycle, yielding 
to an overestimation of G2/M population (Nunez, 2001). Thus, the above 
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statement confirms that there is no chance of having cell doublets in any other 
phase of the cell cycle apart from G2/M. In the cell cycle studies presented in this 
Chapter, there is no indication of increase in G2/M phase after treatment with 
BNIPs in MDA-MB-231 and SKBR-3 cells, after repeating 4 independent 
experiments. 
5.3.2 Annexin V-FITC/7-AAD Staining 
MDA-MB-231 and SKBR-3 cells (16 x 104 cells/2 mL/12-well plate) were seeded 
and incubated for 24 hours, at 37 °C. BNIPs (IC25 concentrations) were added and 
after the desired incubation time (0.5, 4 or 6 hours at 37 °C), medium containing 
BNIPs was removed and discarded. Cells were washed twice with ice-cold PBS, 
collected after trypsinisation and centrifuged at 300 xg for 5 minutes at 4 °C. The 
supernatant was discarded, pellet resuspended in 100 μL of ice-cold Binding Buffer 
(1x in dH2O), containing 10 μL Annexin V-FITC solution and 20 μL 7-AAD viability 
dye. The solutions were mixed gently and incubated on ice for 15 minutes in the 
dark. After the required incubation time, 400 μL of ice-cold Binding Buffer (1x in 
dH2O) was added. Annexin V-FITC and 7-AAD stained cell samples were analysed 
within 30 minutes by flow cytometry. For apoptosis analysis, 10,000 single events 
were recorded and analysed using the FL-1 (525 nm) channel for Annexin V-FITC 
detection and the FL-4 (675 nm) channel for detection of 7-AAD fluorescence. The 
percentage of apoptotic and necrotic cells was gated on the respective histogram 
plots LOG FL-1 and LOG FL-4 (Figure 5.3.2). Formaldehyde (3%) was used as 
positive control to achieve maximal apoptotic cell death after 30 minutes (Barron 
et al, 2015). 
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Figure 5.3.2.: Apoptotic (A4) and necrotic distribution (A2) of MDA-MB-231 cells 
before (left) and after 0.5 hour treatment with BNIPDaCHM IC25 (right). Cells were 
stained with annexin V-FITC/7-AAD and analysed by flow cytometry (10,000 events were 
recorded). Images are representative of the results obtained using EXPO32 ADC analysis 
software. 
  
 
157 
Caspase activity was measured using the manufacturer’s protocol. The principle 
of the assay was to test the protease activity in the cell lysate by the addition of 
a Caspase 3-specific peptide that is conjugated to a colour reporter molecule (p 
nitroaniline) (pNA). The cleavage of the peptide by Caspase-3 releases the 
chromophore, which can be quantitated spectrophotometrically at a wavelength 
of 405 nm. 
 
5.3.3 Caspase-3 Colourimetric assay 
MDA-MB-231 and SKBR-3 cells (1 x 106 cells/T25 flask) were seeded and 
incubated for 24 hours, at 37°C. BNIPs (IC25 concentrations) were added. After 24 
hour incubation time, medium containing BNIPs was removed and discarded. Cells 
were washed twice with ice-cold PBS, collected and centrifuged at 500 xg for 5 
minutes at 4°C. The supernatant was discarded and the cell pellet was lysed by 
the addition of cold Lysis buffer (25 μL). The cell lysate was incubated on ice for 
10 minutes and then centrifuged at 10,000 xg for 1 minute. The supernatants 
were transferred to Eppendorf tubes and kept on ice. The protein content was then 
quantified by protein assay (BCA Protein Assay). 
In a 96-well flat bottom microplate, 50 μL of control or sample (i.e. BNIPs treated), 
50 μL of 2X Reaction Buffer 3 and 5 μL of Caspase-3 colourimetric substrate 
(DEVD-pNA) was added per well. The plate was then incubated for 2 hours at 37 
°C. Caspase-3 absorbance was measured with a microplate reader at 430 nm. 
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5.3.4 Autophagy microplate assay 
Autophagy flux was determined using a Cyto-ID autophagy detection kit according 
to the manufacturer’s instructions. The principle of the assay was to test the 
autophagic activity at the cellular level after treatment with BNIPs. The green 
fluorescent detection reagent supplied in the kit becomes brightly fluorescent in 
vesicles produced during autophagy and can be quantitated 
spectrophotometrically at a wavelength of 488 nm. An increase in the green 
autophagy signal is proportional to the accumulation of the probe within 
autophagic vesicles. Moreover, Rapamycin, an inducer of autophagy and 
Chloroquine, a lysosomal inhibitor, were also tested within the assay at 
concentrations suggested by the manufacturers. 
MDA-MB-231 and SKBR-3 cells (7.5 x 103 cells/well) were seeded and incubated 
for 24 hours in a 96-well plate, at 37°C. BNIP derivatives (IC25 concentrations for 
24 hours), Rapamycin (0.5 μM), Chloroquine (10 μM) and negative control were 
added. After treatment, the medium was carefully removed and discarded. Cells 
were washed with 1X Assay Buffer (100 μL) and dual colour detection solution was 
added in each well (100 μL). The plate was incubated in the dark for 30 minutes 
at 37°C. Cells were washed twice with 1X Assay Buffer (200 μL) to remove excess 
dye and then fresh 1X Assay Buffer (100 μL) was added in each well. The CYTO-
ID Green detection reagent was read with a FITC filter (Excitation 480 nm, 
Emission 530 nm) and the Hoechst 33342 Nuclear Stain was read with a DAPI 
filter set (Excitation 340 nm, Emission 480 nm). 
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5.3.5 Statistical Analysis 
Three independent experiments were conducted and each experiment was 
comprised of at least two internal replicates, unless otherwise stated. Data are 
presented as mean ± SD or ± SEM. Statistical analysis was performed by using 
an unpaired Student’s t-test. Statistically significant data were detailed when 
*p<0.05, **p<0.01, ***p<0.001.  
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5.4 Results and Discussion 
5.4.1 Cell cycle distribution in MDA-MB-231 and SKBR-3 cells 
Cell cycle distribution of MDA-MB-231 and SKBR-3 cells was studied using flow 
cytometry following PI staining (Henry et al, 2013) with the most active compound 
trans,trans-BNIPDaCHM (Chapter 4), together with the parental compound 
BNIPDaCHM (mixture of isomers) that has been reported to induce cell cycle 
instability (Barron et al, 2015). 
In order to accurately study the progression of cells through each phase of the cell 
cycle, MDA-MB-231 and SKBR-3 cells were synchronised by 24 hours serum 
deprivation (Figure 5.4.1). The elimination of serum resulted in the accumulation 
of cells in sub-G1 and G1 phase (Figures 5.4.1a and 5.4.1b) (see Appendix 5). 
A significant increase in the proportion of MDA-MB-231 cells in sub-G1 phase after 
treatment with BNIPDaCHM (IC25), trans,trans-BNIPDaCHM (IC25) and 
camptothecin (21.9%, 25.5% and 20.1% increase) was exhibited relative to the 
control, whilst in G1 phase, the cell population was significantly decreased (by 
16.2%, 15.1% and 9.36% respectively) (Figure 5.4.1.1a). The two BNIPs induced 
sub-G1 arrest in a similar way to camptothecin, which was used as a positive 
control. The proportion of MDA-MB-231 cells in S and G2 phase was not 
significantly different after treatment with the two BNIPs and camptothecin, 
compared to untreated cells.  
These results indicate that both BNIPDaCHM and trans,trans-BNIPDaCHM induced 
sub-G1 cell cycle arrest in a similar way to camptothecin. Camptothecin is a well-
known positive control for sub-G1 arrest (Chu et al, 2014, Doddapadeni et al, 
2015) and for inducing apoptosis, even at low concentrations (e.g. 6 μM) (Kang 
et al, 2016, Hong et al, 2014).  
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Consequently, these findings suggest that BNIPDaCHM and trans,trans-
BNIPDaCHM could use similar mechanisms of action compared to camptothecin 
and may trigger apoptotic cell death in MDA-MB-231 human breast cancer cells.  
Similar experiments were carried out with synchronised SKBR-3 cells (Figure 
5.4.1.1b), where the cell population was significantly increased in sub-G1 phase 
only after treatment with BNIPDaCHM (29.3%) and camptothecin (45.3%), but 
not for trans,trans-BNIPDaCHM compared to the control. This demonstrated that 
the effect of the two BNIPs investigated was different in each cell line and that the 
sole existence of one isomer (trans,trans-BNIPDaCHM) has a different effect on 
cell cycle distribution. Therefore, it is suggested that the mechanisms of cell death 
induced by trans,trans-BNIPDaCHM and BNIPDaCHM may differ among different 
cell lines, even though they belong to the same family of compounds. 
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Figure 5.4.1.: a) Synchronisation of MDA-MB-231 and b) SKBR-3 cells after 24 
hour serum deprivation. The percentage of the cell population in sub-G1, G1, S and 
G2/M were gated from histograms of linear FL-2 plots in the ungated regions (10,000 
events). Data are mean ± SEM of three independent experiments (n = 3), conducted in 
duplicates. ***p< 0.001,*p< 0.05, compared to control. 
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Figure 5.4.1.1.: a) Cell cycle distribution of MDA-MB-231 and b) SKBR-3 cells 
after BNIP treatment (IC25). Quantification of MDA-MB-231 and SKBR-3 cell cycle 
profiles by flow cytometry following PI staining after 24 hour treatment with IC25 
BNIPDaCHM, trans,trans-BNIPDaCHM and camptothecin. DMSO/dH2O (50% v/v) was used 
as the solvent control. The percentage of the cell population in sub-G1, G1, S and G2/M 
were gated from histograms of linear FL-2 plots (10 000 events). Data are mean ± SEM 
of three independent experiments (n = 3), conducted in duplicates. *p< 0.05, compared 
to solvent control for each cell cycle phase.  
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5.4.2 Annexin V-FITC/7-AAD studies in MDA-MB-231 and SKBR-3 
cells. 
PS exposure and plasma membrane integrity in MDA-MB-231 and SKBR-3 cells 
after treatment with BNIPs were quantified using flow cytometry following Annexin 
V-FITC staining and 7-AAD labelling. Initially, cells were exposed to BNIPDaCHM 
for multiple timepoints (0.5, 2 and 4 hours) in order to capture the time frame by 
which the drug induce cell death in the above cell lines (Figure 5.4.2). 
 
 
Figure 5.4.2.: PS exposure and membrane integrity profiles of MDA-MB-231 after 
0.5, 2, and 4 hour treatment with IC25 BNIPDaCHM. Profiles were determined by flow 
cytometry following Annexin V-FITC staining and 7-AAD labelling. 10,000 single events 
were recorded, and cells labelled with Annexin V but not 7-AAD were considered Annexin 
positive. Cells labelled with 7-AAD were 7-AAD positive. DMSO/dH2O (50% v/v) was used 
as the solvent control. Data are mean ± SEM of four independent experiments (n = 4), 
conducted in duplicates. *p< 0.05, compared to solvent control. 
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Apoptotic and necrotic histograms were obtained after 0.5, 2 and 4 hours 
treatment with BNIPDaCHM in MDA-MB-231 cells. Annexin V-FITC stains apoptotic 
cells, whilst 7-AAD viability dye stains necrotic cells. Cells labelled with Annexin 
V-FITC but not 7-AAD were Annexin positive and cells labelled with 7-AAD only, 
were 7-AAD positive. Cells labelled with both dyes were not considered in the 
study, as no change within the double positive population was observed after 
treatment with BNIPs (see Appendix 6). 
Figure 5.4.2 shows that after 0.5 hour treatment with BNIPDaCHM (IC25), a 
significant increase of 277.3% in Annexin V-FITC staining was observed, compared 
to the control. After 2 hours treatment with BNIPDaCHM, the Annexin V-FITC 
staining levels remained high (289.2%), but after 4 hours treatment, a decrease 
of 183.9% in Annexin V-FITC staining was observed, compared to the other two 
time points.  
These results indicate that Annexin V-FITC can bind to PS residues, which are 
externalised to the outer layer of the MDA-MB-231 plasma membranes and this is 
linked to early apoptotic cell death. On the other hand, low levels of 7-AAD staining 
show that plasma membrane integrity of MDA-MB-231 cells is not affected 
(absence of necrotic cell population) compared to the control.  
The decrease in Annexin V-FITC staining after 4 hour treatment with BNIPDaCHM 
confirms that PS exposure is an early apoptotic event. Therefore, it was crucial in 
this study to collect repeated measurements over time, in order to study the right 
time point for early apoptosis. 
Based on the above results, PS exposure and plasma membrane integrity profiles 
after 0.5 hour treatment with all novel BNIPs were further studied. In the following 
experiments, Formaldehyde (3%) was used as positive control, as Formaldehyde 
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treatment has been found to significantly induce apoptotic cell death (Barron et 
al, 2015). 
After 0.5 hour treatment with BNIPs (Figure 5.4.2.1a), significant differences in 
Annexin V-FITC staining compared to the control was observed in MDA-MB-231 
cells. More specifically, after treatment with BNIPDaCHM Annexin V-FITC staining 
levels were increased by 593.8% (p<0.05). After treatment with BNIPPiProp, 
Annexin V-FITC levels were increased by 708.3% (p<0.05). Annexin V-FITC 
staining levels after treatment with BNIPPiEth and trans,trans-BNIPDaCHM were 
increased by 975.0% and 900.8%, compared to untreated cells, respectively. 
Formaldehyde treatment (positive control), increased the Annexin V-FITC staining 
levels by 1816.7%. Moreover, according to statistical analysis, no significance 
difference was found in MDA-MB-231 apoptotic cell populations after treatment 
with BNIPDaCHM, BNIPPiProp, BNIPPiEth and trans,trans-BNIPDaCHM, compared 
to each other. 
According to these findings, the three novel BNIPs and their parental compound 
BNIPDaCHM, induced apoptotis in the cell population, as shown by an increase in 
Annexin V-FITC staining. BNIPPiEth caused the highest increase of Annexin V-FITC 
staining levels in MDA-MB-231 cells (975.0%), followed by trans,trans-NIPDaCHM 
(900.8%), BNIPPiProp (708.3%) and BNIPDaCHM had the lowest (593.8%). On 
the other hand, after treatment with BNIPs or Formaldehyde, 7-AAD viability dye 
staining levels were not increased compared to the control. 7-AAD can only label 
cells without membrane integrity. Therefore, the above results indicate that 
treatment with BNIPs did not compromise membrane integrity, which is associated 
to necrotic cell death. 
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Similar studies were performed in SKBR-3 cells (Figure 5.4.2.1b). After 0.5 hours 
treatment with BNIPs, a significant difference in Annexin V-FITC staining 
compared to the control was observed. More specifically, after treatment with 
BNIPDaCHM, Annexin V-FITC staining levels were increased by 41375.0% 
(p<0.05). After treatment with BNIPPiProp, Annexin V-FITC levels were increased 
by 32800.0% (p<0.05). Annexin V-FITC staining levels after treatment with 
BNIPPiEth and trans,trans-BNIPDaCHM were increased by 33883.3% and 
42900.0%, compared to control cells, respectively. Formaldehyde treatment 
(positive control), increased Annexin V-FITC staining levels by 13466.7.7%, 
compared to the control. According to statistical analysis, no significance 
difference was found in SKBR-3 apoptotic cell populations after treatment with 
BNIPDaCHM, BNIPPiProp, BNIPPiEth and trans,trans-BNIPDaCHM, compared to 
each other. 
Interestingly, BNIPs induce apoptosis not only in MDA-MB-231, but also in SKBR-
3 cells and to a greater extent. trans,trans-BNIPDaCHM was the derivative that 
induced the highest increase of Annexin V-FITC staining levels in SKBR-3 cells 
(42900.0%), followed by BNIPDaCHM (41375.0%), BNIPPiEth (33883.3%) and 
BNIPPiProp was the derivative that caused the lowest increase of Annexin V-FITC 
staining levels (32800.0%).  
Similarly to the previous findings in MDA-MB-231 cells, after treatment with BNIPs 
or Formaldehyde, necrotic cell population was virtually absent. Therefore, these 
results indicate that treatment with BNIPs also did not compromise plasma 
integrity in SKBR-3 cells. In addition, human epidermal growth factor receptor 2-
overexpressing SK-BR-3 cells (hormone receptor positive) seem once more to 
have a better response to BNIP treatments with regards to induction of early 
apoptosis, compared to MDA-MB-231 cells.  
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After 0.5 hours, BNIPs elicit PS residues externalisation in both cell lines, 
preventing early plasma membrane damage. These findings suggest strongly that 
BNIPs induce early apoptosis, which could be the main mechanism in BNIP-
induced cytotoxicity and cell cycle arrest. However, there are no similar finding in 
the literature that shows induction of early apoptosis after 0.5 hour treatment with 
anti-cancer drugs that are already in use, such as Capecitabine (Ershler, 2006). 
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Figure 5.4.2.1.: a) PS exposure and membrane integrity profiles of MDA-MB-231 
and b) SKBR-3 cells, after 0.5 hour treatment with IC25 BNIPs. Profiles were 
determined by flow cytometry following Annexin V-FITC staining and 7-AAD labelling. 
10,000 single events were recorded, and cells labelled with Annexin V but not 7-AAD were 
Annexin positive. Cells labelled with 7-AAD were 7-AAD positive. DMSO/dH2O (50% v/v) 
was used as the solvent control. Data are mean ± SEM of four independent experiments 
(n = 4), conducted in duplicates. *p< 0.05, compared to solvent control. 
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5.4.3 Caspase-3 studies in MDA-MB-231 and SKBR-3 cells 
Caspase-3 is a mediator of programmed cell death and its activity was examined 
to determine the effect of BNIPs on apoptosis pathways in MDA-MB-231 and 
SKBR-3 cells.  
After 24 hours treatment with BNIPs, a difference in Caspase-3 activity compared 
to untreated cells was observed in MDA-MB-231 cells (Figure 5.4.3a). More 
specifically, after treatment with BNIPDaCHM, Caspase-3 activity levels were 
significantly decreased by 81.5% (p<0.01). After treatment with BNIPPiProp, 
Caspase-3 activity was decreased by 81.7% (p<0.05). Similarly, Caspase-3 
activity was not detected after treatment with BNIPPiEth and after treatment with 
trans,trans-BNIPDaCHM, Caspase-3 activity levels were similar to the control. 
These results indicate that the three novel BNIPs investigated and their parental 
compound BNIPDaCHM did not activate Caspase-3 after 24 hour treatment in 
MDA-MB-231 cells, but rather decreased it. BNIPPiEth is the derivative that 
induced the highest decrease of Caspase-3 activity levels in MDA-MB-231 cells 
(100.0%), followed by BNIPPiProp (81.7%), BNIPPiEth (81.5.3%) and trans,trans-
BNIPDaCHM had no change compared to the control. In contrast, after 24 hour 
treatment with BNIPs (IC25), different findings with regards to Caspase-3 activity 
compared to the control was observed in SKBR-3 cells (Figure 5.4.3b). More 
specifically, after treatment with BNIPDaCHM, Caspase-3 activity levels were 
significantly increased by 771.5% (p<0.001). After treatment with BNIPPiProp and 
BNIPPiEth, Caspase-3 activity was not detected (0%, p<0.001). Moreover, 
trans,trans-BNIPDaCHM decreased Caspase-3 activity levels compared to the 
control by 71.9% (p<0.001).  
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Figure 5.4.3.: a) Effect of BNIPs on Caspase-3 activity in MDA-MB-231 and b) 
SKBR-3 cells, after 24 hour treatment at 37 oC with BNIPDaCHM, BNIPPiProp, 
BNIPPiEth and trans,trans-BNIPDaCHM. DMSO/H2O was used as solvent control. Data 
presented as mean ±SEM (n=3). ***p<0.001, **p<0.01, *p<0.05, compared to solvent 
control. 
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Results indicate that only the parental compound BNIPDaCHM, activated Caspase-
3 activity after 24 hours treatment in SKBR-3cells. The other compounds either 
decreased Caspase-3 activity (trans,trans-BNIPDaCHM), or did not alter it at all 
(BNIPPiProp and BNIPPiEth). These findings show that Caspase-3 was not 
activated by any of the BNIPs after 24 hours in MDA-MB-231 cells and that only 
BNIPDaCHM activated Caspase-3 in SKBR-3 cells, which was the cell line that was 
more susceptible to BNIP treatments according to the previous results (Chapter 
3). Consequently, further studies should be undertaken in order to determine the 
accurate time-point where Caspase-3 is potentially activated by BNIPPiProp, 
BNIPPiEth and trans,trans-BNIPDaCHM in MDA-MB-231 and SKBR-3 cells. 
However, according to the literature, there are types of cancer where Caspase-3 
expression and activity can alter during carcinogenesis and not even exist once 
the cancer cells are terminally differentiated (Hague et al, 2006), or cases where 
early apoptosis interferes with autophagy, as both machineries share common 
pathways (Maiuri et al, 2007). Therefore, researchers are currently investigating 
whether specific mechanisms that involve Caspase-3 expression and activity could 
be used as potential targets for therapeutic benefit of cancer patients. Such an 
example is the study of Lee et al. (2016), where lambertianic acid treatment in 
prostate cancer cells was found to lead to apoptotic cell death due to induced sub-
G1 arrest and cleaved Caspase-3 activity. 
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5.4.4 Autophagy studies in MDA-MB-231 and SKBR-3 cells 
Autophagy flux in MDA-MB-231 and SKBR-3 cells was detected by CYTO ID 
fluorescence microplate assay.  
After 24 hour treatment with BNIPs (IC25), significant difference in autophagy flux 
compared to the control were observed in MDA-MB-231 cells (Figure 5.4.4a). More 
specifically, after treatment with BNIPDaCHM, autophagy was significantly 
increased by 26.4% (p<0.001). After treatment with BNIPPiProp, autophagy flux 
was increased by 25.7% (p<0.001). Autophagy levels after treatment with 
BNIPPiEth and trans,trans-BNIPDaCHM were elevated by 18.8% (p<0.001) and 
17.9% (p<0.001), compared to the control, respectively. Rapamycin treatment 
increased the autophagy levels by 1.4% and Chloroquine by 13.4% (p<0.05). 
When Rapamycin and Chloroquine were combined, autophagy was induced, to a 
greater extent than a cumulative effect by 24.6% (p<0.01), suggesting a 
synergistic effect. According to these findings, the three novel BNIPs investigated 
and their parental compound BNIPDaCHM, induced autophagy in MDA-MB-231 
cells after 24 hour treatment. BNIPDaCHM caused the highest increase of 
autophagy levels in MDA-MB-231 cells (26.4% (p<0.001)), followed by 
BNIPPiProp (25.7% (p<0.001)), BNIPPiEth (18.8% (p<0.001)) and trans,trans-
BNIPDaCHM (17.9% (p<0.001)). Moreover, according to statistical analysis, no 
significance difference was found in MDA-MB-231 cell autophagy levels after 
treatment with BNIPDaCHM, BNIPPiProp, BNIPPiEth and trans,trans-BNIPDaCHM, 
compared to each other. 
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Figure 5.4.4.: a) Detection of autophagy by microplate reader in MDA-MB-231 
and b) SKBR-3 cells. Cells were cultured with 0.5 µM rapamycin, 10 µM Chloroquine, 0.5 
µM Rapamycin + 10 µM Chloroquine and BNIPs (IC25), followed by staining with green 
detection reagent as described in the manual. Nuclei were counter stained with Hoechst 
33342. The data indicate the relative green fluorescence intensity normalized by blue 
fluorescence intensity. DMSO/H2O was used as solvent control. Data presented as mean 
±SEM (n=3). ***p<0.001, **p<0.01, *p<0.05, compared to solvent control.  
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Interestingly, all the BNIPs were found to induce autophagy to a greater extent 
than the two positive controls, Rapamycin and Chloroquine, which strongly 
suggests the activation of autophagic response machineries after treatment with 
BNIPs. In addition, treatment with BNIPs may allow accumulation of the drugs in 
lysosomes and inhibit lysosomal function in the same way as Chloroquine 
(lysosomotropic compound). 
With regards to SKBR-3 cells, BNIPs significantly induced differences in autophagy 
flux compared to the control, after 24 hour treatment with BNIPs (Figure 5.4.4b). 
More specifically, after treatment with BNIPDaCHM autophagy was significantly 
increased by 14.3% (p<0.01). After treatment with BNIPPiProp, autophagy flux 
was induced by 16.0% (p<0.05), compared to the control. When the cells were 
treated with BNIPPiEth and trans,trans-BNIPDaCHM, autophagy was elevated by 
11.4% (p<0.01) and 12.8% (p<0.01), compared to control cells, respectively. For 
this cell type, Rapamycin treatment did not have any effect on autophagy and 
Chloroquine induced autophagy only by 5.7% (p<0.05). When Rapamycin and 
Chloroquine were combined, autophagy was induced by 14.5% (p<0.01), 
suggesting a synergistic effect, as shown in MDA-MB-231 cells. 
The above results show that the three novel BNIPs and their parental compound 
BNIPDaCHM induced autophagy in SKBR-3 cells after 24 hour treatment. 
BNIPPiProp was the derivative that caused the highest increase of autophagy 
levels in SKBR-3 cells (16.0% (p<0.05)), followed by BNIPDaCHM (14.3% 
(p<0.01)), BNIPPiEth (12.8% (p<0.01)) and trans,trans-BNIPDaCHM (11.4% 
(p<0.01)). According to statistical analysis, no significant difference was found in 
SKBR-3 cell autophagy levels after treatment with BNIPDaCHM, BNIPPiProp, 
BNIPPiEth and trans,trans-BNIPDaCHM, compared to each other. 
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Caspase-3 activity was inhibited after 24 hour treatment with BNIPDaCHM, 
BNIPPiProp and BNIPPiEth in MDA-MB-231 and after treatment with BNIPPiProp, 
BNIPPiEth and trans,trans-BNIPDaCHM in SKBR-3 cells, despite the evidence of 
early apoptosis (after 0.5 hours) detected with Annexin V by flow cytometry 
(Section 5.4.2): investigating further the mode of cell death with BNIPs has 
brought to light complexity of the mechanisms involved. Interestingly, after 24 
hour treatment with BNIPs in MDA-MB-231 and SKBR-3 cells, the formation of 
autophagosomes and autolysosomes (Sun et al, 2013) was triggered, suggesting 
BNIP-induced autophagy on the above human breast cancer cell lines. Therefore, 
this study demonstrates that, for the 1st time, BNIPs induce both early apoptosis 
and autophagy. The above findings are also supported by Karna et al (2010), 
where a tubulin-binding noscapine analogue, Red-Br-nos, was found to induce 
autophagy followed by caspase-independent apoptotic cell death (CICD) in human 
prostate cancer PC-3 cells, through the generation of ROS (Tait and Green, 2008). 
The findings of Karna et al (2010) are in agreement with the elevated ROS levels 
and inhibition of Caspase-3 activity after treatment with BNIPs (Chapters 4 and 
5). Other studies also show a relationship between ROS levels and autophagy (Li 
et al, 2012). These results open up a new and exciting avenue for understanding 
into the cell death machinery after treatment with BNIPs that can potentially have 
implications for the treatment of cancer  
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5.5 Conclusion 
In Chapter 5, the effect of BNIPs on cell cycle distribution and cell death was 
studied in MDA-MB-231 and SKBR-3 cells. An increase in the proportion of MDA-
MB-231 cells in sub-G1 phase was exhibited compared to untreated cells, whilst 
in G1 phase, the cell population was significantly decreased after treatment with 
BNIPDaCHM and trans,trans-BNIPDaCHM. In SKBR-3 cells, the cell population was 
significantly increased in sub-G1 phase only after treatment with BNIPDaCHM, 
suggesting that the mechanisms of cell death amongst trans,trans-BNIPDaCHM 
and BNIPDaCHM may differ in different cell lines.   
After 0.5 hour treatment with BNIPs, a significant difference in Annexin V-FITC 
staining compared to untreated cells was observed in MDA-MB-231 cells and 
SKBR-3 cells. BNIPPiEth caused the highest increase of Annexin V-FITC staining 
levels in MDA-MB-231 cells, and trans,trans-BNIPDaCHM in SKBR-3 cells, 
respectively, showing that BNIPs induced early apoptosis which could trigger cell 
cycle arrest. On the other hand, after 24 hour treatment, BNIPs were found to 
inhibit Caspase-3 activity in MDA-MB-231 and SKBR-3 cells. In addition, 
autophagy studies revealed that the formation of autophagosomes and 
autolysosomes was triggered after treatment with BNIPs, suggesting BNIP-
induced autophagy on the tested human breast cancer cell lines seems to cross 
talk with caspase-independent apoptotic cell death (Figure 5.5). To further 
elucidate the mode of action of BNIPs, histone deacetylase (HDAC) activity and 
the expression of cell stress-related proteins were studied (Chapter 6). 
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Figure 5.5.: Summary of cell cycle distribution and cell death studies. 
  
 
179 
 
 
 
 
 
 
 
 
 
 
CHAPTER 6 
 
Effect of bisnaphthalimidopropyl derivatives on histone 
deacetylases and cell stress-related proteins 
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6.1 Introduction 
The role of HDACs and HDACi have been previouslly covered in Chapter 1 
(Sections 1.3 & 1.3.1). This chapter will focus on the role of specific Class III 
HDACs (sirtuins) and other cell stress proteins as key regulators in breast 
cancerogenesis. 
 
6.1.2 Sirtuins and their role in tumourigenesis 
Class III HDACs or sirtuins, are NAD+-dependent protein modifying enzymes that 
produce nicotinamide and the by-product O-acetyl adenosine diphosphate (ADP) 
ribose (Jiang, 2008). Sirtuins have certain enzymatic activities, such as lysine 
deacetylation, ADP-ribosylation and ADP-deacylation (Roth and Chen, 2014). The 
mammalian sirtuins occupy three different subcellular compartments: nucleus, 
cytoplasm and mitochondria. Apart from their different subcellular localisation, the 
enzymatic activities differ among the seven members of the sirtuin family, known 
as SIRT1–7 (Roth and Chen, 2014, Yuan and Chen, 2013). SIRT1 is the most 
studied and best-characterised sirtuin and has been reported to have longevity-
promoting effects (Roth and Chen, 2014, Yuan and Chen, 2013) as well as pivotal 
roles as regulator of cellular homeostasis and genomic stability (Yuan and Chen, 
2013). After these findings, researchers started to explore further the roles of 
SIRT1 and other members of the sirtuins family, especially in cases where cellular 
homeostasis and genomic integrity has been lost, such as cancer (Haigis and 
Sinclair, 2010). 
Members of this protein family have been shown to have diverse roles in several 
types of cancer, including breast carcinogenesis (Yuan and Chen, 2013). Apart 
from SIRT1, which is implicated in DNA repair pathways by deacetylating WRN (a 
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member of the RecQ DNA helicase family with functions in maintenance of 
genomic stability), evidence also suggests that SIRT2 has both tumour suppressor 
and promoter functions (Li et al, 2013, McGlynn et al, 2014). SIRT2 deacetylates 
a variety of proteins, implicated in inflammatory responses, such as NF-κB protein 
and activates proteins, like tumour suppressor p53 that are involved in DNA repair 
processed (Peck et al, 2010). Moreover, in several types of tumours, like gliomas, 
oesophageal or gastric adenocarcinomas, SIRT2 expression was shown to be 
reduced (Peters et al, 2010, Hiratsuka et al, 2003), whereas it is upregulated in 
breast cancer tissues (Igci et al, 2016). On the other hand, silencing SIRT2 in 
HeLa cells and in C6 glioma cells was shown to trigger apoptosis (He et al, 2012, 
Li et al, 2011). Expression of SIRT3, which is a tumour suppressor, is reduced in 
human breast and colon carcinoma (Finley et al, 2011), head and neck squamous 
cell carcinoma (Lai et al, 2013) and osteosarcoma (Zhang et al, 2012, Zhang and 
Zhou, 2012). On the other hand, the role of SIRT4 and SIRT6 in cancer formation 
is still unclear, as there are only few reports that show SIRT4 as a possible tumour 
suppressor (Jeong et al, 2013). SIRT6 is downregulated in pancreas malignancy 
(Csibi et al, 2013). SIRT5 has been found to facilitate cancer cell growth and drug 
resistance in non-small cell lung cancer (Lu et al, 2014). Lastly, in breast and 
thyroid cancers SIRT7 expression levels have been shown to be elevated (De Nigris 
et al, 2002). 
The above findings indicate that HDACs and more specifically, sirtuins have a 
crucial role in the development of many tumours, including breast and provide 
potential targets for cancer therapy. Although it is still unclear how HDACs work 
in relation to cancer, researchers are investigating their role as therapeutic targets 
as well as any potential synergistic activity with other anti-cancer compounds.  
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Several methods have been developed for the assessment of cellular HDAC 
activity. Apart from antibody-based techniques, such as chromatin 
immunoprecipitation based analyses or western blotting, which are powerful tools 
for detecting histone acetylation levels, chemical tools and methods have been 
developed, to circumvent the issue of antibody quality (Egelhofer et al, 2011). 
Activity-based probes, such as suberoylanilide hydroxamic acid (SAHA), PET-
active probes, such as fluorine-18, for in vivo imaging, and fluorogenic probes, 
such as Fluor De Lys, that switch their fluorescence properties upon enzymatic 
reaction, are the main methods for detecting HDAC activity (Minoshima and 
Kikuchi, 2015). Recently, HDAC cell-based assays have been developed, providing 
a useful tool for studying HDAC activity modulators in whole cells (Johnstone and 
Licht, 2003). 
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6.1.3 Aims  
The aim of the work presented in Chapter 6 was to understand further the mode 
of action of the three novel BNIPs and their parental compound, with regards to 
HDACs and stress-related proteins. The objectives of the experimental work was 
to study the effect of BNIPs on HDAC activity in breast cancer cells, with emphasis 
on SIRT2 and cell stress-related proteins, based on our previous findings, where 
BNIPs were found to increase the intracellular levels of ROS and induce DNA 
damage in MDA-MB-231 and SKBR-3 cells. Moreover, a characterstic of many 
SIRT2 inhibitors is that they bear a naphthalene moiety, suggesting a possible link 
between BNIPs and HDAC inhibition. In addition, previous findings have already 
reported that BNIPDaCHM inhibits SIRT2 enzyme activity in vitro (Lima et al, 
2013). Protein-protein interaction (PPI) network analysis was constructed to link 
the proteins of interest (based on the protein array) in breast cancer, applying 
Cytoscape V3.0 (Shannon et al, 2003) and STRING V10.0 (Szklarczyk et al, 2015) 
softwares, which will be discussed in this Chapter. 
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6.2 Materials  
6.2.1 HDAC cell-based activity assay 
HDAC cell-based activity assay     Cayman, UK  
 
6.2.2 Total protein extraction  
Phosphate buffered saline     Sigma-Aldrich, UK 
Cell lysis buffer (10X)      Cell Signalling, UK 
Proteinase Inhibitor Cocktail     Sigma-Aldrich, UK 
Phenylmethanesulfonyl fluoride solution    Sigma-Aldrich, UK 
 
6.2.3 Bradford protein concentration (BSA) assay  
Bovine Serum Albumin (BSA) solution    Sigma-Aldrich, UK 
DCTM Protein Assay Kit      Bio-Rad, UK 
Triton X-100        Sigma-Aldrich, UK 
 
6.2.4 Sodium dodecyl sulphate (SDS) Polyacrylamide gel electrophoresis 
(PAGE) 
Resolving gel 9% (10 mL): 
2.5 mL 1.5 M Tris pH 8.8      Fisherbrand, UK  
100 µL 10% SDS       Fisherbrand, UK 
2.25 mL 40% Acrylamide/Bisacrylamide   Bio-Rad, UK 
5.1 mL H2O 
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50 µL 10% Ammonium Persulphate    Sigma-Aldrich, UK 
5 µL Tetramethylethylenediamine (TEMED)   Sigma-Aldrich, UK 
 
1.5 M Tris pH 8.8 (250 mL) 
45.4 g Tris        Fisherbrand, UK 
250 mL distilled H2O      MilliQ, Millipore, UK 
 
Stacking gel (5 mL): 
0.625 mL 1M Tris pH 6.8      Fisherbrand, UK 
50 µl 20% SDS       Fisherbrand, UK 
0.750 mL 30% Acrylamide/Bisacrylamide   Bio-Rad, UK 
3.525 mL H2O 
25 µL 10% Ammonium Persulphate    Sigma-Aldrich, UK 
5 µL TEMED        Sigma-Aldrich, UK 
 
Loading buffer stock (10 ml): 
5 mL 10% SDS       Sigma-Aldrich, UK 
2.5 mL 100% Glycerol      Sigma-Aldrich, UK 
2.5 mL 0.5 M Tris       Fisherbrand, UK 
0.5% Bromophenol Blue (50 mg)    Sigma-Aldrich, UK 
On the day, 7.5 µL β-mercaptoethanol (Sigma-Aldrich, UK), was added to 100 
µL loading buffer stock. 
 
Electrophoresis buffer x10 (500 mL): 
15.125 g Tris       Fisherbrand, UK 
93.75 g Glycine       Sigma-Aldrich, UK 
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5 g SDS        Fisherbrand, UK 
 
Transfer Buffer x1 (1000 mL) 
700 mL Electrophoresis Buffer x10    Prepared above 
100 mL mL distilled H2O      MilliQ, Millipore, UK 
200 mL Methanol       Fisherbrand, UK 
 
TBS/T x 10 (500 mL) 
1.21 g Tris        Fisherbrand, UK 
4 g NaCl        Fisherbrand, UK 
0.5 mL Tween20       Sigma-Aldrich, UK 
Precision Protein Kaleidoscope     Bio-Rad, UK 
 
6.2.5 Western blotting and Detection 
Methanol        Fisherbrand, UK 
PVDF membrane HybondTM-P    Amersham  
Bioscience, UK 
SuperSignal West Pico Substrate    Fisherbrand, UK 
KODAK RP X-OMAT LO Developer and Fixer    Carestream, UK 
 
6.2.6 Proteome Profiler Array 
Proteome Profiler Human Cell Stress Array   R&D, USA 
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6.2.7 Instrumentation  
Plate reader        Synergy/HT, BIOTEK 
ALC PK 121R multispeed refrigerated centrifuge   Beckman Coulter, UK 
WhirliMixerTM vortex mixer     Fisherbrand, UK 
Bio-Rad Electrophoresis System     Bio-Rad, UK 
Bio-Rad PowerPack Power Supply    Bio-Rad, UK  
Bio-Rad Electrophoresis System     Bio-Rad, UK 
Bio-Rad PowerPack Power Supply    Bio-Rad, UK  
CL-XPosure X-ray film      Thermoscientific, UK 
FUSION-FX7- SPECTRA      Vilber, Germany 
BIO-1D™ imaging software  PeqLab, a VWR 
company, UK 
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6.3 Methods 
6.3.1 HDAC cell-based activity assay 
HDAC activity was determined using the HDAC Assay Kit according to the 
manufacturer’s instructions. Briefly, MDA-MB-231 and SKBR-3 cells (7,500 
cells/well) were seeded in culture medium (100 μL) in black, clear bottomed 96-
well plates. Cells were incubated for 24 hours at 37 oC with BNIPs at IC25. After 
24 hours, the plate was centrifuged at 500×g for 5 minutes at 37 oC and the culture 
medium was aspirated. Assay Buffer (200 μL) was added to each well, the plate 
was centrifuged at 500×g for 5 minutes at 37 oC. The supernatant was aspirated 
and 90  μL of culture medium or positive control (recombinant HDAC1) was added 
to the non-inhibited samples, while 80  μL culture medium with 10  μL Trichostatin 
A (HDAC inhibitor) was added to the appropriate control wells. The HDAC reaction 
was initiated by adding 10  μL of the diluted HDAC substrate to each well. The 
plate was incubated for three hours at 37 °C. Cells were lysed with 50  μL 
Lysis/Developer Mixture and the plate was shaken for 2 minutes. After 15 minutes 
incubation at 37 °C, fluorescence was measured at an excitation wavelength of 
360 nm and an emission wavelength of 440 nm on a 96-well plate reader.  
 
6.3.2 Total protein extraction  
MDA-MB-231 and SKBR-3 cells (1x106 cells/T25 flask) were treated with 
BNIPDaCHM IC25 concentration for 24 hours at 37 oC. After 24 hours incubation, 
the flasks were placed on ice and washed three times with ice cold PBS. Extraction 
buffer (200 μL) was added in each flask and incubated for 5 minutes on ice. The 
cells were harvested with a scraper and transferred to an Eppendorf tube. The 
samples were sonicated (2x 10 seconds) and then centrifuged at 2,000 xg for 10 
minutes at 4 oC. The supernatant was collected in clean Eppendorf tube and stored 
at -20 °C until used. 
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6.3.3 Bradford protein concentration assay  
The Bradford protein assay is a simple and colourimetric method commonly used 
to determine the total protein concentration of a sample, where the colour 
intensity is proportional to the protein concentration.  
Briefly, 25 mg/mL solution of BSA was prepared and stored at -20 oC. For use, a 
1:10 dilution of BSA stock solution was prepared, 1% (v/v) Triton X-100 was 
added and further dilutions of 0.5-1.25 mg/mL BSA were prepared. Into a 96-well 
plate, 5 μL of BSA standard protein sample and protein samples were added, in 
replicates of 8 and 4 respectively. Once all the standards and samples were plated, 
25 μL of solution A (alkaline copper tartrate) and 200 μL of solution B (folin) were 
added in each well. The 96-well plate was incubated for 30 minutes at room 
temperature and the absorbance was measured at 650 nm on a 96-well plate 
reader. 
 
6.3.4 Sodium dodecyl sulphate (SDS) Polyacrylamide gel electrophoresis 
(PAGE) 
Total protein extracts (10, 15 and 20 µg) from MDA-MB-231 and SKBR-3 cells 
were subjected to SDS-PAGE. The gels were composed of a 9% resolving gel, 
which required 30 minutes polymerisation at room temperature and a stacking 
gel, which was left for 45 minutes at room temperature to polymerise. Alongside 
the protein samples, a protein marker ladder was loaded to enable the 
determination of the molecular weight of the detected protein bands. 
Electrophoresis was performed at 150 V for 50 minutes in 1x Electrophoresis 
Buffer. After electrophoresis, separated proteins were transferred to PVDF 
membrane. Each membrane was immersed in 100% Methanol for 10 minutes. On 
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the black side of the transfer cassette the stack was built as follows: one sponge, 
two filter papers, the activated PVDF membrane, the gel, two filters and one 
sponge on top. Sponges and filters were all soaked in 1x Transfer Buffer. Once 
the transfer cassette was placed in the tank with the black side of the cassette 
facing the black side of the tank, an ice block was added and the tank was filled 
with 1x Transfer Buffer. Transfer was performed at 360 mA for 45 minutes. After 
completion of the protein transfer, the PVDF membrane was washed with 1xTBS/T 
for 5 minutes at RT and blocked in 25 mL blocking buffer (1.25 g dried milk, 25 
mL 1xTBS/T) for 1 hour at RT. The PVDF membrane was then washed three times 
with 15 mL TBS/T. Afterwards, 10 mL primary antibody solution was added and 
the membrane was left to be rolling for 2 hours at RT. The membrane was washed 
as before and the secondary antibody solution was added. Dilutions and incubation 
times for each primary and secondary antibody were optimised as detailed in Table 
6.3.4. 
Table 6.3.4.: Details of primary and secondary antibodies used for β-actin and 
SIRT2 protein detection. 
Antibody Dilution Incubation Time 
β-actin 
(Santa Cruz Biotechnology) 
1/5000 
Band size: 42 kDa 
2 hours 
(Room temperature) 
Anti-mouse secondary 
(Santa Cruz Biotechnology) 
1/10000 
1 hour 
(Room temperature) 
SIRT2 
(Abcam) 
1/500 
Band size: 43 kDa 
Overnight 
(Cold room, 4 oC) 
Anti-rabbit secondary 
(Santa Cruz Biotechnology) 
1/1000 
2 hours 
(Room temperature) 
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The antibodies were detected using SuperSignal WestPico chemiluminescent 
substrate. After washing the membrane as before, it was incubated with a 1:1 
mixture of substrate A : substrate B in the dark. After 5 minutes at room 
temperature, the excess of detecting reagent was drained off and the membrane 
was placed in a development cassette between cling film sheet, avoiding bubbles. 
The detection was completed in the dark room, where a CL-XPosure X-ray film 
was placed on top of the PVDF membrane, the cassette was closed and left for 15 
minutes. 
The film was then soaked in developer solution for 1 minute, washed with water, 
soaked in fixer solution for 2 minutes and then washed with water. The dried film 
was then labelled and the bands from the molecular weight ladder were recorded 
(i.e. drawn) on the film.Once SIRT2 was detected, the membrane was incubated 
for 10 minutes at room temperature in stripping buffer to remove the antibody 
before undertaking the detection of the housekeeping protein, β-actin. The 
antibody incubation and the detection were performed as for SIRT2. 
 
6.3.5 Cell stress-related Proteome Profiler Array 
The Human Cell Stress Proteome Profiler Array kit was used to determine the 
expression profile of cell stress-related proteins, in MDA-MB-231 and SKBR-3 
treated with BNIPs (Table 6.3.5). All steps were carried out according to the 
manufacturer's instructions. After 24hours, MDA-MB-231 and SKBR-3 cells were 
treated with the BNIPs of interest (BNIPDaCHM and BNIPPiEth) at IC25.  
After 24 hour incubation, the total protein content was extracted (Section 6.3.2) 
and the protein concentrations determined as previously described in Section 
6.3.3 and 300 μg of protein lysate was used for each array membrane (maximum 
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amount of protein that was recommended by manufacturer). After a 1 hour 
membrane blocking step, the samples were pre-incubated with a cocktail of 
biotinylated detection antibodies (15 µL) and added to the membrane for an 
overnight incubation at 4 °C.  
After three 10 minute washes, the membranes were incubated with streptavidin-
horseradish peroxidase (HRP, 2 mL) for 30 minutes and the detection was 
performed by adding the chemiluminescence detection reagents in equal volumes 
to the membranes for 1 minute in the dark. The signal was detected by exposing 
the membrane to CL-XPosure X-ray film for 5 and 10 minutes and developed as 
previously described in Section 6.3.4.  
The mean pixel density of the duplicate spots produced on each film was 
determined using a FUSION FX7™ imaging instrument with Fusion 1 and BIO-1D™ 
imaging software. Once the final pixel density was obtained after substracting the 
pixel density of the negative control, the control versus treatment ratio was 
calculated in order to assess the relative change in protein expression.  
Two independent expreriments (two mebranes per sample) were carried out and 
values (mean ± SD, n = 2) were plotted using GraphPad Prism V7.0.  
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Table 6.3.5.: Cell stress-related proteins that were studied before and after 
treatment with BNIPDaCHM and BNIPPiEth in MDA-MB-231 and SKBR-3 cells. 
ADAMTS1 HIF-2 alpha 
Phospho-p38 alpha 
(T180/Y182) 
Bcl-2 Phospho-HSP27 (S78/S82) Phospho-p53 (S46) 
Carbonic Anhydrase IX HSP60 PON1 
Cited-2 HSP70 PON2 
COX-2 IDO PON3 
Cytochrome c 
Phospho-JNK Pan 
(T183/Y185) 
Thioredoxin-1 
Dkk-4 NF-kappa-B1 SIRT2 
FABP1/L-FABP p21/CIP1 SOD2 
HIF-1 alpha p27/Kip1  
 
Abbreviations: ADAMTS1= ADAM Metallopeptidase with Thrombospondin Type 1 Motif 1,  
Bcl-2= B-cell lymphoma 2, Cited-2=Cbp/p300-interacting transactivator 2, COX-2= 
Cytochrome c Oxidase Subunit 2, Dkk-4= Dickkopf WNT Signaling Pathway Inhibitor 4, 
FABP1/L-FABP= Fatty Acid-Binding Protein 1, HIF-1 alpha= Hypoxia Inducible Factor 1 
Alpha Subunit, HIF-2 alpha= Hypoxia Inducible Factor 2 Alpha Subunit, Phospho-HSP27 
(S78/S82)= Phosphorylated Heat Shock Protein Family A (Hsp70) Member 1A, HSP60= 
Heat Shock Protein Family D (Hsp60), HSP70= Heat Shock Protein Family A (Hsp70) 
Member 1A, IDO= Indoleamine 2,3-Dioxygenase 1, Phospho-JNK Pan (T183/Y185)= 
Mitogen-Activated Protein Kinase 8, NF-kappa-B1= Nuclear factor NF-kappa-B, p21/CIP1= 
Cyclin-dependent kinase inhibitor 1, p27/Kip1= Cyclin-dependent kinase inhibitor 1B, 
Phospho-p38 alpha (T180/Y182)= P38 mitogen-activated protein kinase alpha, Phospho-
p53 (S46)= Phosphoprotein 53, PON1=Paraoxonase 1, PON2=Paraoxonase 2, 
PON3=Paraoxonase 3, SIRT2= Sirtuin 2, SOD2= Superoxide dismutase 2. 
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6.3.6 Bioinformatic studies 
From the results obtained with the cell stress-related protein arrays, proteins that 
demonstrated a level of expression that was 0.5 relative different between 
untreated and BNIP-treated MDA-MB-231 and SKBR-3 cells were recorded and 
used to construct a network where each protein, defined as a node, interacts with 
others (Zhang et al, 2016; Shannon et al, 2003). 
The important topological parameters for the construction of a network are the 
degree (K), the betweenness centrality (BC) and the closeness centrality (CC) 
(Shannon et al, 2003). K represents the numbers of edges (i.e. links) that connect 
directly to a node. The BC of a node represents the degree (between 0 and 1) of 
which nodes stand between each other. Comparatively, CC is the inverse of the 
average length of the shortest paths going through a node (Shannon et al, 2003). 
In this study, the PPI network construction and analysis was performed by 
Cytoscape V3.0 (Shannon et al, 2003), plus ClueGO V2.3.2 and CluePedia V1.3.2 
(Bindea et al, 2009) and STRING V10.0 (Szklarczyk et al, 2015). The above 
softwares and their applications are powerful tools to provide useful data and 
information for the mapping of PPI networks. The used cut-off for interaction 
evidence was set at 0.05 (p-value threshold).  
6.3.7 Statistical analysis 
Three independent experiments were conducted and each experiment was 
comprised of at least two internal replicates, unless otherwise stated. Data are 
presented as mean ± SD or ± SEM. Statistical analysis was performed by using 
an unpaired Student’s t-test. Statistically significant data were detailed when 
*p<0.05, **p<0.01, ***p<0.001. 
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6.4 Results and Discussion 
6.4.1 Histone deacetylase activity of BNIPs 
Targeting HDACs for breast cancer treatment has been a topic of debate, due to 
conflicting reports and lack of potent inhibitors. However, several studies have 
shown that HDACs are overexpressed in tumour cells and also under various 
environmental conditions, such as hypoxia or serum deprivation (Kim et al, 2001, 
Hu et al, 2003). Furthermore, HDAC inhibition is the primary cause of reduction 
of cancer cell proliferation and cell cycle inhibition (Ropero et al, 2006). Therefore, 
it is important to test novel anti-cancer drugs as potential HDAC inhibitors.  
The effect of BNIPs on HDAC activity after 24 hour treatment in both cell lines was 
investigated to further explore the mechanism by which these derivatives inhibit 
cell growth and arrest the cell cycle, by performing the HDAC cell-based activity 
assay. The assay measured the activity of various protein lysine-specific 
deacetylases in intact cells, after incubation with a cell-permeable HDAC 
substrate. The fluorescence of the deacetylated reaction product was analysed 
using a plate reader. 
As shown in Figure 6.4.1a, after 24 hour treatment with BNIPs, a difference in 
HDAC activity compared to untreated cells was observed in MDA-MB-231 cells. 
More specifically, after treatment with BNIPDaCHM, HDAC activity levels were 
decreased by 22.6%. After treatment with BNIPPiProp, HDAC activity was also 
decreased by 37.5%, while after treatment with BNIPPiEth, HDAC activity was 
significantly decreased by 50.9% (p<0.05). After treatment with trans,trans-
BNIPDaCHM, HDAC activity levels were only slightly affected compared to 
untreated cells, with a decrease of 13.1%.  
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Figure 6.4.1.: Histone deacetylase (HDAC) activity of BNIPDaCHM, BNIPPiProp, 
BNIPPiEth and trans,trans-BNIPDaCHM in a) MDA-MB-231 and b) SKBR-3 cells. 
DMSO/dH2O (50% v/v) was used as the solvent control. Data are mean ± SEM of three 
independent experiments (n = 3), conducted in duplicates. *p<0.05, compared to 
untreated cells.  
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These results indicate that the three novel BNIPs and their parental compound 
BNIPDaCHM reduced the HDAC activity after 24 hour treatment in MDA-MB-231 
cells. However, BNIPPiEth was the only derivative that significantly reduced HDAC 
activity levels in MDA-MB-231 cells compared to the untreated cells.  
A difference in HDAC activity after 24 hour treatment with BNIPs compared to 
untreated cells was also observed in SKBR-3 cells (Figure 6.4.1b). After treatment 
with BNIPDaCHM, HDAC activity levels were decreased by 24.1%, HDAC activity 
was decreased by 44.6% after treatment with BNIPPiProp, while after treatment 
with BNIPPiEth HDAC activity was decreased by 47.3% (p<0.05), compared to the 
untreated cells. After treatment with trans,trans-BNIPDaCHM, HDAC activity levels 
were slightly affected compared to untreated cells, with a decrease of 17.8%.  
According to the above results, BNIPs have been shown to reduce HDAC activity 
after 24 hour treatment in SKBR-3 cells, in a similar pattern to that observed in 
MDA-MB-231 cells. As in MDA-MB-231 cells, BNIPPiEth was the derivative that 
significantly inhibited HDAC activity levels in SKBR-3 cells. 
The HDAC activity in both cell lines was reduced after 24 hour treatment with 
BNIPs, implying that the inhibition of cell growth and cell cycle arrest that was 
found in this study can potentially be related to the inhibition of HDAC activity. In 
addition, BNIPs inhibited HDAC activity even after exposure to small BNIP doses, 
i.e. IC25 and not IC50, in order to avoid extensive loss of the cell population. 
Currently, there are four HDAC agents (Romidepsin, Belinostat, Panobinostat and 
Vorinostat) that inhibit HDAC enzymes and are commercially available for the 
treatment of cutaneous and peripheral T-cell lymphoma (Moskowitz and Horwitz, 
2016). However, a recent study is introducing novel HDACi in breast cancer 
hormone therapy treatment as a tumour survival strategy, in order overcome 
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resistance to hormonal therapy, such as Tamoxifen (Munster et al, 2011). In 
addition, exposure to HDAC inhibitors seems to sensitise triple-negative breast 
cancer cells, according to preclinical research of Dr Bhalla and his group (35th San 
Antonio Breast Cancer Symposium, 2012). 
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6.4.2 SIRT2 expression in MDA-MB-231 and SKBR-3 cells 
Based on the results presented in Section 6.4.1 where the HDAC activity in both 
cell types was inhibited after 24 hour treatment with BNIPs, and the fact that 
many SIRT2 inhibitors  bear a naphthalene moiety, which seem to be responsible 
for their anti-cancer activity (Lima et al, 2013), the possible link between BNIPs 
and HDAC inhibition was further investigated.  
The expression of SIRT2 was initially evaluated in MDA-MB-231 cells after 24 hour 
treatment with the parental compound, BNIPDaCHM at the IC25 concentration. 
Optimisation experiments were conducted with various amounts of total protein 
extracts (10, 15 and 20 µg) and subjected to SDS-PAGE and western-blot analysis 
to detect SIRT2 protein expression. After detection, samples containing 20 µg total 
protein were chosen. SIRT2 is not highly expressed in breast cancer tissues and 
therefore, the anti-SIRT2 antibody did not work for low protein amount (<20 µg). 
Beta-actin was used as the housekeeping protein to ensure equal protein loading. 
 
 
Figure 6.4.2.: Representative western blot showing the expression of SIRT2 and 
β-actin in MDA-MB-231 and SKBR-3 cells, after 24 hour treatment with 
BNIPDaCHM. 
  
 
200 
In MDA-MB-231 cells, no change was observed by visual assessment in SIRT2 
expression after treatment with BNIPDaCHM. The band signal (43 kDa) was similar 
for both treated and control samples (Figure 6.4.2). Similar experiments were 
conducted in SKBR-3 cells, where SIRT2 expression was decreased after 24 hour 
treatment with BNIPDaCHM. In SKBR-3 cells, the band signal in treated samples 
was weaker compared to untreated cells.  
However, the above results have to be validated by repeating confirmatory 
experiments, as it was not possible to repeat this experiment consistently. 
Different parameters such as decreasing the dilution factor of the primary antibody 
(1/500), modifying the antibody incubation time and/or the exposure time during 
detection, were tested to further optimise this experiment however the bands 
were either not detected or the signal was very weak. 
However, these results indicate that SIRT2 expression differs among the two cell 
lines tested after treatment with BNIPDaCHM. Moreover, BNIPDaCHM could be a 
potential SIRT2 inhibitor, as in SKBR-3 cells SIRT2 expression was found to be 
visually decreased after 24 hours treatment with BNIPDaCHM. 
Involvement of SIRT2 in tumourigenesis seems to be controversial. Indeed, recent 
genetic studies using SIRT2 knockout mice have revealed that SIRT2 may function 
as a tumour suppressor (Kim et al, 2011), whilst several reports show that SIRT2 
promotes tumourigenesis (Chen et al, 2013, Sunami et al, 2013).  
The reason for this discrepancy is still unknown, however, it may depend on cancer 
progression stage or cell type and this could explain why SIRT2 expression varies 
between the two cell types investigated in this study. It is also important to 
mention that currently there are no similar studies undertaken (making it difficult 
to draw conclusion), based on SIRT2 expression in MDA-MB-231 and SKBR-3 
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cancer cells, as according to the Human Protein Atlas data base 
(www.proteinatlas.org), SIRT2 expression in breast cancer tissues is low 
compared to glioma cancers (Table 6.4.2) 
 202 
Table 6.4.2.: Levels of SIRT2 antibody staining/expression (high (dark blue), partially detected (light blue), not detected 
(white)) in breast cancer tissues. The Human Protein Atlas (www.proteinatlas.org). 
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6.4.3 Human cell stress-related protein expression after treatment with 
BNIPs in MDA-MB-231 and SKBR-3 cells 
According to the results presented in Chapter 4, BNIPs increase the intracellular 
levels of ROS in MDA-MB-231 and SKBR-3 cells. Therefore, proteome profiler 
human cell stress arrays were used for the first time in this study to further explore 
and identify differences in cell stress-related protein expression that could be 
responsible for BNIP anti-cancer activity in both cell lines.  
Levels of protein expression in control cells were compared to those in cells that 
were treated with BNIPDaCHM (parental compound) and BNIPPiEth (best BNIP 
candidate from the effects obtained on the parameters tested earlier). A cut-off of 
0.5 ratio was used as considered threshold for meaningful changes in protein 
arrays studies. 
In MDA-MB-231 cells (Figure 6.4.3.1), out of the 26 examined proteins, 7 proteins 
demonstrated a level of expression that was relatively different after treatment 
with BNIPPiEth and BNIPDaCHM. More specifically, Cytochrome c (382.0- relative 
change) showed an increased expression (ratio>0.5) compared to untreated cells, 
after treatment with BNIPPiEth. Increased expression was also noticed in SIRT2 
(1.0- relative change) and SOD2 (0.9- relative change) (ratio>0.5). On the 
contrary, treatment with BNIPPiEth decreased the expression of PON1 (-1.0- 
relative change), PON2 (-1.0- relative change), HIF-1a (-0.7- relative change) and 
HSP60 (-0.7- relative change) (ratio<0.5). In parallel, SIRT2 (1.8- relative 
change) showed increased expression (ratio>0.5) compared to untreated cells, 
after treatment with BNIPDaCHM to a greater extent (0.8- relative change 
increase) than in BNIPPiEth-treated cells. 
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Figure 6.4.3.1.: Comparison of BNIPDaCHM and BNIPPiEth effects upon cell stress related proteins in MDA-MB-231 cells. 
Data are mean ± SD of two independent experiments (n = 2), values were plotted using GraphPad Prism V7.
 205 
SOD2 (0.5 relative change) expression, however, was decreased (ratio<0.5) 
after treatment with BNIPDaCHM, compared to BNIPPiEth-treated cells. 
Moreover, 19 proteins showed either no change or a relative change inferior to a 
0.5 ratio in MDA-MB-231 cells (effects of BNIPs that do not lead to changes in 
protein abudance, such as post-translational modifications, can not be detected). 
In SKBR-3 cells (Figure 6.4.3.2), out of the 26 examined proteins, 12 proteins 
demonstrated a level of expression that was relatively different after treatment 
with BNIPPiEth and BNIPDaCHM. More specifically, HIF-1a (0.9- relative change), 
HIF-2a (0.8- relative change), IDO (0.7- relative change), p21 (0.7- relative 
change), p27 (1.2- relative change), PON1 (1.0- relative change) and PON3 (1.0- 
relative change) showed increased expression (ratio>0.5) compared to untreated 
cells, after treatment with BNIPPiEth. In SKBR-3 cells, none of the examined 
proteins showed decreased expression after treatment with BNIPPiEth Moreover, 
ADAMTS1 (0.8- relative change), Bcl-2 (1.7- relative change), Carbonic Anhydrase 
IX (1.1- relative change), COX-2 (1.0- relative change), Dkk-4 (1.5- relative 
change), HIF-1a (1.0- relative change), IDO (0.9- relative change), p21 (1.0- 
relative change), p27 (1.2- relative change) and PON3 (89.0- relative change) 
showed an increased expression (ratio>0.5) after treatment with BNIPDaCHM and 
PON1 (-0.8- relative change) protein expression was the only protein to be 
decreased after treatment with BNIPDaCHM (ratio<0.5) compared to untreated 
cells. 
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Figure 6.4.3.2.: Comparison of BNIPDaCHM and BNIPPiEth effects upon cell stress related proteins in SKBR-3 cells. Data are 
mean ± SD of two independent experiments (n = 2), values were plotted using GraphPad Prism V7.0. 
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Also, in SKBR-3 cells, 14 proteins showed either no change or a relative change 
inferior to 0.5 (effects of BNIPs that do not lead to changes in protein abudance, 
such as post-translational modifications, can not be detected). 
In summary, the above results revealed that BNIPDaCHM and BNIPPiEth alter the 
expression (up- or downregulation) of cell stress-related proteins in a different 
pattern depending on the cell type, suggesting that the mechanism of action of 
BNIPs could be cell line dependent. To further validate the obtained experimental 
results and in order to reveal the biological processes involved, the cellular 
compartment localisation and the different pathways in which the above panel of 
proteins are involved (only cell stress-related proteins were examined, so more 
proteins could have been potentially affected after treatment treatment with 
BNIPs), bioinformatics studies were employed and findings are presented and 
discussed in the following section (Section 6.4.4). 
  
 208 
6.4.4 Construction and analysis of Protein–Protein Interaction (PPI) 
Networks  
Since interactome analysis can provide a candidate biomarker panel related to a 
disease, protein-protein interaction (PPI) network analysis was used to introduce 
the involved crucial proteins in breast cancer cells, based on the outcome of the 
protein array studies described in Section 6.4.3. 
Proteins that demonstrated a level of expression 0.5 relatively different between 
untreated and BNIP-treated cells were determined and matched to construct the 
corresponding PPI networks. Three PPI networks were constructed and cellular 
compartment localisation of the examined proteins was predicted. The cut-off used 
for interaction evidence was set at 0.05 (p-value threshold).  
The first step of the study was to construct a PPI network that included the 26 
proteins examined via the Proteome Profiler Human Cell Stress Array, employing 
Cytoscape 3.4 (ClueGO V2.3.2. and CluePedia V1.3.2). The biological processes, 
in which these proteins (Table 6.4.4a) are involved (in both cell lines), are 
described in Figure 6.4.4.1. 
The PPI network validated that the examined proteins were indeed cell stress 
related. Moreover, on Figure 6.4.4.1, their biological processes were determined 
and classified in four distinct categories:  
- cellular response to oxidative stress (dark blue),  
- response to oxygen levels (light blue),  
- regulation of interlucin-12 production (dark green), and  
- cellular oxidant detoxification (light green).  
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Protein names Input names 
ADAMTS1 ADAMTS1 
Bcl-2 BCL2 
Carb. Anhydrase CAIX 
Cited-2 MRG1 
COX-2 COX2 
Cytochrome c COX1 
Dkk-4 DKK4 
FABP-1 FABP1 
HIF-1a HIF1A 
HIF-2a HIF2A/EPAS1 
Phospho-HSP27 HSP27 
HSP60 HSPD1 
HSP70 HSP70 
IDO IDO1 
JNK Pan JNK1 
NFkB1 NFKB1 
p21 CDKN1 
p27 CDKN1B 
p38a MAPK1 
Phospho-p53 TP53 
PON1 PON1 
PON2 PON2 
PON3 PON3 
Thioredoxin-1 TXN 
SIRT2 SIRT2 
SOD2 SOD2 
 
Table 6.4.4.: List of examined proteins/input names for bioinformatic studies. 
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Figure 6.4.4.1.: Representation of the statistically significant (p-value threshold: 0.05) biological processes of proteins 
examined via the Proteome Profiler Human Cell Stress R&D Array, employing Cytoscape 3.4 (ClueGO V2.3.2 and CluePedia 
V1.3.2). 
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Figure 6.4.4.2.: Cellular compartment localisation prediction of the statistically significant (p-value threshold: 0.05) 
biological processes of proteins examined via the Proteome Profiler Human Cell Stress R&D Array, employing Cytoscape 3.4 
(ClueGO V2.3.2 and CluePedia V1.3.2). 
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In addition, ClueGO V2.3.2 and CluePedia V1.3.2 were employed determining 
protein cellular compartment localisation, as seen in Figure 6.4.4.2. More 
specifically, the examined proteins are found in five cellular compartments: the 
nucleus, the nuclear membrane, the plasma membrane, intracellular and/or 
extracellular (Figure 6.4.4.2). Then, the 7 proteins (Cytochrome c, SIRT2, SOD2, 
PON1, PON2, HIF-1a and HSP60) that demonstrated a level of expression that was 
0.5 relatively different between untreated and BNIP-treated MDA-MB-231 cells 
were grouped and used to construct the PPI network presented in Figure 6.4.4.3a. 
The PPI network consists of three connected nodes, SOD2, HIF-1A and SIRT2, 
while PON1 and HSP60 are represented as isolated nodes (which denotes no 
known interaction). Cytochrome c and PON2 did not meet the statistically 
significant cut-off of 0.05, and as a result, the corresponding nodes do not appear 
on the PPI network. The biological processes of the 7 examined proteins involve 
oxygen homeostasis, positive regulation of T cell mediated immune response to 
tumour cell and negative regulation of plasma lipoprotein particle oxidation 
(summarised in Figure 6.4.4.3b).  
SOD2 is a well-known antioxidant protein highly involved in mitochondrial 
catabolic pathway, by binding to the superoxide byproducts of oxidative 
phosphorylation and converting them to hydrogen peroxide and/or diatomic 
oxygen (Fukai and Ushio-Fukai, 2011). On the other hand, HIF-1a (alpha subunit 
of transcription factor hypoxia-inducible factor-1 (HIF-1)) is a main regulator of 
cellular and systemic homeostatic response to hypoxia and activates the 
transcription of genes related to energy metabolism, angiogenesis, apoptosis or 
oxygen delivery (Ziello et al, 2007). The above network highlights a potential 
pathway, where the intracellular production of ROS after treatment with BNIPs 
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could alter the expression SOD2, which can interact with the transcription factor 
HIF-1a to regulate the expression of SIRT2 and therefore histone deacetylation.  
Furthermore, cellular localisation of the proteins revealed that PON1 and HSP60 
are located in more than one compartment (mainly extracellular/intracellular). 
However, there is no confirmed interaction with the rest of the examined proteins 
that could correlate with a mechanism of action of BNIPPiEth and BNIPDaCHM in 
MDA-MB-231 cells (Figure 6.4.4.4). 
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Figure 6.4.4.3.: Network (a) and pie chart (b) representation of the statistically 
significant (p-value threshold: 0.05) biological processes, of proteins that met 
the ± 0.5 relative change criteria (Figure 6.4.3.1) in MDA-MB-231 cells after 
treatment with BNIPs, employing Cytoscape 3.4 (ClueGO V2.3.2 and CluePedia 
V1.3.2). 
a. 
b. 
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Figure 6.4.4.4.: Cellular compartment localisation prediction of selected proteins 
that met the ± 0.5 relative change criteria (Figure 6.4.3.1) in MDA-MB-231 cells 
after treatment with BNIPs, employing Cytoscape 3.4 (ClueGO V2.3.2 and 
CluePedia V1.3.2). 
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Based on these findings, the 5 candidate proteins (SOD2, HIF-1a, SIRT2, PON1 
and HSP60) were further examined via String functional protein association 
network analysis. This analysis performed both literature and proteomic/genomic 
database searches and represents putative or known associations between input 
proteins/genes.  
As shown in Figure 6.4.4.5, the 5 proteins that met the cut-off criteria were found 
to be associated in a String network. The thin association lines between nodes 
indicate low confidence interactions (as derived from gene co-expression and 
literature searches) while thicker association lines indicate high confidence 
interactions (as derived from co-IPs, proteomic assays and multiple citations in 
the literature search).  
PON1 (hydrolytic enzyme with antioxidant properties) (Mackness and Mackness, 
2015) interacts with SOD2 and, in turn, SOD2 interacts with HSP60 which, while 
employing a linker protein, HSP90AA1 (heat shock protein, involved in hypoxic 
and oxygen homeostasis regulation of HIF-1a pathway) (Zuehlke et al, 2015), 
interacts with HIF-1a. HIF-1a, as previously mentioned, was found to interact 
directly with SIRT2. In addition, PON1, which was found to have an extracellular 
localisation (Figure 6.4.4.4), is suggested to be the upstream element of the 
proposed pathway, while HIF-1a and SIRT2 are suggested to be its downstream 
and terminal components, respectively. As a result, the construction of PPI 
networks indicated the crucial role of the highlighted proteins in MDA-MB-231 cells 
after treatment with BNIPs and, the possible mechanism of BNIP action, which 
seems to be related with the activation/regulation of a novel protein complex. 
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Figure 6.4.4.5.: Network with the statistically significant (p-value threshold: 
0.05) proteins that met the ± 0.5 relative change criteria (Figure 6.4.3.1) in MDA-
MB-231 cells after treatment with BNIPs (in red ring), and other non-examined 
proteins, after employing String V10.0. 
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The 12 proteins of interest which related to BNIP-treated SKBR-3 cells (i.e 
ADAMTS1, Bcl-2, Carbonic Anhydrase IX, COX-2, Cytochrome c, Dkk-4, HIF-1a, 
IDO, p21, p27, PON1 and PON3) have been studied, grouped and used for the 
construction of the PPI network presented in Figure 6.4.4.6a. The PPI network 
consists of several connected nodes (including ADAMTS1, Bcl-2, Carbonic 
Anhydrase IX, COX-2, Cytochrome c, HIF-1a, IDO, p21, p27 and PON3) with 
similar “linker” proteins and share similar biological processes; while only two 
proteins, PON1 and Dkk-4, are represented as isolated nodes (no known 
interaction). The interesting finding in the above network is that none of the 12 
examined proteins interacts directly with each other. More specifically, the 
biological processes of the examined proteins involve negative regulation of the 
ROS metabolic process, intestinal epithelial cell maturation and regulation of 
transcription from RNA polymerase II promoter in response to hypoxia as 
presented in Figure 6.4.4.6b. Furthermore, cellular localisation of the above 
proteins revealed that PON1 and Dkk-4 are located in more than one compartment 
(mainly extracellular/intracellular) and there is no confirmed interaction with the 
rest of the examined proteins that could correlate with a mechanism of action of 
the BNIPPiEth and BNIPDaCHM studied in SKBR-3 (Figure 6.4.4.7). 
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Figure 6.4.4.6.: Network (a) and pie chart (b) representation of the statistically 
significant (p-value threshold: 0.05) biological processes of proteins that met the 
± 0.5 relative change criteria (Figure 6.4.3.2) in SKBR-3 cells after treatment 
with BNIPs, employing Cytoscape 3.4 (ClueGO V2.3.2 and CluePedia V1.3.2). 
a. 
b. 
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Figure 6.4.4.7.: Cellular compartment localisation prediction of selected proteins 
that met the ± 0.5 relative change criteria (Figure 6.4.3.2) in SKBR-3 cells after 
treatment with BNIPs, employing Cytoscape 3.4 (ClueGO V2.3.2 and CluePedia 
V1.3.2). 
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Similarly to the MDA-MB-231 cell line, string functional protein association 
network analysis was performed for proteins that met the cut-off criteria for SKBR-
3 cells. 
Carbonic Anhydrase IX (transmembrane protein and one of only two tumour-
associated carbonic anhydrase isoenzymes known) interacts with Bcl-2 (apoptosis 
regulator, one out of the 154 genes involved in the Integrated Breast Cancer 
Pathway- Superpath (Belinky et al, 2015)) which then interacts with both p21 and 
p27 (cyclin dependent inhibitors and regulators of cell cycle progression) involved 
in G1 arrest (Belinky et al, 2015) (Figure 6.4.4.8). p21 interacts directly with HIF-
1a which subsequently interacts with HIF-2a (transcription factor involved in the 
induction of genes regulated by oxygen and paralog of HIF-1a).  
Carbonic Anhydrase IX, localized mainly in plasma membrane (Figure 6.4.4.4), is 
suggested to be the upstream element of the proposed pathway. However, even 
if there is not an established interaction with PON1 and PON3, a possible protein-
protein interaction of the three should be studied, as PON1 and PON3 are localised 
on the extracellular compartment (Figure 6.4.4.7b) and could be potentially 
upstream elements of this pathway, as observed in MDA-MB-231 cells. HIF-1a and 
HIF-2a are suggested to be the downstream and terminal components, 
respectively.  
As before, the construction of PPI networks indicated the crucial role of the 
highlighted proteins in BNIP-treated SKBR-3 cells and, the possible mechanism of 
BNIP action, which seems to be related with the activation/regulation of a novel 
protein complex, in which common protein elements compared to MDA-MB-231 
cell/pathway are involved.  
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Figure 6.4.4.8.: Network with the statistically significant (p-value threshold: 
0.05) proteins that met the ± 0.5 relative change criteria in SKBR-3 cells after 
treatment with BNIPs (in red ring), and other non-examined proteins, after 
employing String V10.0. 
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6.5 Conclusion 
In Chapter 6, the effect of BNIPs on HDAC activity in breast cancer cells, with 
emphasis on SIRT2, and on cell stress-related proteins, was studied. The three 
novel BNIPs and their parental compound BNIPDaCHM (all at IC25 concentrations), 
decreased HDAC activity after 24 hours treatment in MDA-MB-231 cells. Similarly, 
BNIPs were found to decrease HDAC activity after 24 hour treatment in SKBR-3 
cells, in a similar pattern to that observed in MDA-MB-231 cells. However, 
BNIPPiEth was the only derivative that significantly decreased HDAC activity levels 
in both MDA-MB-231 and SKBR-3 cells. Protein expression of SIRT2 only showed 
differences between the two different cell lines visually after 24 hour treatment 
with BNIPDaCHM. Moreover, BNIPDaCHM could be a potential SIRT2 inhibitor in 
SKBR-3 cells, where SIRT2 expression was found to decrease after 24 hours 
treatment with BNIPDaCHM. However, the above results have to be further 
validated by repeating confirmatory experiments to assess the optimum protein 
amount required and to define the most appropriate antibody concentration and 
incubation time. Proteome profiler arrays demonstrated that in BNIP-treated MDA-
MB-231 cells, three proteins (Cytochrome c, SIRT2 and SOD2) had an increased 
expression and four (PON1, PON2, HIF-1a and HSP60) had a decreased 
expression. On the other hand, in BNIP-treated SKBR-3 cells, the protein 
expression of 12 proteins (ADAMTS1, Bcl-2, Carbonic Anhydrase IX, COX-2, 
Cytochrome c, Dkk-4, HIF-1a, IDO, p21, p27, PON1 and PON3) were increased 
and 1 (PON1) was decreased. Thus, BNIPDaCHM and BNIPPiEth altered the 
expression of cell stress-related proteins in a cell dependent manner. In addition, 
PPI network analysis was used to further validate the outcome of the protein array 
studies. Bioinformatic analysis revealed two novel, putative pathways for BNIP-
induced oxidative stress-mediated cell death in MDA-MB-231 and SKBR-3 cells 
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(Figure 6.5). These findings create the stepping stone for further research and 
validation towards the delineation of the suggested pathways, as well as the 
mode/mechanisms of BNIP action in breast cancer. 
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Figure 6.5.: Schematic representation of proposed mechanism for BNIP-induced 
oxidative stress-mediated cell death in MDA-MB-231 and SKBR-3 cells. Black 
arrows indicate pathways for cell death, green circles the upstream components, red 
circles the downstream components and yellow circles the linker proteins of the pathway. 
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CHAPTER 7. 
 
Conclusion and future work. 
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This project focused on determining the role of novel compounds as anti-cancer 
drugs and to identify their mechanism(s) of action in breast cancer cells. The novel 
compounds were based on the parental compound BNIPDaCHM and were 
described to define the impact of the different types of isomers. The three novel 
BNIPs, BNIPPiProp, BNIPPiEth and trans,trans-BNIPDaCHM were successfully 
synthesised and characterised as presented in Chapter 2. The N-alkylation 
reaction that has been used previously for the synthesis of other BNIPs in the 
series has been proved a suitable synthetic process to produce the above 
compounds. Apart from high % yields, it resulted in formation of compounds 
without by-products (Lima et al, 2013, Barron et al, 2010, Kopsida et al, 2016).  
The successful synthesis of the three novel BNIPs allowed further investigation on 
their DNA binding properties which is one of the main characteristics of certain 
cancer drugs. In Chapter 3, physical properties of three novel BNIPs, BNIPPiProp, 
BNIPPiEth and trans,trans BNIPDaCHM were further investigated. Their DNA 
binding affinities were assessed by using different in vitro techniques, such as 
thermal denaturation studies, EtBr competitive displacement and UV binding 
studies. Thermal denaturation studies have shown that BNIPPiProp and BNIPPiEth 
can intercalate and stabilise the double helix of Calf Thymus DNA that was 
confirmed by their increased Tm values compared to Calf Thymus DNA alone. 
BNIPPiEth was identified as the most active DNA binding member of the BNIPs. In 
addition, it was observed that the length of the linker sequence seems to affect a 
drug’s binding potential to the DNA (O’Hare et al, 2001, Kopsida et al, 2016). 
Moreover, studies on competitive displacement of EtBr by BNIPs were performed 
to further evaluate their DNA binding affinity. Each BNIP competitively displaced 
EtBr from DNA in a dose dependent manner, confirming the hypothesis of DNA 
intercalation being responsible, at least in part, for their mode of action (Dance et 
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al, 2005). BNIPPiEth was identified as the BNIP with the strongest binding affinity. 
Moreover, the structure of BNIPDaCHM and its mixture of three isomers was found 
to improve its interacting properties within the DNA base pairs, compared to 
trans,trans-BNIPDaCHM. This was confirmed since trans,trans-BNIPDaCHM (1.1 ± 
0.2 μM) resulted in a lower C50 value compared to BNIPDaCHM (2.3 ± 0.1 μM), 
revealing that each of the three or more than one (trans,trans/cis,trans or 
trans,trans/cis,cis) isomers co-existing in BNIPDaCHM, are involved in the 
intramolecular complexes/interactions with DNA. By isolating one of its isomers 
(trans,trans-BNIPDaCHM), the DNA binding affinity was significantly decreased. 
Thus, the structures of BNIPDaCHM with the presence of the aromatic 
naphthalimido rings allow them to fit between the base pairs (intercalation) and 
in parallel to the previous feature, the ability of possible rotational freedom within 
the plane of the aromatic rings, may allow their exposure of more than one 
intercalating sidechain to DNA (Kopsida et al, 2016). Strong K binding constants 
to reflect the binding potential of the compounds with DNA were determined for 
the three novel BNIPs, after carrying out UV binding studies, which is in agreement 
with the previous findings presented in Chapter 3. To further determine the DNA 
binding affinity of the three novel BNIPs and the molecular aspects of BNIP-DNA 
interactions, it would be important to verify their groove binding potential and 
sequence specificity via NMR. 
Subsequently in Chapter 4, BNIPs were screened for biological activity in breast 
cancer MDA-MB-231 and SKBR-3 cells. After 24 hour treatment, all novel BNIPs 
exhibited strong cytotoxicity with IC50 values ranging from 1.4 μM to 3.3 μM in 
MDA-MB-231 cells and from 0.2 to 0.7 μM in SKBR-3 cells, confirming the 
importance of the bisnaphthalimidopropyl functionality for anticancer activity. 
More specifically, the current linker sequence modifications showed stronger 
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cytotoxic effects against MDA-MB-231 and SKBR-3 cells, when compared to the 
parental compound BNIPDaCHM. The lower IC50 value range shows that SKBR-3 
cells are more sensitive to BNIP treatment, compared to MDA-MB-231 (triple 
negative breast cancer cells). Trans,trans-BNIPDaCHM exhibited stronger 
cytotoxicity compared to BNIPDaCHM in MDA-MB-231 cells, showing that the 
existence of a single isomer in the linker sequence results in a more cytotoxic 
compound, compared to a mixture of different isomers. BNIPPiEth was more 
cytotoxic than BNIPDaCHM, suggesting that the shorter length of the linker chain, 
as well as the incorporation of the nitrogen atom within the cyclohexane ring, not 
only improved the binding properties of BNIPPiEth, but enhanced significantly its 
in vitro cytotoxicity too. Regarding BNIPPiProp, the derivative with the longest 
linker sequence and the highest IC50 value, it was found that the linker chain 
length plays an important role in the functionality and effectiveness of the BNIPs. 
In addition, all the derivatives followed a similar pattern of cytotoxicity in both cell 
lines; however, they appeared more cytotoxic against SKBR-3 cells compared to 
MDA-MB-231 ones, which is probably due to the cells different mutational and 
tumourigenic statuses (Kao et al, 2009). Thus, it would be important to further 
investigate the cytotoxicity of the three novel BNIPs against different cell lines, as 
this would offer a valuable insight into their potential as anti-cancer agents not 
only in breast, but more types of cancer. 
The effect of BNIPs in tuning the levels of intracellular ROS was also investigated 
in Chapter 4 as ROS production has been linked to cell death. BNIPDaCHM is the 
derivative that caused the highest increase of ROS levels in MDA-MB-231 cells, 
after 8 hour treatment, followed by BNIPPiEth, BNIPPiProp and trans,trans-
BNIPDaCHM. In SKBR-3 cells, BNIPPiProp caused the highest increase of ROS 
levels, followed by BNIPDaCHM, BNIPPiEth, and trans,trans-BNIPDaCHM.  
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The above findings indicated that production of ROS was increased in both MDA-
MB-231 and SKBR-3 cells, in relation to treatment with individual BNIPs. However, 
the increase in ROS levels does not seem to parallel the cytotoxicity values 
determined by MTT assay after 24 hour treatment (Chapter 3) for each compound 
in the two cell lines. For example, although trans,trans-BNIPDaCHM was the most 
cytotoxic BNIP derivative in both MDA-MB-231 and SKBR-3 cells, it was not 
responsible for the highest increase of ROS levels. ROS levels were increased in a 
dose dependent manner, as for less cytotoxic compounds, such as BNIPDaCHM, 
BNIPPiProp and BNIPPiEth, and in order to achieve IC25, more of the compounds 
had to be used: this led to higher levels of ROS being detected. The lower ROS 
production induced by trans,trans-BNIPDaCHM compared to the other BNIPs, 
seem to be linked with the melting points and DNA binding studies results. The 
more stable the chemical structure (existence of one isomer) is, the more difficult 
for the agent to undergo oxidation by electron transfer hydrogen abstraction. As 
a result, the possible sites of attack for free radical oxidants (Davasagaya et al. 
2004) and trans,trans-BNIPDaCHM are decreased compared to BNIPDaCHM, 
which retains its rotational freedom due to its structure and the existence of three 
stereoisomers (see Chapter 3). In addition, the above results revealed that SKBR-
3 cells (hormone receptor positive) have a stronger response to BNIP treatments 
compared to MDA-MB-231 cells, which is in agreement with our cytotoxicity 
findings. 
The effect of ROS in DNA damage after treatment with BNIPs was also investigated 
(Chapter 4). DNA damage studies revealed that BNIPs induced a significant 
increase in DNA strand breaks compared to endogenous levels, after 24 hour 
treatment in MDA-MB-231 and SKBR-3 cells. Interestingly, a higher number of 
DNA strand breaks after treatment with BNIPs was observed in MDA-MB-231 cells, 
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compared to SKBR-3 cells. MDA-MB-231 cells were found to be more susceptible 
to DNA instability after treatment with BNIPs, which appears to relate to different 
proliferation index rates between the two cells lines (Kenny et al, 2007). MDA-MB-
231 cells proliferate at a 49.5% rate and SKBR-3 cells at 35.2% (Kenny et al, 
2007). According to these observations, the faster the cells proliferate, the higher 
the DNA damage is caused over time. Moreover, BNIPPiEth (second most cytotoxic 
compound in MDA-MB-231 cells and SKBR-3 cells after trans,trans-BNIPDaCHM 
and highly ROS-inducing compound and strong intercalating BNIP) was the best 
candidate out of the three novel compounds in this study, suggesting that its short 
linker sequence may enhance its cellular uptake (better cytotoxicity, more DNA 
strand breaks). To further elucidate the mode of action of BNIPs, it would be 
interesting to study DNA repair and any potential DNA repair mechanisms that are 
activated after treatment with BNIPs. 
In Chapter 5, the effect of BNIPs on cell cycle distribution and cell death was 
studied. An increase in the proportion of MDA-MB-231 cells in sub-G1 phase was 
exhibited relative to the control, whilst in G1 phase, the cell population was 
significantly decreased, after treatment with BNIPDaCHM (1µM) and trans,trans-
BNIPDaCHM (1µM). In SKBR-3 cells, the cell population was significantly increased 
in sub-G1 phase only after treatment with BNIPDaCHM. In addition, the two BNIPs 
induced sub-G1 cell cycle arrest in both cell lines to a greater extent than 
camptothecin, which is a well-known positive control for sub-G1 arrest (Chu et al, 
2014, Doddapadeni et al, 2015) and for inducing apoptosis (Hong et al, 2014, 
Kang et al, 2016). Moreover, the above findings demonstrated that the effect of 
the two BNIPs investigated was different in each cell line and that the sole 
existence of one isomer (trans,trans-BNIPDaCHM) has a different effect on cell 
cycle distribution. Supplementary studies into cell-cycle regulators, such as p27Kip1 
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and cyclin E, alone and in combination, would be also beneficial, as they have 
been proved indicative of tumour behaviour in several types of cancer, including 
breast cancer (Porter et al, 2006). 
The mode of cell death in MDA-MB-231 and SKBR-3 cells, several studies was 
investigated further. After 0.5 hour treatment with BNIPs, a significant difference 
in Annexin V-FITC staining compared to the control was observed in MDA-MB-231 
and SKBR-3 cells. BNIPPiEth caused the highest increase of Annexin V-FITC 
staining levels in MDA-MB-231 cells, and trans,trans-BNIPDaCHM in SKBR-3 cells, 
suggesting that BNIPs induce early apoptosis, which could be the main mode of 
cell death in BNIP-induced cytotoxicity and cell cycle arrest. In addition, after 24 
hour treatment, BNIPs were found to inhibit Caspase-3 activity in both cell lines 
and autophagy studies revealed for the very first time that the formation of 
autophagosomes and autolysosomes was triggered. This suggests that BNIP-
induced autophagy on the tested human breast cancer cell lines seem to cross talk 
with caspase-independent apoptotic cell death. These findings should be further 
investigated in order to determine any other potential cross talk with other modes 
for cell death, such as necroptosis; a mode of cell death, which has been 
associated with a substantial decrease in Caspase-3 activity with increase in 
autophagic flux (Tait and Green, 2008). 
In Chapter 6, the effect of BNIPs on HDAC activity in breast cancer cells, with 
emphasis on SIRT2, and on cell stress-related proteins, was studied. The three 
novel BNIPs and their parental compound BNIPDaCHM (all at IC25 concentrations), 
inhibited HDAC activity after 24 hour treatment in MDA-MB-231 cells. BNIPPiEth 
was the derivative that caused the highest decrease of HDAC activity, followed by 
BNIPPiProp, BNIPDaCHM and, finally, trans,trans-BNIPDaCHM. Similarly, BNIPs 
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were found to inhibit the HDAC activity after 24 hour treatment in SKBR-3 cells, 
in a similar pattern to that observed in MDA-MB-231 cells. This implies that the 
inhibition of cell growth and cell cycle arrest that was observed earlier can 
potentially be related to the inhibition of HDAC activity. 
Protein expression of SIRT2 only showed differences between the two different 
cell lines after 24 hour treatment with the parental compound, BNIPDaCHM. It 
could therefore be a potential SIRT2 inhibitor in SKBR-3 cells, where SIRT2 
expression was found to decrease after 24 hour treatment by visual observations. 
However, the above results have to be further validated by repeating confirmatory 
experiments to assess the optimum protein amount required, define the most 
appropriate antibody concentration and incubation time for detection by Western-
blot analysis. 
Finally, proteome profiler arrays demonstrated that after treatment with the 
parental compound, BNIPDaCHM, and BNIPPiEth (the best candidate, as defined 
by the previous experiments) in MDA-MB-231 cells, three cell stress-related 
proteins (Cytochrome c, SIRT2 and SOD2) had an increased expression while four 
(PON1, PON2, HIF-1a and HSP60) were decreased. On the other hand, in BNIP-
treated SKBR-3 cells, the protein expression of 12 proteins (ADAMTS1, Bcl-2, 
Carbonic Anhydrase IX, COX-2, Cytochrome c, Dkk-4, HIF-1a, IDO, p21, p27, 
PON1 and PON3) were increased and only the expression of PON1 was decreased 
after treatment with BNIPDaCHM. The above results revealed that BNIPDaCHM 
and BNIPPiEth alter the expression of cell stress-related proteins in a different 
pattern depending on the cell type, suggesting that the mechanism of action of 
BNIPs could be cell line dependent, as it has been suggested in previous chapters. 
To further validate the obtained experimental results and in order to study the 
biological processes involved, bioinformatics studies were employed, where the 
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cellular compartment localisation and the different pathways in which the above 
panel of proteins are involved were explored. This study revealed two novel, 
putative pathways for BNIP-induced oxidative stress-mediated cell death in MDA-
MB-231 and SKBR-3 cells, creating the stepping stone for further research and 
validation towards the delineation of the suggested pathways, as well as the 
mode/mechanisms of BNIP action in breast cancer in future studies. 
In conclusion, the results obtained in this study highlight the importance of the 
three novel BNIPs, BNIPPiProp, BNIPPiEth and trans,trans-BNIPDaCHM and their 
parental compound, BNIPDaCHM, as potential anti-cancer agents and a summary 
of their proposed modes of action are presented in Figure 7.1. The work performed 
here could help with the design, synthesis of novel anti-cancer drugs, and also 
with the understanding and investigation of the cellular and molecular 
mechanisms relevant to future cancer treatment. 
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Figure 7.1.: Schematic representation of the proposed mode of action of BNIPs in MDA-MB-231 and SKBR-3 cells.
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Appendix 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.1.: Example of C50 values calculation obtained by EtBr Fluorescence studies.
 Appendix 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.2.: Example of K binding constants calculation with the formula A0/A-A0. 
 267 
Appendix 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.3.: Example of IC50 values calculation obtained by cytotoxicity studies.
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Appendix 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.4.: Example of IC50 values calculation obtained by fitting the 4 parameter Hill 
equation to dose-response curve. 
 
BNIPs  
IC
50
 values (µM)   
MDA-MB-231            
BNIPDaCHM 3.61                  
BNIPPiProp 3.54          
BNIPPiEth 2.00     
trans,trans-
BNIPDaCHM 
3.35    
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Appendix 5 
 
Figure A.5a.: Example of plotting forward scatter versus side scatter before and after 
treatment with BNIPDaCHM. No presence of cell doublets. 
 
 
 
 
 
 
 
 
Figure A.5b.: Example of cell cycle distribution of MDA-MB-231 cells +/- FBS on a graph 
showing the % of the total population in each phase, without normalising it to the control. 
Serum starvation has caused synchronisation (more cells in G1, no increase in SubG1) - 
similar results as presenting the data after normalisation to the control. 
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Appendix 6 
 
 
 
Figure A6.: PS exposure and membrane integrity profiles of MDA-MB-231 after 0.5, 2, and 
4 hour treatment with IC25 BNIPDaCHM. Profiles were determined by flow cytometry following 
Annexin V-FITC staining and 7-AAD labelling. 10,000 single events were recorded, and cells labelled 
with Annexin V but not 7-AAD were considered Annexin positive. Cells labelled with 7-AAD were 7-
AAD positive. Annexin/7-AAD labelled cells were considered double positive. However, no change 
was observed within Annexin/7-AAD population after treatment with BNIPs (see the example above, 
after treatment with BNIPDaCHM). 
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Novel bisnaphthalimidopropyl (BNIPs) derivatives
as anticancer compounds targeting DNA in human
breast cancer cells†
Maria Kopsida,a Gemma A. Barron,a,b Giovanna Bermano,b Paul Kong Thoo Lina and
Marie Goua*a
Bisnaphthalimidopropyl (BNIP) derivatives are a family of compounds that exert anti-cancer activities
in vitro and, according to previous studies, variations in the linker sequence have increased their DNA
binding and cytotoxic activities. By modifying the linker sequence of bisnaphthalimidopropyl
diaminodicyclohexylmethane (BNIPDaCHM), a previously synthesised BNIP derivative with anti-cancer
properties, three novel BNIP derivatives were designed. Bisnaphthalimidopropyl-piperidylpropane
(BNIPPiProp), a structural isomer of BNIPDaCHM, bisnaphthalimidopropyl ethylenedipiperidine dihydro-
bromide (BNIPPiEth), an isoform of BNIPDaCHM with a shorter linker chain, and (trans(trans))-bisnaphtha-
limidopropyl diaminodicyclohexylmethane (trans,trans-BNIPDaCHM), a stereoisomer of BNIPDaCHM,
were successfully synthesised (72.3–29.5% yield) and characterised by nuclear magnetic resonance spec-
troscopy (NMR) and mass spectrometry (MS). Competitive displacement of ethidium bromide (EtBr) and
UV binding studies were used to study the interactions of BNIP derivatives with Calf Thymus DNA. The
cytotoxicity of these derivatives was assessed against human breast cancer MDA-MB-231 and SKBR-3
cells by MTT assay. Propidium iodide (PI) ﬂow cytometry was conducted in order to evaluate the cellular
DNA content in both breast cancer cell lines before and after treatment with BNIPs. The results showed
that all novel BNIPs exhibit strong DNA binding properties in vitro, and strong cytotoxicity, with IC50
values in the range of 0.2–3.3 µM after 24 hours drug treatment. Two of the novel BNIP derivatives,
BNIPPiEth and trans,trans-BNIPDaCHM, exhibited greater cytotoxicity against the two breast cancer cell
lines studied, compared to BNIPDaCHM. By synthesising enantiopures and reducing the length of the
linker sequence, the cytotoxicity of the BNIP derivatives was signiﬁcantly improved compared to
BNIPDaCHM, while maintaining DNA binding and bis-intercalating properties. In addition, cell cycle
studies indicated that trans,trans-BNIPDaCHM, the most cytotoxic BNIP derivative, induced sub-G1 cell
cycle arrest, indicative of apoptotic cell death. Based on these ﬁndings, further investigation is under way
to assess the potential eﬃcacy of trans,trans-BNIPDaCHM and BNIPPiEth in treating human breast
cancer.
Introduction
Breast cancer is the most commonly occurring cancer in
women, with incidence rates approaching 1.38 million cases
per year worldwide.1 Breast cancer, depending on whether it
develops in response to the hormone oestrogen, is divided in
two categories: oestrogen dependent (ER+) and oestrogen inde-
pendent (ER−) cancer.2 ER+ breast cancers respond better to
anti-oestrogen (endocrine) therapies, such as tamoxifen and
exemestane, by inhibiting the eﬀect of oestrogen and decreas-
ing the uncontrolled proliferation of breast cancer cells.2 On
the other hand, ER-breast cancers are more invasive and less
responsive to current standard-of-care treatment regimes, such
as fluorouracil, epirubicin and doxorubicin, which do not
selectively target breast cancer cells hence leading to severe
side eﬀects.3 Over the last few decades, there have been
numerous attempts to develop novel breast cancer-specific
therapies that will act on specific molecular targets, increasing
selectivity and potentially reducing treatment resistance and
side eﬀects.4 DNA was one of the first biochemical targets
identified in anti-cancer therapeutics,5–7 which lead to a new
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
c6ob01850e
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generation of agents with improved eﬃcacy and solubility.
In the 1990s naphthalimido compounds, such as mitonafide,
were found for the first time to be highly active against cervical
cancer and leukaemia cells, however, a Phase I clinical trial
revealed that mitonafide treatment at doses above 118 mg m−2
× 5 days lead to central nervous system toxicity.8 Subsequently,
bisnaphthalimido compounds were synthesised with improved
therapeutic properties. They had also overcome the dose-limit-
ing toxicity issues,9 however, their aqueous insolubility limited
their potential use as anti-cancer agents.10 Kong Thoo Lin and
Pavlov10 designed and synthesised a number of bisnaphthal-
imidopropyl derivatives, by incorporating natural polyamines
and, diamino or triamino alkyl chains into the bisnaphthal-
imide structure. This led to improved aqueous solubility, as
well as anti-cancer activity.11,12 Additional alterations to the
linker were performed to confirm that BNIP moiety was crucial
for in vitro anti-cancer activity. One such alteration was the
introduction of a bicyclohexylmethane group (in the linker
chain). This tended to reduce the flexibility of the linker but it
enhanced its DNA binding properties, resulting in the syn-
thesis of BNIPDaCHM (Fig. 1). BNIPDaCHM contained a
pseudo-asymmetrical centre with a mixture of three isomers
(cis,cis; trans,trans and cis,trans) (indicated by asterisks,
Fig. 1).13,14 This linker chain modification resulted in a more
cytotoxic BNIP derivative against triple negative breast cancer
cells MDA-MB-231 (IC50 value 6.8 µM), compared to chemo-
therapy drug doxorubicin (IC50 value 14.4 µM), after 24 hours
treatment.13 With regards to selectivity, non-tumourigenic
breast epithelial MCF-10A cells were found to be less respon-
sive to BNIPDaCHM (IC50 value 6.06 µM) than doxorubicin.
13
In the present work, we describe for the first time, the syn-
thesis and characterisation of three novel BNIP derivatives that
were designed by considering several modifications to the
structure of BNIPDaCHM (Fig. 1). The first BNIP derivative,
bisnaphthalimidopropyl-piperidylpropane dihydrobromide
(BNIPPiProp) is a structural isomer of BNIPDaCHM that con-
sists of only one species (enantiopure). The aim of synthesis-
ing BNIPPiProp was to investigate whether cytotoxicity and
DNA binding properties diﬀer among structural isomers and
how the position of the ring structure in the linker chain
aﬀects cytotoxicity. The second BNIP derivative, bisnaphthal-
imidopropyl-ethylenedipiperidine (BNIPPiEth), consists of one
carbon less between the two piperidine ring structures, com-
pared to BNIPPiProp and was synthesised in order to assess
the eﬀect of a shorter linker chain on cytotoxicity and DNA
binding properties. In parallel, it is still unknown whether the
cytotoxicity of BNIPDaCHM is associated with the existence of
the three isomers in its structure, therefore (trans(trans))-4,4′-
methylenebis (cyclohexylamine), the only commercially avail-
able stereoisomer precursor required to synthesise trans,trans-
BNIPDaCHM the latter being, the third BNIP derivative used
in this study. The synthesis of trans,trans-BNIPDaCHM lead to
the investigation into the importance of this stereoisomer
compared to the mixture of three stereoisomers present in
BNIPDaCHM in relation to DNA binding aﬃnities, cytotoxicity
in MDA-MB-231 and SKBR-3 breast cancer cell lines and the
possible mode of cell death via cell cycle analysis were studied
for the three novel compounds. By using two cell lines which
are unresponsive to currently available anti-cancer regimes, it
is possible to extend our knowledge on BNIP derivative cyto-
toxicity against diﬀerent breast cancer cells types and to gain
more information about their mode of action.
Results and discussion
Chemical synthesis
The synthesis of bisnaphthalimidopropyl-dipiperidyl-propane
and ethane free bases was carried out by reacting 1,3-bis-(4-
piperidyl) propane or 1,3-bis-(4-piperidyl)ethane and
toluenesulfonyloxypropylnaphthalimide in tetrahydrofuran
(THF) under reflux with subsequent addition of cesium car-
Fig. 1 Chemical structure of BNIP derivatives: BNIPDaCHM with its
three stereo isomers, bisnaphthalimidopropyl-piperidylpropane
(BNIPPiProp), bisnaphthalimidopropyl-ethylenedipiperidine (BNIPPiEth)
and (trans(trans))-4,4’-methylenebis(cyclohexylamine) (trans,trans-
BNIPDaCHM).
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bonate (Scheme 1). The corresponding BNIPPiProp and
BNIPPiEth dihydro chloride and bromide salts were prepared
by their treatment with HBr/g·CH3CO2H and conc. HCl (72.3%
and 29.5% yield), respectively.
The synthetic strategy of trans,trans-BNIPDaCHM
(Scheme 2) was based on methods previously developed in our
group for the synthesis of BNIPDaCHM.13 Here the single
isomer trans,trans-4,4′-methylenebiscyclohexylamine was used
as the starting material. The synthesis of trans,trans-N4,N4-
dimesityl-dicyclohexylmethane was carried out by reacting
trans,trans-4,4′-methylenebis(cyclohexylamine), with 2-mesity-
lenesulfonyl chloride (Mts-Cl) in anhydrous pyridine (21.1%
yield). N-Alkylation was performed by reacting trans,trans-N4,N4-
dimesityl-dicyclohexylmethane with toluenesulfonyloxypropyl-
naphthalimide in DMF (37.0% yield). For the final step,
trans,trans-bisnaphthalimido-dimesityl-dicyclohexylmethane
was dissolved in DCM, followed by treatment with hydro-
bromic acid/glacial acetic acid (HBr/g·CH3CO2H). All new com-
pounds were fully characterised by NMR and high resolution
mass spectrometry (see Experimental section). The melting
point of trans,trans-BNIPDaCHM was found to be 120–125 °C
indicating good purity. In contrast, BNIPDaCHM exhibited a
higher melting point range (105–130 °C) compared to trans,
trans-BNIPDaCHM. BNIPPiProp and BNIPPiEth had melting
points in the range of 160–170 °C and 120–125 °C, respectively,
indicating their high purity.
According to matched molecular pair (MMP) analysis,
which has been broadly used in the last few years to investigate
the eﬀects of hydrogen bond donors/acceptors and rotatable
bonds on the melting point of drug-like compounds,15–17 has
shown that an increase in rotatable bonds leads to a decrease
of the melting point.18 Therefore, the existence of the three
isomers on BNIPDaCHM increases its flexibility and leads to a
low melting point, compared to the three novel compounds.
On the other hand, BNIPPiProp, with the longest linker
sequence, has the highest melting point (160–170 °C), due to
the increase of hydrogen bond donors/acceptors that stabilize
the crystal lattice.18
DNA binding studies
Competitive displacement of ethidium bromide from Calf
Thymus DNA. Competitive displacement of ethidium bromide
(EtBr) with BNIPs from Calf Thymus DNA was carried out to
investigate their DNA interactions. EtBr is a well known DNA
structural probe and intercalating dye that exerts fluorescence
once it binds to DNA.19 A compound with higher DNA binding
aﬃnity than EtBr either displaces EtBr or breaks the DNA sec-
ondary structure, resulting in fluorescence quenching and a
decrease in fluorescence intensity.20 All three novel BNIP
derivatives competitively displaced EtBr from Calf Thymus DNA
duplexes. For each derivative, a range of concentrations
Scheme 1 Synthetic pathway of bisnaphthalimidopropyl-piperidylpro-
pane (BNIPPiProp) and bisnaphthalimidopropyl-ethylenedipiperidine
dihydrobromide (BNIPPiEth).
Scheme 2 Synthetic pathway of (trans(trans))-4,4’-methylenebis(cyclo-
hexylamine) (trans,trans-BNIPDaCHM).
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(0–7 µM) were tested and the corresponding IC50 values calcu-
lated. All BNIP derivatives displaced EtBr with IC50 values
ranging from 1.1 to 5.6 µM confirming their high DNA
binding aﬃnity (Table 1). BNIPDaCHM was included in the
following studies in order to evaluate and compare its binding
properties to the novel BNIP derivatives.
The order of their binding aﬃnity to Calf Thymus DNA from
highest to lowest was BNIPPiEth (1.1 ± 0.2 µM), BNIPDaCHM
(2.3 ± 0.1 µM), BNIPPiProp (3.9 ± 0.3 µM) and trans,trans-
BNIPDaCHM (5.6 ± 0.2 µM).
BNIPPiEth, which has the shortest linker with two piper-
idine rings attached to an ethyl group, had the lowest IC50
value. The shorter length of the linker chain, as well as the
incorporation of a nitrogen atom within the cyclohexane ring,
compared to BNIPDaCHM, resulted in increased DNA binding.
On the other hand, the incorporation of the nitrogen atom
within the cyclohexane ring was not found to improve the
binding properties of BNIPPiProp (3.9 ± 0.3 µM), compared to
BNIPDaCHM and BNIPPiEth, confirming that the length of
the bridging alkyl linkers is crucial and aﬀects significantly
BNIP binding to DNA duplexes.21
The trans,trans-BNIPDaCHM, a stereoisomer of
BNIPDaCHM, gave a IC50 value of 5.6 ± 0.2 µM. BNIPDaCHM,
which consists of three isomers, gave a IC50 value of 2.3 ±
0.1 µM, which indicated that in absence of cis,cis or/and cis,
trans, trans,trans-BNIPDaCHM was not able to achieve as high
DNA-binding interactions as BNIPDaCHM. Based on the above
results, the planar structure of BNIPDaCHM and its mixture of
three isomers was found to improve its interacting properties
within the DNA base pairs, compared to trans,trans-
BNIPDaCHM. This was confirmed since trans,trans-
BNIPDaCHM resulted in a lower IC50 value compared to
BNIPDaCHM, revealing that each of the three or more than one
(trans,trans/cis,trans or trans,trans/cis,cis) isomers co-existing in
BNIPDaCHM, are involved in the intramolecular complexes/
interactions with DNA. By isolating one of its isomers (trans,
trans-BNIPDaCHM), the DNA binding aﬃnity was decreased
(p < 0.01). The planar structure of BNIPDaCHM allows it to fit
between the base pairs and in parallel, its rotational freedom
within the plane of the aromatic rings, may allow the exposure
of more than one intercalating sidechain to DNA.22
UV binding studies
The binding of the novel BNIP derivatives with Calf Thymus
DNA was also studied by UV spectroscopy. A continuous
decrease in UV absorption was observed at 260 nm, within the
range of drug concentrations (0–7 µM) investigated. The appar-
ent binding constants for the compounds under study, were
calculated from the intercept and the slope by plotting
A0/(A − A0) against BNIP derivative concentrations,23 where
A0 and A correspond to the absorbance values in the absence
and presence of each BNIP compound (Fig. 2a), respectively.
Binding constant values K for the BNIP derivatives range
between 3.25 × 104–12.23 × 104 (Fig. 2b), and indicate that
all BNIP derivatives interact with the DNA helix. The
highest binding constant was observed with BNIPDaCHM
(12.23 × 104), followed by trans,trans-BNIPDaCHM (11.38 × 104)
and BNIPPiEth (10.85 × 104). The lowest K binding constant
was observed for BNIPPiProp (3.25 × 104). This outcome is in
agreement with the competitive displacement of EtBr studies
(Table 1), highlighting the importance of linker chain length
in achieving strong DNA binding interactions. In addition, the
UV absorption studies revealed that trans,trans-BNIPDaCHM,
the less eﬀective derivative in displacing EtBr from DNA,
obtained a high binding constant (11.38 × 104), compared to
BNIPDaCHM (12.23 × 104: highest K binding constant). This
suggests that trans,trans-BNIPDaCHM exhibits lower inter-
Fig. 2 (a) Competitive displacement of EtBr from Calf Thymus DNA.
Plot of A0/(A − A0) versus 1/CBNIP of the interaction between BNIP
derivatives and Calf Thymus DNA. (b) K constant values of BNIPP deriva-
tives after UV binding studies.
Table 1 Competitive displacement of EtBr from Calf Thymus DNA.
Eﬀect of diﬀerent BNIP concentrations (0–7 µM) on % ﬂuorescence
intensity compared to Calf Thymus DNA alone. IC50 value: concen-
tration of each BNIP derivative required to cause a 50% decrease on
ﬂuorescence intensity of DNA-EtBr complex. Data are the mean ± SD of
three independent experiments (n = 3). *P < 0.05, **P < 0.01, compared
to BNIPDaCHM
BNIP derivatives Mean ± SD IC50 value (µM)
Calf Thymus DNA alone –
BNIPDaCHM 2.3 ± 0.1
BNIPPiProp 3.9 ± 0.3*
BNIPPiEth 1.1 ± 0.2*
trans,trans-BNIPDaCHM 5.6 ± 0.2**
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calation capacity than the other two isomers present in the
BNIPDaCHM. However, the trans,trans isomer has similar DNA
aﬃnity to the mixture of isomers present in BNIPDaCHM as
demonstrated by their binding constant (Fig. 2b). Previous
molecular modelling studies have revealed that for the most
stable conformation of bis-1,8-naphthalimide in presence of
DNA, the naphthalimide rings obtain an antiparallel orien-
tation and are detected in the major groove.24 Furthermore,
they have been reported to induce strand cleavage, allowing
the electron transfer and formation of hydrogen bonding
between the nitrogen atoms and the nucleobases (excluding
guanine) of the minor groove,25 suggesting that the high
K binding constant of trans,trans-BNIPDaCHM is obtained not
only via intercalation, but also via binding on the major and
minor groove of DNA.
Biological studies
Cytotoxicity. Cytotoxicity evaluation of BNIPDaCHM,
BNIPPiProp, BNIPPiEth and trans,trans-BNIPDaCHM was
performed by using MTT assay26 against MDA-MB-231 and
SKBR-3 cells (Table 2). After 24 hours treatment, all novel BNIP
derivatives, exhibited strong cytotoxicity with IC50 values
ranging from 1.4 μM to 3.3 μM in MDA-MB-231 cells (Table 2),
compared to previously synthesised BNIPs or DNA intercalat-
ing drugs (doxorubicin) that have been tested against the same
cell line, with IC50 values ranging from 4.9 μM to 12.7 μM.13
In particular, trans,trans-BNIPDaCHM exhibited the lowest
IC50 value of 1.4 μM, BNIPPiEth an IC50 of 1.8 μM and
BNIPPiProp an IC50 of 3.3 μM. A similar pattern of cytotoxicity
was found for SKBR-3 cells, although the IC50 values were
between 0.2–0.7 μM (Table 2).
trans,trans-BNIPDaCHM (1.4 μM) was more active (p < 0.01)
than BNIPDaCHM (2.3 μM) against MDA-MB-231 cells,
showing that the existence of a single isomer in the linker
sequence results in a more cytotoxic compound, compared to
a compound which contains a mixture of isomers. BNIPPiEth
was more cytotoxic (p < 0.05) than BNIPDaCHM, suggesting
that the shorter length of the linker chain, as well as the incor-
poration of the nitrogen atom within the cyclohexane ring, not
only improved the binding properties of BNIPPiEth, but
enhanced significantly its in vitro cytotoxicity, too. Regarding
BNIPPiProp, the derivative with the longest linker sequence
and the highest IC50 value, it was found that the length of the
linker chain length plays an important role in the functionality
and eﬀectiveness of a BNIP derivative. In addition, all the
derivatives followed a similar pattern of cytotoxicity in both
cell lines however, they appeared more cytotoxic against
SKBR-3 cells. This may be due to the diﬀerent mutational and
tumorigenic statuses.
MDA-MB-231 cells are triple negative breast cancer cells
(TNBC) (oestrogen receptor negative (ER−), progesterone recep-
tor negative (PR−), human epidermal growth factor receptor
2 negative HER2−) with four gene mutations being reported
(BRAF, CDKN2A, KRAS and TP53) and a fast-growing basal B
tumour classification (49.5% proliferation rate),27 which
makes them less responsive to anti-cancer treatments, such as
docetaxel or carboplatin, compared to cells that are hormone
receptor positive.27 On the other hand, SKBR-3 cells are double
negative breast cancer cells (DNBC) (ER−, PR−, HER2+) without
gene mutations and with a luminal tumour classification
(35.2% proliferation rate),27 resulting in a better response to
anti-cancer treatments compared to TNBCs, which is in agree-
ment with our findings.
Cell cycle analysis
Cell cycle distribution of MDA-MB-231 and SKBR-3 cells after
cell synchronisation was studied using flow cytometry follow-
ing PI staining28 with the most active compound trans,trans-
BNIPDaCHM (Table 2), together with BNIPDaCHM (mixture of
isomers) that has been reported to induce cell cycle
instability.29
An increase in the proportion of MDA-MB-231 cells in sub-
G1 phase (122.3%, 139.3% and 142.2% increase, respectively)
was exhibited relative to the control, whilst in G1 phase, the
cell population was decreased after treatment with
BNIPDaCHM (1 µM) and trans,trans-BNIPDaCHM (1 µM)
(31.3% and 29.4% decrease, both p < 0.05) (Fig. 3a). The above
results indicate that both BNIPDaCHM and trans,trans-
BNIPDaCHM induced sub-G1 cell cycle arrest to a greater
extent than camptothecin. Camptothecin is a well known posi-
tive control for sub-G1 arrest30,31 and for inducing
apoptosis.32,33
Therefore, this suggests that BNIPDaCHM and trans,trans-
BNIPDaCHM could use similar mechanisms of action com-
pared to camptothecin and may trigger apoptotic cell death in
MDA-MB-231 and SKBR-3 human breast cancer cells.
Similar experiments were carried out with synchronised
SKBR-3 cells (Fig. 3b), where the cell population was signifi-
cantly increased in sub-G1 phase only after treatment with
BNIPDaCHM (136.4%) and camptothecin (210.2%), but not for
trans,trans-BNIPDaCHM, demonstrating that the eﬀect of the
two BNIP derivatives was diﬀerent in each cell line and that
the existence of one isomer has a diﬀerent eﬀect on cell cycle
distribution. Therefore, it is suggested that the mechanisms of
cell death among trans,trans-BNIPDaCHM and BNIPDaCHM
may diﬀer, even though they belong to the same family of
compounds.
Table 2 Cytotoxicity of BNIP derivatives against MDA-MB-231 and
SKBR-3 cells. MDA-MB-231 and SKBR-3 cells were treated with diﬀerent
BNIP concentrations (0–10 μM) for 24 hours at 37 °C. IC50 values corres-
pond to the concentration required to reduce cell growth by 50% com-
pared to control cells. Data presented as mean ± SEM of 3 independent
experiments (n = 3). *P < 0.05, **P < 0.01, compared to BNIPDaCHM
BNIP derivatives
IC50 values (µM)(Mean ± SEM)
MDA-MB-231 SKBR-3
BNIPDaCHM 2.3 ± 0.1 0.4 ± 0.1
BNIPPiProp 3.3 ± 0.1** 0.7 ± 0.1*
BNIPPiEth 1.8 ± 0.1* 0.3 ± 0.1*
trans,trans-BNIPDaCHM 1.4 ± 0.1** 0.2 ± 0.0*
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Conclusions
In this study, we have shown that three BNIP derivatives,
BNIPPiProp, BNIPPiEth and trans,trans-BNIPDaCHM could
have potential as anti-cancer agents. DNA binding aﬃnity was
confirmed as each BNIP derivative had the ability to competi-
tively displace EtBr from DNA and quenched UV absorption in
presence of DNA in a dose dependent manner. Linker
sequence modifications showed stronger cytotoxic eﬀects
against MDA-MB-231 and SKBR-3 cells, compared to the par-
ental compound BNIPDaCHM. In addition, cell cycle analysis
showed that trans,trans-BNIPDaCHM induced sub-G1 arrest in
MDA-MB-231 cells, but not in SKBR-3 cells, suggesting that its
mode of action could be cell line dependent, in contrast to
BNIPDaCHM that shows a similar trend in cell cycle arrest in
both cell lines. This study has confirmed that BNIPPiProp,
BNIPPiEth and trans,trans-BNIPDaCHM have the ability to
interact with DNA, intercalate and stabilise the double helix,
and exhibit better cytotoxic activities, compared to previously
synthesised BNIP derivatives. Further research is ongoing into
the mode of DNA damage, cell death or pathway deregulations
in human breast cancer cell lines.
Experimental
Chemical synthesis
BNIPPiProp, BNIPPiEth and trans,trans-BNIPDaCHM were syn-
thesised according to the methods (with some modifications)
previously described by Kong Thoo Lin and Pavlov.10 The
chemical structure, purity and stability of the derivatives were
confirmed by TLC, NMR, MS and melting point determi-
nation. All reagents were purchased from Fisher Scientific or
Sigma-Aldrich, unless otherwise stated. TLC was performed on
silica gel 60 F254 aluminium plates (EMD/Merck) in chloro-
form/methanol (95 : 5). NMR was recorded on a Bruker 400
Ultrashield spectrometer operating at 400.1 MHz for 1H and
100.6 MHz for 13C. Accurate mass spectra were obtained by
were obtained on Thermo Scientific LTQ Orbitrap XL or
Waters Xevo G2-S analytical instruments (EPSRC National
Mass Spectrometry Service Centre at Swansea University,
Swansea).
Synthesis of bisnaphthalimidopropyl-dipiperidyl-propane base
1,3-Bis-(4-piperidyl)propane (1.19 × 10−3 mol, 0.25 g) and
toluenesulfonyloxypropylnaphtalamide (2.39 × 10−3 mol,
0.98 g) were dissolved in tetrahydrofuran (THF) (6 mL). Using
a reflux condenser, the reaction was stirred at 50 °C for
15 minutes and after the addition of caesium carbonate (3.069
× 10−3 mol, 1 g), the reaction was left to stir overnight at 50 °C.
The reaction was monitored with TLC and once complete, the
solution was poured into icy water (100 mL). A precipitate was
formed and after vacuum filtration, the product was dried in a
vacuum oven at 45 °C overnight. The crude product (base of
BNIPPiProp) was recrystallized from ethanol and the pure
product was characterised by 1H-NMR (64.8% yield).
1H-NMR (CDCl3): δH 8.53–8.51 (2H, CH aromatic protons),
8.14–8.12 (2H, CH aromatic protons), 7.70–7.66 (2H, CH aro-
matic protons), 4.17–4.14 (2, CH2 protons), 2.84–2.82 (2H, CH2
protons), 2.41–2.37 (2H, CH2 protons), 1.91–1.83 (2H, CH2
protons), 1.79–1.74 (2H, CH2 protons), 1.51–1.48 (2H, CH2
protons), 1.71–1.09 (H, CH proton) ppm (parts per million).
Synthesis of BNIPPiProp salt
The base of BNIPPiProp (1.459 × 10−3 mol, 1 g) was dissolved
in DCM (20 mL) and HBr/CH3CO2H (2 mL) was added slowly.
The reaction was stirred for 2 hours at room temperature and
reaction completion was monitored by TLC yielding a preci-
pitate. The precipitate was filtered by vacuum filtration and
washed with DCM (30 mL) and ether (10 mL). The BNIPPiProp
salt was dried under negative pressure in a vacuum oven set at
45 °C for 2 hours (72.3% yield).
1H-NMR (CDCl3): δH 8.53–8.51 (2H, CH aromatic protons),
8.14–8.12 (2H, CH aromatic protons), 7.70–7.66 (2H, CH aro-
matic protons), 4.69 (2H, CH2 protons), 4.17–4.14 (2H, CH2
protons), 2.84–2.82 (2H, CH2 protons), 2.41–2.37 (2H, CH2
Fig. 3 Cell cycle distribution of MDA-MB-231 and SKBR-3 cells after
BNIP treatment. (a) Quantiﬁcation of MDA-MB-231 and (b) SKBR-3 cell
cycle proﬁles by ﬂow cytometry following PI staining after 24 hours
treatment with BNIPDaCHM, trans,trans-BNIPDaCHM and camptothe-
cin. DMSO/dH2O (50% v/v) was used as the solvent control. The percen-
tage of the cell population in sub-G1, G1, S and G2/M were calculated
from histograms of linear FL-2 plots in the ungated regions (10 000
events). Data are mean ± SEM of three independent experiments (n = 3),
conducted in duplicates. *P < 0.05, compared to solvent control.
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protons), 1.91–1.83 (2H, CH2 protons), 1.79–1.74 (2H, CH2
protons), 1.51–1.48 (2H, CH2 protons), 1.71–1.09 (H, CH
proton) ppm.
13C-NMR (CDCl3): δH 164.24 (CvO), 131.87 (CH aromatic),
131.60 (C aromatic), 131.24 (CH aromatic), 127.75 (C aro-
matic), 126.94 (CH aromatic), 122.80 (C aromatic), 56.58 (CH2),
54.03 (CH2), 39.10 (CH2 aromatic), 36.77–35.69 (CH), 32.34
(CH2), 25.33 (CH2) and 23.76 (CH2) ppm.
Mass spectrum (HRMS), m/z = 685.3739 (M + H)+
C43H48N4O4 requires 685.3748 (M + H)
+.
Synthesis of 4,4-ethylenedipiperidine
4,4-Ethylenedipiperidine dihydrochloride (7.428 × 10−4 mol,
0.2 g) was dissolved in distilled water (2 mL), sodium hydrox-
ide (2 M, 1 mL) was added, which resulted in the formation of
a precipitate. The pH was 14. The resulting was transferred
into a separating funnel (100 mL) followed by extraction with
DCM (300 mL). The organic layer was collected, dried with
sodium sulfate and filtered. The solvent was evaporated by a
rotary film evaporator. The final white solid product was left to
dry under negative pressure in a vacuum oven at 45 °C for
30 minutes (90.6% yield). The synthesis of the free base was
confirmed by 1H-NMR.
1H-NMR (CDCl3): δ 2.98–2.95 (2H, CH2 protons), 2.52–2.45
(2H, CH2 protons), 1.8 (NH), 1.60–1.57 (2H, CH2 protons),
1.25–1.21 (H, CH protons) and 1.19–1.16 (2H, CH2 protons)
ppm.
Synthesis of BNIPPiEth base
4,4-Ethylenedipiperidine (5.044 × 10−4 mol, 0.1 g) was reacted
with toluenesulfonyloxypropyl-naphthalamide (1.001 × 10−3
mol, 0.41 g, 2.01 excess). Caesium carbonate (3.069 × 10−3
mol, 1 g) was added in the reaction. All the reagents were dis-
solved in THF (6 mL) and the solution refluxed overnight at
60 °C. The reaction was monitored using TLC. Once the reac-
tion was complete, the solution was poured into icy water
(100 mL), which resulting in the formation of a precipitate.
The precipitate was filtered using a Buchner funnel and the
product was left to dry under negative pressure in a vacuum
oven at 45 °C for 60 minutes (72.3% yield). The crude product
was recrystallised from ethanol and the pure product was
characterised by 1H-NMR.
1H-NMR (CDCl3): δH 8.52–8.50 (2H, CH aromatic protons),
8.13–8.11 (2H, CH aromatic protons), 7.69–7.65 (2H, CH aro-
matic protons), 4.18–4.14 (2H, CH2 protons), 2.83–2.80 (2H,
CH2 protons), 2.40–2.36 (2H, CH2 protons), 1.90–1.83 (2H, CH2
protons), 1.79–1.71 (2H, CH2 protons), 1.48 (2H, CH2 protons),
1.2 (H, CH protons) and 1.00–0.80 (2H, CH2 protons) ppm.
Synthesis of BNIPPiEth
BNIPPiEth (0.1 g) was dissolved in DCM (20 mL). Then, conc.
HCl (1.5 mL) was added dropwise and the solution stirred at
room temperature for 60 minutes, which resulted in the for-
mation of a pale, blue precipitate. The latter was filtered and
washed with ether (50 mL) and afterwards with ethanol
(50 mL). The product was left under negative pressure in a
vacuum oven at 45 °C for 60 minutes (29.5% yield).
1H-NMR (CDCl3): δH 8.42–8.38 (2H, CH aromatic protons),
7.82–7.78 (2H, CH aromatic protons), 4.05–4.01 (2H, CH2
protons), 2.7 (2H, CH2 protons), 2.44–2.43 (2H, CH2 protons),
2.05 (2H, CH2 protons), 1.70–1.67 (2H, CH2 protons), 1.35–1.32
(H, CH protons) and 1.090 (2H, CH2 protons) ppm.
13C-NMR (CDCl3): δH 164.10 (CvO), 134.81 (CH aromatic),
131.76 (C aromatic), 131.18 (CH aromatic), 127.92 (C aro-
matic), 127.68 (CH aromatic), 122.59 (C aromatic), 55.40 (CH2),
52.27 (CH2), 37.79 (CH), 29.43 (CH2) 23.04 (CH2) and 22.54
(CH2) ppm.
Mass spectrum (HRMS), m/z = 671.5372 (M + H)+
C42H46N4O4 requires 671.3592 (M + H)
+.
Synthesis of N-(3-hydroxypropyl)naphthalimide
1,8-Naphthalic anhydride (0.050 mol, 10 g) was dissolved in di-
methylformamide (DMF) (140 mL). Once the 1,8-naphthalic
anhydride was totally dissolved, 3-amino-1-propanol
(0.050 mol, 3.75 g) and 1,8-diazabicylo[5.4.0]undec-7-ene
(DBU) (13 mL) were added. The reaction was left to stir for
5 hours at 85 °C. Reaction completion was monitored with
TLC and once completed; the solution was poured into icy
water (200 mL) while stirring with a glass rod to form a precipi-
tate. The precipitate was filtered and washed with water. The
pure product was characterised using 1H-NMR. Yield was cal-
culated as: 53.9%.
1H-NMR (CDCl3): δH 8.66–8.63 (2H, aromatic H, doublet, J =
7.2 Hz), 8.29–8.25 (2H, aromatic H, doublet, J = 8.4 Hz),
7.83–7.78 (2H, aromatic H, doublet, J = 8.0 Hz), 4.41–4.38 (3H,
triplet, J = 5.6 Hz), 3.64–3.59 (2H, CH2, multiplet) 3.23 (OH,
singlet) and 2.06–2.00 (2H, CH2 multiplet) ppm.
Synthesis of toluenesulfonyloxypropylnaphthalimide
N-(3-Hydropropyl)naphthalimide (0.0196 mol, 5.0 g) was dis-
solved in anhydrous pyridine (70 mL), whilst stirring on ice.
Once the N-(3-hydroxypropyl)naphthalimide was completely
dissolved, p-toluenesulfonyl chloride (Ts-Cl) (0.0394 mol,
7.51 g, 2.01 excess) was slowly added to the reaction. The reac-
tion was left at 4 °C overnight. The reaction was monitored
using TLC and once it was complete, the solution was poured
into icy water (200 mL) to form a precipitate which was filtered
and washed thoroughly with water. The crude product was
recrystallised from ethanol (68.2% yield).
1H-NMR (CDCl3): δH 8.59–8.57 (2H, aromatic H, doublet,
8.2 Hz), 8.25–8.23 (2H, aromatic H, triplet, 7.2 Hz), 7.81–7.76
(2H, multiplet), 7.30 (2H, aromatic H, doublet, 1.2 Hz),
4.27–4.20 (2H, CH2, multiplet), 2.44 (3H, CH3, singlet) and
2.19–2.12 (2H, CH2, multiplet) ppm.
Synthesis of N4,N4-dimesityl-dicyclohexylmethane
4,4′-Methylenebis(cyclohexylamine) (4.75 × 10−3 mol, 1.0 g)
was dissolved in anhydrous pyridine (10 mL) and left to stir for
15 minutes. 2-Mesitylenesulfonyl chloride (Mts-Cl) (9.56 ×
10–3 mol; 2.1 g) was added. The reaction was left to stir over-
night at room temperature and TLC confirmed completion of
Paper Organic & Biomolecular Chemistry
9786 | Org. Biomol. Chem., 2016, 14, 9780–9789 This journal is © The Royal Society of Chemistry 2016
reaction. The solution was poured into icy water (150 mL) with
the formation of a precipitate. The latter was filtered by
vacuum filtration, left to dry in a vacuum oven set at 45 °C for
24 hours (43.3% yield).
1H-NMR (CDCl3): δH 7.30 (NH), 6.97 (4H, CH aromatic
protons), 2.99 (4H, CH protons), 2.67–2.66 (6H, CH3-Mts
protons) and 1.73–1.49 (CH2 and cyclohexane protons) ppm.
Synthesis of protected bisnaphthalimido-dimesityl-
dicyclohexylmethane
N4,N4-Dimesityl-dicyclohexylmethane (6.968 × 10−4 mol, 0.4 g)
and toluenesulfonyloxypropylnaphthalimide (1.400 × 10−3
mol, 2.01 excess) were dissolved in DMF (8 mL). Afterwards,
excess of caesium carbonate (1.13 g, 3.5 × 10−3 mol, 2.5 g
excess) was added slowly. The reaction was left to stir for
48 hours at 60 °C. After TLC confirmed the reaction was com-
plete, the solution was poured into icy water (150 mL) to form
a precipitate. After vacuum filtration and several washes with
water, the product was left to dry under negative filtration in a
vacuum oven at 45 °C for 3 hours (92.2% yield). The product
was recrystallised from ethanol and characterised by NMR.
1H-NMR (CDCl3): δH 8.50–8.47 (2H, aromatic H), 8.18–8.15
(2H, aromatic H), 7.72–7.67 (2H, aromatic H), 6.87 (2H,
CH-Mts H), 6.55–6.53 (2H, CH-Mts H), 3.94–3.92 (2H, CH2),
3.12–3.10 (2H, CH2), 2.87–2.80 (2H, CH2), 2.35–2.32 (3H, CH3),
2.05–2.04 (3H, CH3), 1.61–1.58 (H, CH), 1.61 (2H, CH2)
1.49–1.37 (2H, CH) and 1.04 (2H, CH2) ppm.
13C-NMR (CDCl3): δH 163.87–162.76 (CvO), 134.36 (C aro-
matic), 131.40–130.74 (C aromatic), 127.75 (C aromatic), 35.75
(CH2), 30.41 (CH2), 21.97 (CH3) and 20.32 (CH3) ppm.
Synthesis of bisnaphthalimidopropyl-diamino-
dicyclohexylmethane dihydro-bromide salt
Bisnaphthalimido-dimesityl-dicyclohexylmethane (3.813 × 10−4
mol, 0.4 g) was dissolved in dichloromethane (DCM) (8 mL).
Afterwards, hydrobromic acid/glacial acetic acid (HBr/
CH3CO2H) (1 mL) was added drop wise. The reaction was
stirred overnight at room temperature. TLC was used to
confirm that the reaction was complete. The precipitate
formed, was filtered by vacuum filtration and washed with
DCM (15 mL) and ether (5 mL). The final product was dried
under negative pressure in a vacuum oven set at 45 °C for
3 hours (37.5% yield).
1H-NMR (CDCl3): δH 8.32–8.25 (2H, aromatic Hs), 7.73–7.65
(2H, aromatic Hs), 3.70–3.64 (2H, CH2 protons), 3.13 (2H, CH2
protons), 2.90–2.30 (3H, CH3 protons), 2.09–2.02 (3H, CH3
protons), 1.83–1.80 (H, CH proton), 1.43–1.33 (2H, CH2
protons) ppm.
13C-NMR(CDCl3): δ 163.87–162.76 (CvO), 134.36 (C aro-
matic), 131.40–130.74 (C aromatic), 127.75 (C aromatic), 35.75
(CH2) and 30.41 (CH2) ppm.
Mass spectrum (HRMS), m/z = 685.3764 (M + H)+
C43H48N4O4 requires 685.3748 (M + H)
+.
Synthesis of trans,trans-N4,N4-dimesityl-dicyclohexylmethane
trans,trans-4,4′-Methylenebis(cyclohexylamine) (2.38 × 10−4
mol, 0.05 g) was added in anhydrous pyridine (1.5 mL) and left
to stir for 15 minutes with warming. After dissolution, 2-mesi-
tylenesulfonyl chloride (Mts) (4.76 × 10−4 mol; 0.10 g) was
added. The reaction was left to stir overnight at room tempera-
ture and TLC confirmed reaction completion. The solution
was poured into icy water (10 mL) and stirred with a glass rod
until the formation of a precipitate. The suspension was cen-
trifuged and was washed 3 times with distilled water and the
precipitate was left to dry under negative pressure in a vacuum
oven set at 45 °C for overnight (21% yield). The product was
afterwards characterised by 1H-NMR.
1H-NMR (CDCl3): δH 7.31 (NH), 6.98 (4H, CH aromatic
protons), 3.87 (4H, CH protons), 2.67 (6H, CH3-Mts protons),
2.33 (3H, CH3-Mts protons), 1.84–1.82 (CH2-cyclohexane ring),
1.65–1.62 (CH2-cyclohexane ring), 1.16–1.10 (CH-cyclohexane
ring) and 0.99–0.95 (CH2 cyclohexane protons) ppm.
Synthesis of protected trans,trans-bisnaphthalimidopropyl-
dimesityl-dicyclohexylmethane
trans,trans-N4,N4-Dimesityl-dicyclohexylmethane (6.44 × 10−5
mol, 0.037 g) and toluenesulfonyloxypropylnaphthalimide
(1.29 × 10−4 mol, 0.053 g, 2.01 excess) were dissolved in DMF
(1 mL). Afterwards, excess of caesium carbonate (n = 3.07 ×
10−4 mol, 0.1 g, 5.0 excess) was added slowly. The reaction was
left to stir for 48 hours at 60 °C. After TLC confirmed the reac-
tion was complete, the solution was poured into icy water
(10 mL) to form a precipitate. The suspension was centrifuged
and was washed twice with distilled water. The product was
left to dry under negative pressure in a vacuum oven at 45 °C
for 24 hours. The crude product (59 mg, 88% yield) was puri-
fied using column chromatography and the final product
(25 mg, 37% yield) was characterised by 1H-NMR.
1H-NMR (CDCl3): δH 8.65–8.59 (2H, CH aromatic protons),
8.30–8.25 (2H, CH aromatic protons), 7.84–7.78 (2H, CH aro-
matic protons), 6.65 (4H, CH-Mts protons), 4.41–4.38 (2H,
CH2 protons), 4.06–4.04 (2H, CH2 protons), 3.71–3.68 (2H, CH2
protons), 2.68 (3H, CH3 protons), 2.46–2.44 (3H, CH3 protons),
2.34 (H, CH protons), 2.16–2.15 (2H, CH2 protons) 1.84 (2H,
CH protons) and 1.73–1.71 (2H, CH2 protons) ppm.
13C-NMR (CDCl3): δH 141.93 (CvO), 138.76 (C aromatic),
135.17 (C aromatic), 131.95 (C aromatic), 43.72 (CH2),
33.93–31.99 (CH2), 23.02 (CH3) and 20.97 (CH3) ppm.
Synthesis of trans,trans-bisnaphthalimidopropyl-diamino-
dicyclohexylmethane dihydro-bromide salt
trans,trans-Bisnaphthalimido-dimesityl-dicyclohexylmethane
(2.38 × 10−5 mol, 25 mg) was dissolved in dichloromethane
(DCM) (1.0 mL). Afterwards, hydrobromic acid/glacial acetic
acid (HBr/CH3CO2H) (0.2 mL) was added slowly. The reaction
was stirred overnight at room temperature. TLC was used to
confirm that the reaction was complete. The suspension
formed was transferred to Eppendorf tubes and centrifuged,
was with DCM (1.0 mL) and ether (1.0 mL). The final product
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was dried under negative pressure in a vacuum oven set at
45 °C for 3 hours to give the product as a white solid (8.3 mg,
41% yield).
1H-NMR (CDCl3): δ 8.53–8.49 (2H, CH aromatic protons),
4.16–4.12 (2H, CH aromatic protons), 3.42 (2H, CH aromatic
protons) 3.04 (2H, CH2 protons), 2.94 (2H, CH2 protons),
2.51–2.49 (3H, CH3 protons), 2.09–1.99 (3H, CH3 protons),
1.75–1.72 (H, CH proton), 1.31–1.28 (2H, CH2 protons) ppm.
13C-NMR(CDCl3): δ 164.26 (CvO), 131.82–131.23 (C aro-
matic), 127.99–127.75 (C aromatic), 122.66 (C aromatic), 42.45
(CH2) and 40.61–37.61 (CH2) ppm.
Mass spectrum (HRMS), m/z = 685.3732 (M + H)+
C43H48N4O4 requires 685.3748 (M + H)
+.
Ethidium bromide (EtBr) fluorescence displacement studies
BNIPDaCHM, BNIPPiProp, BNIPPiEth and trans,trans-
BNIPDaCHM working solutions (100 µM) were prepared from
stock solutions (10 mM in 50% DMSO/H20) and were further
diluted to a final concentration of 50 µM in 0.01 M saline
sodium citrate (SSC) buﬀer. Calf Thymus DNA (0.5 g) was dis-
solved in 0.01 M SSC buﬀer (100 mL). EtBr solution (200 µM)
was prepared by dissolving 3.94 mg of EtBr in distilled water
(50 mL) and was further diluted in 0.01 SSC buﬀer to give the
final concentration of 20 µM. Test solutions were prepared by
adding varying volumes of SSC buﬀer, Calf Thymus DNA solu-
tion, EtBr solution and BNIP derivative solution. The final
solutions were thoroughly mixed and analysed at 510 nm (exci-
tation) and 520 nm (emission) using a Shimadzu RF-5301
spectrophotometer. The IC50 values were determined as the
concentration (µM) required to decrease the fluorescence of
DNA bound EtBr by 50%.
UV binding studies
BNIPDaCHM, BNIPPiProp, BNIPPiEth and BNIPDaCHM
working solutions (100 µM) were prepared from their stock
solutions (10 mM) as before, and were further diluted to
20 µM final concentration in 0.01 M SSC buﬀer. Calf Thymus
DNA and 0.01 SSC buﬀer were prepared as described before
(EtBr Fluorescence Displacement studies). Test solutions were
prepared by adding Calf Thymus DNA solution (1 mL) in a
quartz cuvette and BNIP derivative solution (100 µL) was
added. The final solutions were thoroughly mixed and ana-
lysed at 260 nm using an Agilent 8453 UV-visible spectrophoto-
meter. The values of apparent binding constants (K) were cal-
culated from the intercept and slope by plotting A0/(A − A0)
against the BNIP derivative concentrations, where A0 and A
correspond to the absorbance values in absence and presence
of a compound.
Cell culture maintenance
MDA-MB-231 (ECACC, Public Health England, UK, 92020424)
and SKBR-3 (ATCC, HTB-30) cells were maintained in Roswell
Park Memorial Institute 1640 medium (RPMI-1640) (contain-
ing GlutaMAX-1 with 25 mM HEPES), supplemented with 10%
(v/v) Fetal Bovine Serum (FBS) and 1% penicillin/streptomycin
(10 000 µg mL−1). Cells were grown at 37 °C (5% CO2).
Cytotoxicity
Colourimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
dium bromide (MTT) assay was performed to access the
growth/inhibitory eﬀects of each BNIP compound.
MDA-MB-231 and SKBR-3 cells (7.5 × 103 cells per 100 μL) were
treated with diﬀerent concentrations (0–10 μM) of BNIP deriva-
tives. After 24 hours treatment, sterile-filtered MTT solution
(1 mg mL−1) was added to each well. After 4 hours incubation
at 37 °C, the MTT solution was removed and formazan crystals
solubilised in DMSO. The plates were shaken for 20 minutes at
room temperature and absorbance measured at 560 nm
(Synergy/HT, BIOTEK, UK). For each compound, three inde-
pendent experiments were carried out and each treatment con-
sisted of six replicates per plate. Curves were used to represent
the percentage growth inhibition of MDA-MB-231 and SKBR-3
cells treated with BNIP derivatives, compared to DMSO/H2O
control that represented 100% cell viability. IC50 values were
defined as the drug concentration that reduces absorbance
compared to control values by 50%.
Cell cycle analysis
MDA-MB-231 and SKBR-3 cells (1 × 106 cells per T75 flask)
cells were washed with PBS and serum free medium added in
the flasks in order to achieve cell synchrony. The cells were
incubated in serum free medium for 24 hours. BNIP deriva-
tives (IC25 concentrations) were added and incubated for
24 hours, at 37 °C. After 24 hours treatment, the medium was
removed and collected. The cells were washed twice with PBS.
Both washes were collected and the cells trypsinised, mixed
with the collected washes and centrifuged at 2500 rpm for
5 minutes at 4 °C. The supernatant of each sample was dis-
carded, the pellet was resuspended in PBS (1 mL) and centri-
fuged at 2500 rpm for 5 minutes at 4 °C, the supernatant was
discarded and the pellet resuspended in PBS (100 µL). Then,
70% (v/v) ice-cold ethanol (900 µL) was added and samples
incubated for 2 hours at −20 °C. The cells were centrifuged at
5000 rpm for 5 minutes at 4 °C, the supernatant was discarded
and the pellet resuspended in PBS (1 mL), followed by re-
centrifugation at 5000 rpm for 5 minutes at 4 °C. The super-
natant was discarded once more and the pellet resuspended in
PBS (500 µL) and DNA extraction buﬀer (0.2 M Na2HPO4, 4 mM
citric acid, pH 7.8, 500 µL) and incubated for 5 minutes at
room temperature. The extracts were centrifuged at 5000 rpm
for 5 minutes at 4 °C, the supernatant was removed and the
pellets were resuspended in DNA staining solution (0.2 mg mL−1
Ribonuclease A (DNAse-free) and 20 µg mL−1 propidium
iodide (PI) in PBS). The samples were incubated for
30 minutes at 4 °C in the dark and PI nuclei were examined by
flow cytometry (EXPO32 ADC XL 4 color, Beckman Coulter,
UK). For cell cycle analysis, EXPO32 ADC analysis software
(Beckman Coulter, UK) was used to record and analyse 10 000
single events. The percentage of cells with DNA content in
sub-G1, G1, S and G2/M phases was calculated from histograms
of linear FL-2 plots (575 nm) in the gated region.
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Statistics
Three independent experiments were conducted and each
experiment was comprised of at least two internal replicates.
Data are presented as mean ± SD or mean ± SEM. Statistical
analysis was performed by using an unpaired Student’s t-test.
Statistically significant data were detailed when P < 0.05).
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Bisnaphthalimidopropyl (BNIP) derivatives are a family of DNA intercalating compounds 
that exert anti-cancer activity against a variety of cancer cell lines in vitro 1,2. Variations 
in the linker sequence have been found to improve the aqueous solubility and cytotoxic 
activity of BNIP derivatives, thus enhancing their potential application as anticancer drugs 
3,4. The aim of this study was to investigate the effect of three novel BNIP derivatives 
against triple negative human breast carcinoma cells and their mode of action, with 
regards to cell death. Bisnaphthalimidopropyl-piperidylpropane (BNIPPiProp), 
bisnaphthalimidopropyl- ethylenedipiperidine dihydrobromide (BNIPPiEth) and 
(trans(trans))-4,4’-methylenebis-cyclohexylamine (trans,trans-bisnaphthalimidopropyl 
diaminodicyclohexylmethane or trans,trans-BNIPDaCHM) were synthesised and 
characterised for the first time. The chemical structure of the BNIP derivatives was 
confirmed by Thin Layer Chromatography (TLC), Nuclear Magnetic Resonance (NMR), Mass 
Spectrometry (MS) while their DNA binding properties were determined by UV and 
fluorescence spectroscopy. Cytotoxicity of BNIP derivatives was assessed against human 
breast cancer MDA-MB-231 cells by MTT assay 5, resulting in IC50 values between 1.4-3.3 
µM after 24 hours treatment. In addition, using the single cell gel electrophoresis (COMET) 
assay 6, it was found that BNIPPiProp, BNIPPiEth and trans,trans-BNIPDaCHM, showed 
significant DNA damage to treated MDA-MB-231 cells after 24 hours treatment. 
Intracellular reactive oxygen species (ROS) accumulation was studied by flow cytometry, 
showing that the generation of ROS levels was induced after 4, 8 and 12 hours treatment 
with BNIP derivatives. After cell synchronisation, cell cycle distribution was conducted 
using propidium iodide (PI) staining of MDA-MB-231 cells and indicated that trans,trans-
BNIPDaCHM induces  sub-G1 cell cycle arrest, which has been previously associated with 
apoptotic cell death 7. In particular, an increase of 139% and 142% in sub-G1 cell 
population after 24 hours treatment was observed with 1 µM trans,trans-BNIPDaCHM and 
6 µM Camptothecin (positive control for sub-G1 arrest), respectively, compared to 
untreated cells. The above findings indicate that BNIPPiProp, BNIPPiEth and trans,trans-
BNIPDaCHM exhibit dose-dependent cytotoxic effects in vitro (trans,trans-
BNIPDaCHM>BNIPPiEth>BNIPPiProp), induce DNA damage and enhance ROS 
accumulation. Further investigation to confirm apoptotic cell death is on-going and this 
could define the potential use of BNIP derivatives as anti-cancer agents in the future. 
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Bisnaphthalimidopropyl (BNIP) derivatives are a family of DNA intercalating compounds 
that exert anti-cancer activity against a variety of cancer cell lines in vitro 1,2. Variations 
in the linker sequence have been found to improve the aqueous solubility and cytotoxic 
activity of BNIP derivatives, thus enhancing their potential application as anticancer drugs 
3,4. The aim of this study was to investigate the effect of three novel BNIP derivatives 
against triple negative human breast carcinoma cells and their mode of action, with 
regards to cell death. Bisnaphthalimidopropyl-piperidylpropane (BNIPPiProp), 
bisnaphthalimidopropyl- ethylenedipiperidine dihydrobromide (BNIPPiEth) and 
(trans(trans))-4,4’-methylenebis-cyclohexylamine (trans,trans-bisnaphthalimidopropyl 
diaminodicyclohexylmethane or trans,trans-BNIPDaCHM) were synthesised and 
characterised for the first time. The chemical structure of the BNIP derivatives was 
confirmed by Thin Layer Chromatography (TLC), Nuclear Magnetic Resonance (NMR), Mass 
Spectrometry (MS) while their DNA binding properties were determined by UV and 
fluorescence spectroscopy. Cytotoxicity of BNIP derivatives was assessed against human 
breast cancer MDA-MB-231 cells by MTT assay5, resulting in IC50 values between 1.4-3.3 
µM after 24 hours treatment. In addition, using the single cell gel electrophoresis (COMET) 
assay6, it was found that BNIPPiProp, BNIPPiEth and trans,trans-BNIPDaCHM, showed 
significant DNA damage to treated MDA-MB-231 cells after 24 hours treatment. 
Intracellular reactive oxygen species (ROS) accumulation was studied by flow cytometry, 
showing that the generation of ROS levels was induced after 4, 8 and 12 hours treatment 
with BNIP derivatives. After cell synchronisation, cell cycle distribution was conducted 
using propidium iodide (PI) staining of MDA-MB-231 cells and indicated that trans,trans-
BNIPDaCHM induces  sub-G1 cell cycle arrest, which has been previously associated with 
apoptotic cell death7. In particular, an increase of 139% and 142% in sub-G1 cell 
population after 24 hours treatment was observed with 1 µM trans,trans-BNIPDaCHM and 
6 µM Camptothecin (positive control for sub-G1 arrest), respectively, compared to 
untreated cells. The above findings indicate that BNIPPiProp, BNIPPiEth and trans,trans-
BNIPDaCHM exhibit dose-dependent cytotoxic effects in vitro (trans,trans-
BNIPDaCHM>BNIPPiEth>BNIPPiProp), induce DNA damage and enhance ROS 
accumulation. Further investigation to confirm apoptotic cell death is on-going and this 
could define the potential use of BNIP derivatives as anti-cancer agents in the future. 
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Breast cancer is the most commonly occurring cancer in women, with incidence rates 
approaching 1.38 million cases per year worldwide. Over the last few decades, there have 
been numerous attempts to develop, synthesise and advance into the clinic, novel and 
selective breast cancer therapies. As previously reported1, bisnaphthalimidopropyl 
diaminodicyclohexylmethane (BNIPDaCHM) (Figure 1) exerted potent in vitro anti-cancer 
activities and strong DNA binding properties. Here we report for the first time the 
synthesis, characterisation and biological activity of the trans,trans-BNIPDaCHM isomer. 
1H-NMR, 13C-NMR, MS and melting point determination were used to confirm the structural 
identity of trans,trans-BNIPDaCHM derivative. The cytotoxicity of trans,trans-BNIPDaCHM 
was assessed against a human breast cancer cell line (MDA-MB-231) by MTT assay. In 
parallel, DNA binding properties of trans,trans-BNIPDaCHM were determined using 
Fluorescence and UV quenching experiments. This novel compound exhibited strong 
cytotoxic activity against MDA-MB-231 cells, with an IC50 value of 1.4 µM after 24 hours 
treatment. trans,trans-BNIPDaCHM competitively displaced EtBr from DNA, with a C50 
value of 5.6 µM and the DNA binding K constant of trans,trans-BNIPDaCHM was 11.38 x 
104. In conclusion, the above findings signify that trans,trans-BNIPDaCHM exhibits strong 
cytotoxic and DNA binding properties in vitro. Future work will study the potential 
molecular targets of trans,trans-BNIPDaCHM in breast cancer cells. 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structure of the parental compound, BNIPDaCHM, with its three stereo isomers 
including trans,trans-BNIPDaCHM. 
 
1Barron, G., Bermano, G., Gordon, A. and Kong Thoo Lin, P., Eur. J. Med. Chem., 2010, 45 
(4), 1430-1437. 
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Advances in the development and applications of novel DNA intercalators in drug design 
have created new opportunities for anticancer compound development. A series of novel 
bisnaphthalimidopropyl (BNIP) derivatives, bisnaphthalimidopropyl-piperidylpropane 
(BNIPPiProp), bisnaphthalimidopropyl- ethylenedipiperidine (BNIPPiEth) and 
(trans(trans))-4,4’-methylenebis-cyclohexylamine (trans,trans-BNIPDaCHM) were 
synthesised, characterised and studies for their DNA binding and anticancer activities 
against human breast cancer MDA-MB-231 cells. Fluorescence binding/UV binding studies 
were used to determine their DNA binding properties. Cytotoxicity evaluation was 
performed by 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazodium bromide (MTT) 
assay. All compounds induced cell death (1.4-2.3 μM) after 24 hours treatment, with 
trans,trans-BNIPDaCHM being the most promising candidate. Further evaluation of the 
cellular DNA content after 24 hours treatment with BNIPs showed induction of sub-G1 cell 
cycle arrest, indicative of apoptotic cell death and confirmed by studies on the 
externalization of phosphatidylserine residues in MDA-MB-231 cells. In addition, 
intracellular reactive oxygen species levels were increased after 4, 8 and 12 hours 
treatment with BNIP derivatives, while DNA damage studies showed a significant upturn 
in the number of DNA strand breaks in MDA-MB-231 cells. The above findings, relating to 
oxidative stress, form the basis to explore further BNIPs as potential treatment for triple 
negative breast cancer cells. 
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Bisnaphthalimidopropyl (BNIP) derivatives are a family of compounds that were initially 
synthesised with natural polyamines incorporated into their linker chain and were found 
to exert anti-cancer activities1, 2. According to previous studies3, 4, variations in the linker 
sequence seem to improve the aqueous solubility and cytotoxic activity of BNIP 
derivatives, enhancing their potential application as anticancer drugs. The aim of this 
project was to synthesise and characterise three novel BNIP derivatives, 
bisnaphthalimidopropyl-piperidylpropane (BNIPPiProp), bisnaphthalimidopropyl- 
ethylenedipiperidine dihydrobromide (BNIPPiEth-HBr) and (trans(trans))-4,4’-
methylenebis-cyclohexylamine (trans,trans-BNIPDaCHM). 1H-NMR, 13C-NMR, MS and 
melting point determination confirmed the structural identity of derivative. The cytotoxicity 
of novel BNIP derivatives was assessed against human breast cancer MDA-MB-231 cells 
by MTT assay5. In parallel, DNA binding studies investigated whether the BNIP derivatives 
can successfully target DNA. Fluorescence-binding experiments and UV binding studies 
were used to determine their DNA binding properties6. Propidium Iodide (PI) flow 
cytometry was conducted in order to evaluate the cellular DNA content in breast cancer 
cells and assess the induction of apoptotic cell death by BNIP derivatives. All the 
derivatives exhibited strong cytotoxic activity against MDA-MB-231 cells, with IC50 values 
ranging between 1.4-2.3 µM after 24 hours treatment. Competitive ethidium bromide 
displacement experiments revealed that BNIPPiProp, BNIPPiEth-HBr and trans,trans-
BNIPDaCHM competitively displace EtBr from DNA, with C50 values in a range of 1.1-5.6 
µM. Corresponding values for K binding constants varied from 3.25 x 104 to 12.23 x 104, 
according to UV spectroscopy studies. Furthermore, cell cycle distribution of MDA-MB-231 
cells after cell synchronisation indicated that trans,trans-BNIPDaCHM induces a sub-G1 
cell cycle arrest which is associated with apoptotic cell death. In particular, an increase of 
139.3% and 142.2% in sub-G1 cell population after 24 hours treatment with 1µM 
trans,trans-BNIPDaCHM and 6µM Camptothecin (a known control for sub-G1 arrest), 
respectively was observed compared to untreated cells. In conclusion, the above findings 
signify that novel BNIP derivatives exhibit strong cytotoxic and DNA binding properties in 
vitro and further investigation in mode of cell death, in relation to apoptosis, would be 
beneficial for their development as potential anticancer agents.  
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